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ABSTRACT 
This thesis describes a new method for the synthesis of pseudodisaccharides containing 
a carbasugar analogue attached to a “true” sugar.  The methodology is based on a Diels-
Alder cycloaddition of vinyl sugars and appropriately substituted pyran-2-ones, 
followed by chemical manipulation of the resulting cycloadducts. The thesis also 
describes the synthesis of inhibitors of Golgi α-mannosidase II and glucokinase.  
The first chapter is a comprehensive survey of the reported synthetic routes to 
pseudodisaccharides from the literature.  
The results and discussions are presented in chapter 2. This chapter starts by discussion 
of the preparation of vinyl sugars and pyran-2-ones and the regio- and stereoselectivity 
of their cycloadditions. This is followed by reporting the chemical manipulations of 
these cycloadducts and the synthesis of a pseudodisaccharide. Cycloadducts are shown 
to lose carbon dioxide at elevated temperatures to afford dihydrobenzenes. The loss of 
the bridging carbon dioxide from the cycloadducts is experimentally and 
computationally investigated. The resulting dihydrobenzenes are shown to also be 
useful as precursors in the synthesis of pseudodisaccharides. The chemical manipulation 
of these dihydrobenzenes is used towards the synthesis of a pseudodisaccharide.  
The third and fourth chapters focus on the synthesis of new inhibitors of Golgi α-
mannosidase II and glucokinase respectively. A range of 6-aminoglucose and mannose 
derivatives were prepared and tested for the inhibition of Jack bean α-mannosidase, but 
were found to lack any inhibition. Similarly, a range of 6-triazologlucose derivatives 
were prepared but were found to lack any cytotoxicity. 
The fifth chapter contains the details of the preparation, experimental procedures and 
spectroscopic characterisation of the synthesised chemical compounds. 
Rate calculations are reported in Appendix I and the X-ray crystallographic data are 
presented in the Appendix II. 
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ABBREVIATIONS 
 
Å    angstrom  
Ac    acetyl 
AM1    Austin model 1 
aq.    aqueous  
ADP    adenosine diphosphate 
ATP    adenosine triphosphate 
Bn    benzyl 
Bu    butyl 
BVE                                 butyl vinyl ether 
Bz    benzoyl 
cat.    catalyst 
conc.    concentrated 
DA    Diels-Alder 
DBU    1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC    N,N'-dicyclohexylcarbodiimide 
DCM    dichloromethane 
DC-SIGN   dendritic cell-specific intercellular adhesion  
               grabbing non-integrin 
DFT    density functional theory 
DIBAL-H   diisobutylaluminium hydride 
DIPEA   N,N-diisopropylethylamine 
DMAP    4-(N,N-dimethylamino)pyridine 
DME    dimethoxyethane 
DMF    N,N-dimethylformamide 
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DMSO    dimethyl sulfoxide  
DNA    deoxyribonucleic acid 
EDG        electron donating group 
Et    ethyl 
EWG    electron withdrawing group 
FAD    flavin adenine dinucleotide 
FMO    frontier molecular orbital 
G6P    glucose-6-phosphate 
GAPDH   glyceraldehydes-3-phosphate dehydrogenase 
Glc    glucose 
GlcNAc   N-acetyl-glucosamine 
GMII    Golgi mannosidase II 
GTP    guanosine-5'-triphosphate    
HIF-1    hypoxia inducible transcription factor-1 
HIV    human immunodeficiency virus 
HMPA    hexamethylphosphoramide 
HOMO   highest occupied molecular orbital 
IC50    half maximal inhibitory concentration 
LDH-A   lactate dehydrogenase A 
Lit.    literature  
LUMO   lowest unoccupied molecular orbital  
o    ortho   
p    para 
Man    mannose 
m-CPBA   meta-chloroperoxybenzoic acid  
Me    methyl 
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m.p.    melting point 
MS    mass spectroscopy 
Ms    methanesulfonyl (mesyl) 
NADH    nicotinamide adenine dinucleotide (reduced form)  
NBS    N-bromosuccinimide 
NMR    nuclear magnetic resonance 
PCC    pyridinium chlorochromate  
PCD    programmed cell death 
PDK1    pyruvate hydrogenase kinase-1 
PGK    phosphoglycerate kinase 
Ph    phenyl 
ppm    part(s) per million 
py    pyridine 
RNA    ribonucleic acid 
r.t.    room temperature 
TBAI    tetrabutylammonium iodide 
TCA     tricarboxylic acid  
TBDMS   t-butyldimethylsilyl 
TFA    trifluoroacetic acid 
THF    tetrahydrofuran 
TIBAL   triisobutylaluminium 
TLC    thin layer chromatography  
TMS    trimethylsilyl 
Ts    4-methylbenzenesulfonyl (tosyl) 
TS    transition state 
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1.1 Introduction 
 
In recent years, naturally occurring and synthetic carbasugars have found a great deal of 
application in medicinal chemistry.1  Strictly speaking, carbasugars are defined as a 
class of pseudosaccharides in which the oxygen atom in the parent sugar has been 
replaced by a methylene group (Figure 1).2
 
  However, the recent literature has seen a 
more liberal use of the terminology and carbasugars can be more generally defined as 
molecules in which the sugar’s polyhydroxylated furanose or pyranose ring is mimicked 
by a polyhydroxylated five or six membered carbocycle respectively. 
 
Figure 1  
 
Carbasugars lack the hemiacetal function which is responsible for a great deal of the 
chemistry of “true’’ sugars and is the key to their oligomerisation, but mostly preserve 
the functional groups and shape of their parent saccharide.  Since carbasugars mimic the 
structure of their “true’’ sugar analogues, they can interact with many carbohydrate-
handling enzymes, including glycosyltransferases, and with many carbohydrate-
recognising receptors and proteins. 3   As these enzymes, receptors and proteins are 
involved in disease processes, carbasugars and their derivatives have become important 
tools in medicinal chemistry.  Indeed, many naturally occurring carbasugars and their 
11 
 
derivatives have an important and wide range of biological activities hence important in 
the drug discovery process.4 These include carbocyclic nucleoside aristeromycin 1,5 the 
validamycin A-H 2-9 family of antibiotics,6 antidiabetic agent acarbose 10,7 trestatin B 
11, 8  and salbostatin 12, 9
 
 a basic non-reducing pseudodisaccharide consisting of 
valienamine attached to 2-amino-1,5-anydro-2-deoxyglucitol which is a potent trehalase 
inhibitor (Figure 2).  
Furthermore, direct replacement of a “true” sugar with its “carba” analogue in an 
enzyme’s substrate is the most straightforward means of rationally designing inhibitors 
of that enzyme.  For example, the carbasugar analogue of cytidine monophosphate sialic 
acid 13, designed as a sialyltransferase inhibitor, 10  and the carbasugar analogue of 
uridinediphosphate galactose 14, designed as a galactosyltransferase and 
glucosylceramide inhibitor, have both been shown to inhibit their target enzymes with 
good potency and selectivity.11
 
 
 
12 
 
 
 
 
 
 
 
 
Figure 2: Important molecules containing carbasugars  
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Within this context, pseudodi- and pseudopolysaccharides, (oligomers containing a 
carbasugar linked to true sugars) have a prominent role.  The lack of an acetal linkage in 
the non-reducing end of a carbasugar means that these sugar molecules cannot be 
cleaved at that position by hydrolases and glycosidases (Scheme 1).  Provided they are 
sufficiently recognised to bind at the active sites of these enzymes, they are potential 
enzyme inhibitors.12
 
 
Pseudodi- and pseudooligosaccharides have a significant advantage over the use of 
single residue carbasugars in that they can possess significant selectivity on the 
biological target.  Many carbohydrate handling enzymes have a large active site that 
recognises a significant portion of their substrate.  For example, heparanase, a β-endo- 
glucuronidase can recognise four residues spanning the cleavage site of heparan sulfate, 
thus giving it the ability to selectively cleave this substrate and not the plethora of 
heparins and other sulfated oligosaccharides.13
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The need to have access to these biologically important molecules is becoming 
increasingly important.  In this chapter we will explore current methodologies directed 
at the synthesis of pseudodisaccharides, and their biological importance.  The chapter 
will cover the three main methodologies that have been used for the synthesis of “true” 
sugar-cabasugar disaccharides. 
 
1. Coupling Reactions 
2. Electrophilic cyclisation 
I. TIBAL-Induced Reductive rearrangement 
II. Titanium(IV)-Assisted Rearrangement 
III. Oxocarbenium Ion-Enol Ether Cyclisation 
3. Diels-Alder cycloaddition approach 
 
1.2 Coupling Reactions 
 
 
 
Figure 3 
 
The most widely used methods of making pseudodisaccharides involve the syntheses of 
the carbasugar as a distinct moiety, followed by its coupling to the “true” sugar.  Steric 
and electronic factors play important roles when coupling a true sugar with a 
carbasugar.  Joining the carbasugar at the anomeric position of the sugar is easiest, due 
to electronic factors (easy formation of the oxonium intermediate).  Joining the 
15 
 
carbasugar at the primary hydroxyl is less difficult than connecting the carbasugar at the 
C-2, C-3 and C-4 hydroxyls due to steric factors (Figure 3).  This steric problem can be 
overcome by employing either a true sugar epoxides or carbasugar epoxides as 
acceptors.  Epoxides are more reactive because of the three-membered ring strain which 
is relieved upon epoxide opening. 
 
Ogawa’s group has contributed most in this area and their general approach is described 
in Scheme 2. 14
 
  The first method involves coupling monosaccharide donors with 
appropriately protected carbasugar acceptors to give a pseudodisaccharide with the 
carbasugar located at the reducing end.  The second approach employs 1,2-epoxides of 
5a-carbapyranoses as 5a-carbahexopyranosyl donors.    
 
 
1.2.1 Synthesis of pseudodisaccharides with a carbasugar attached to the 
anomeric position 
 
Towards the total synthesis of validamycin A 2 and related compounds, Ogawa and co-
workers reported the synthesis of β-D-glucopyranosylvalidamine 19a (Scheme 3) in 
1980. 15   The synthesis of 19a assumed a structure of validamycin A which was 
16 
 
previously assigned by Horii and Kameda on the basis of degradation studies. 16
15
  
Condensation of a suitably protected (DL)-validamine 15 with glucose derivative 16 
using mercury(II) cyanide and anhydrous calcium sulfate in a mixture of benzene and 
dioxane (2:1, v/v), at 65 oC for a week, gave two diastereomers α and β-D-
glucopyranosylvalidamine 17a and 17b in 47% and 50% yield respectively.  Treatment 
of 17a and 17b with 80% aqueous acetic acid afforded the corresponding dihydroxy 
compounds 18a and 18b in 44% and 76% yields, respectively.  Treatment of 18a and 
18b with boiling 10% aqueous barium hydroxide gave the desired pseudodisaccharides 
19a and 19b (Scheme 3).  
 
 
Figure 4 
 
However, on the basis of 1H and 13C NMR, and chromatographic behaviour, the 
resulting β-D-glucopyranosylvalidamine 19a was not to be identical to the authentic 
sample derived from validamycin A 2.  In the same year Ogawa’s group reported, using 
the same methodology, the synthesis of glucopyranosyvalidamine 20 (Figure 4) in 
which D-glucopyranose is attached to the C-1 hydroxyl group of (+)-validamine, similar 
to the authentic sample derived from Validamycin A 2.17  On the basis of these studies 
the correct structure of validamycin A 2 could be assigned (Figure 4).18 
17 
 
 
 
 
Ogawa and co-workers also reported in 1987 the synthesis of pseudodisaccharides 25a 
and 25b (Scheme 5).19
19
  Protection of compound 21 with 2,2-dimethoxypropane in DMF 
in the presence of tosic acid afforded a mixture of 1,2:3,4-, 1,2:4,7-, and 2,3:4,7 di-O- 
isopropylidene derivatives 22a, 22b and 22c (Scheme 4).  
18 
 
 
 
 
 
 
Condensation of compound 22a with 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl 
bromide 16 in boiling benzene in the presence of mercury(II) cyanide and anhydrous 
calcium sulfate for 21 h gave diastereomeric 23a and 23b in 34% and 26% yields, 
19 
 
respectively. O-Deisopropylidenation of the diastereomers followed by aceylation gave 
24a and 24b in quantitative yields (100%).  Global deprotection afforded the desired 
products 25a and 25b in 72% and 70% yields, respectively (Scheme 5).19 
 
 
Figure 5 
 
α,α-Trehalose 26 (Figure 5) is an energy source in the plant and animal kingdoms and 
acts as a carbohydrate reserve in insects.20  Trehalase, a disaccharide hydrolase, cleaves 
α,α-trehalose into two D-glucopyranose moieties. 21   Ogawa and co-workers have 
synthesised all four possible diastereomers (α,α-, α,β-, β,α-, β,β-) of 5’a-carbatrehalose 
27 where one of the pyranose ring oxygens is replaced with a methylene group.22
22
  These 
diastereoisomers were synthesised by condensation of the appropriately protected 
pseudo-α- and -β-(DL)-glucopyranoses with D-glucopyranose derivatives in the presence 
of trimethylsilyl trifluoromethanesulfonate.  All the pseudotrehaloses were inactive as 
inhibitors of the trehalase enzyme.  
 
Ogawa’s group have also utilised the method described above to synthesise 5’a-
carbamaltose 28, 5’a-carbacellobiose 29 and 5’a-carbalaminarabiose 30 (Figure 6).23
 
  
20 
 
 
Figure 6 
 
1.2.2 Synthesis of pseudodisaccharides with a carbasugar attached to non-
anomeric positions 
 
For the synthesis of pseudodisaccharides where the carbasugar is attached either at the 
C-3, C-4 or C-6 hydroxyl group of the true sugar component, Ogawa’s group developed 
the use of epoxides of 5a-carbapyranoses as versatile 5a-carbahexopyranosyl donors.  
 
 
Figure 7 
 
Methyl acarviosin 31 (Figure 7) is a strong inhibitor of glycoside hydrolases.  In 1996, 
Ogawa and co-workers reported the synthesis of methyl acarviosin derivatives and 5’a-
carbamaltoses linked by amino, ether and sulfide bridges in order to study their 
biological activity.24  Amino-linked 5’a-carbamaltoses 36 were synthesised by coupling 
21 
 
5a-carbaglucopyranosylamine 32 with methyl 3,4-anhydro-α-D-galactopyranoside 33 in 
a sealed tube in 2-propanol for 6 days at 120 oC to afford products 34 and 35 in 37% 
and 36% yields, respectively.  Deprotection of 34 with methanolic sodium methoxide 
gave 36 in 88% yield (Scheme 6).24 
 
 
 
Ether-linked 5’a-carbamaltose was synthesised by coupling epoxide 37 with the 
alkoxide anion derived by treatment of methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside 
38 with NaH in DMF in the presence of 15-crown-5 ether at 70 oC to give 
carbadisaccharide 39 with the α-manno configuration in 45% yield. Compound 39 was 
acetylated and then the configuration of the C-2’ was inverted by first oxidising 40 and 
then reducing the resulting ketone with sodium borohydride to afford 41 (45%) in the α-
gluco configuration, and 39 (38%).  Hydrogenation of 41 with 10% palladium on 
charcoal afforded the target 5’a-carbadisaccharide 42 in 76% yield (Scheme 7).24 
 
22 
 
 
 
 
For the sulphide-linked 5’a-carbomaltose synthesis, epoxide 43 was coupled with 2,3,6-
tri-O-benzoyl-4-deoxy-4-thioacetyl-α-D-glucopyranoside 44 in HMPA and in the 
presence of 1,4-dithioerythritol and 2-aminoethanethiol at room temperature to afford 
trans-diaxially opened product 45 in 89% yield.  Oxidation of 45 with DMSO/acetic 
anhydride followed by reduction with sodium borohydride in methanol afforded the α-
gluco configuration 46 in 52% yield. O-Deacylation of 46 afforded the desired methyl 
carbamaltose 47 in 100% yield (Scheme 8).24 
 
23 
 
 
 
 
In the synthesis of unsaturated 5’a-carbadisaccharide 52, Ogawa’s group utilised O-
benzylidenation of 5’a-carbadisaccharide 42 with benzaldehyde dimethylacetal in DMF 
followed by acetylation to give 48.  Refluxing 48 with NBS and barium carbonate in 
carbon tetrachloride afforded 6’-bromide 49 in 52% yield.  Treatment of 49 with DBU 
in toluene afforded exo-alkene 50 in 90% yield.  Reaction of 50 with bromine in carbon 
tetrachloride followed by treatment with excess sodium benzoate in DMF at 60 oC 
afforded alkene 51 in 45% yield.  Deprotection of 51 gave the desired unsaturated 
carbadisaccharide 52 in 96% yield (Scheme 9).24 
24 
 
 
 
 
For the synthesis of sulphide-linked unsaturated pseudodisaccharide 58, 2,3,6-tri-O-
benzoyl-4-deoxy-4-thioacetyl-α-D-glucopyranoside 54 was coupled with epoxide 53 to 
afford exclusively the diaxially opened product 55 in 34% yield.  Substitution of the C-
7’ hydroxyl of 55 with chloride is achieved by treating 55 with thionyl chloride in 
pyridine to give 56 in 77% yield.  Dehydrochlorination of 56 with DBU in toluene 
afforded alkene 57 in 52% yield.  Deprotection of 57 gave the desired product 58 in 
quantitative yield (Scheme 10).24 
 
25 
 
 
 
 
Compounds 36, 42, 47, 52 and 58 were screened for inhibition of baker’s yeast α-
glucosidase (Table 1).24  Only the amino-linked derivatives showed significant 
inhibition against the enzyme.  It was concluded that amino-linked carbamaltose 
derivatives may be useful as inhibitors for glycohydrolases or glycotransferases, whilst 
ether-linked analogues were believed to be useful for the elucidation of enzymatic 
actions and as intermediates for the development of new active inhibitors.24 
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Table 1. Inhibitory activity of methyl 5a’-carbamaltoses 35, 41 and 46 and unsaturated 
derivatives 51 & 57 against baker’s yeast α-glucosidase.24 
Compound      Inhibition at 100 μg/ml (%) 
Methyl acarviosin 31     88 (0.38)a 
36       28 
42       17 
47       2 
52       0 
58       16    
a. Numbers in parentheses denote IC50 (μg/ml). 
 
To this end, Ogawa’s group reported the synthesis of ether-linked 5’a-carbadisaccharide 
derivatives 63, 65a and 65b with the α-manno configuration for the true sugar.25
25
  1,2-
Anhydro-3-O-benzyl-4,6-O-benzylidene-5a-carba-β-D-mannopyranose 59 was coupled 
with 1,6-anhydro-2,3-O-isopropylidene-β-D-mannopyranose 60 by heating with sodium 
hydride and 15-crown ether at 80 oC to afford 5’a-carbadisaccharide 61 in 52% yield.  
Compound 61 was then oxidised at the C-2’ hydroxyl with pyridinium chlorochromate 
(PCC) in DCM for 5 min or with acetic anhydride/DMSO for 7 h to afford ketone 62 in 
quantitative yield.  Reduction of 62 with sodium borohydride gave a mixture of 61 and 
epimeric alcohol 63. However, reduction of 62 with L-selectride gave exclusively 
alcohol 63 in 77% yield.  Epimerisation of 62 at C-1’ was achieved by treatment with 
potassium tert-butoxide in tert-butyl alcohol at room temperature for 2 days to afford β-
anomer 64 in 93% yield.  Reduction of 64 with sodium borohydride gave a mixture of 
alcohols 65a and 65b, which after separation and acetylation gave β-manno acetate 66a 
(42%) and the β-gluco acetate 66b (25%).  In contrast, reduction of 64 with L-selectride 
afforded preferentially the β-manno configuration 65a in 67% yield (Scheme 11).  
27 
 
 
 
 
The authors then demonstrated the versatility of these intermediates by using them for 
the synthesis of the carbasugar analogue of β-D-GlcpNAc(1→4)-D-Manp 71.  They did 
so by introducing an amine group at the C-2’ position of 67.25  Mesylate 67 was treated 
with excess sodium azide in aqueous DMF at 80 oC to afford the desired azide 68 in 
72% yield.  Hydrogenation of 68 with Raney nickel in ethanol containing acetic 
28 
 
anhydride gave amine 69 in 82% yield.  Treatment of 69 with a mixture of acetic 
anhydride/acetic acid/sulphuric acid (30:11:1) gave 70 (34%) and 71 (15%) (Scheme 
14).25 
 
 
 
Ogawa’s group have utilised similar methodologies described above for the synthesis of 
ether and amino linked 5’a-carbadisaccharides 72, 73, 74, and 80 as potent 
sialyltransferase inhibitors.24,26,27 Sialyltransferases transfer a sialic acid residue to the 
non-reducing end of the oligosaccharide chain.  Sialyltransferase inhibitors have 
attracted much attention recently28 because sialic acid glycol-conjugates are involved in 
many diseases.29
24
  The ether-linked methyl 5’a-carba-β-lactoside 72 was prepared by 
coupling 1,2-anhydro-3-O-benzylidene-5a-carba-β-D-mannopyranoside 58 with 
appropriately protected sugar acceptors,  whereas 1,2-anhydro-6-O-benzyl-3,4-O-
isopropylidene-5a-carba-α-D-galactopyranose 76 was utilised to prepare the amino 
linked methyl 5’a-carba-β-lactoside 73, methyl N-acetyl-5’a-carba-β-isolactosaminide 
74, and methyl N-acetyl-5’a-carba-β-lactosaminide 75 (Figure 8).26,27 The activities of 
compounds 72-75 as sialyltransferase inhibitors are summarised in Table 2.26   
29 
 
 
 
Figure 8 
 
Table 2 
 
Compound 
Inhibitory activity (IC50/μM) 
α-2,3-sialyl-transferase α-2,6-sialyl-transferase 
O-Linked 5a’C-β-Lac-OMe: 72 419 903 
N-Linked 5a’C-β-Lac-OMe: 73 185 533 
N-Linked 5a’C-β-IsolacNAc-OMe: 74 245 265 
N-Linked 5a’C-β-LacNAc-OMe: 75 >1mM >1mM 
 
 
Bernardi and co-workers have synthesised pseudo-1,2-mannobiosides 77, 78, and 79 
which have similar three dimensional structures and conformational behaviours to 1,2-
mannobioside 80 but are more stable to hydrolysis by jack-bean mannosidase (Figure 
9).30,31  1,2-Mannobioside 80 is recognised by the dendritic cell receptor DC-SIGN, 
which recognises HIV glycoprotein (gb120) and other pathogens and is therefore a 
potential antiviral agent.32
 
 
30 
 
 
Figure 9 
 
Diacid 81 was protected and then treated with m-chloroperoxybenzoic acid followed by 
trans-diaxial epoxide ring opening with allyl alcohol in the presence of copper triflate to 
afford 82.  Condensation of 82 with tetra-acetylmannose trichloroacetimidate 83 in the 
presence of trimethylsilyl triflate in dichloromethane at -20 oC initially afforded 
intermediate 84 (about 10 minutes), but leaving the reaction longer (about 20 min) the 
desired product 85 was obtained in 65% yield.  Deacetylation of 86 with sodium 
methoxide in methanol gave the desired pseudo-1,2-mannobioside 77 in quantitative 
yield (Scheme 13).30 
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A similar approach was adapted to prepare pseudo-1,2-mannobiosides 78 and 79 
starting from diacid 81.31 
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For the synthesis of (1→6) ether-linked 5’a-carbadisaccharides, Ogawa’s group coupled 
methyl 3-O-allyl-2,4-di-O-benzyl-α-D-mannopyranoside 86 and 36 in the presence of 
boron trifluoride to give protected 5’a-carbadisaccharide 87 in 37% yield.  Compound 
87 was converted into acetate 88 (for characterisation) and then O-deallyated using 
selenium dioxide in acetic acid/dioxane.  Hydrogenation and acetylation gave 89 in 67% 
yield.  Full deprotection of 90 using sodium methoxide afforded the desired (1→6) 
ether linked 5’a-carbadisaccharide 91 in quantitative yield (Scheme 14).33
 
  
 
 
 
Another route to the synthesis of (1→6) ether -linked 5’a-carbadisaccharides is the 
coupling of triflate derivative 91 with 92 to give protected 5’a-carbodisaccharide 93 in 
86% yield.  Desilylation and debenzylation followed by acetylation gave acetate 94 in 
79% yield. Deacetylation of 94 afforded (1→6) 5’a-carbadisaccharide 95 in 91% yield 
(Scheme 15).34
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Using similar methodologies described above, Ogawa’s group have prepared 5’a-
carbadisaccharide 9635 and 5’a-carbatrisaccharide 9736
 
 (Figure 10). 
 
Figure 10 
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1.3 Electrophilic cyclisation 
 
1.3.1 TIBAL-Induced Reductive rearrangement 
 
Sinaÿ and co-workers reported in 1997 that hex-5-enopyranoside 98 undergoes 
reductive rearrangement upon treatment with triisobutylaluminium (TIBAL) to afford 
highly functionalised cyclohexane 99 with retention of the anomeric configuration 
(Scheme 16). 37   The key step in this rearrangement is the endo cleavage of the 
glycosidic bond, leading to zwitterionic aluminium enolate intermediate A, which then 
recyclises and undergoes reduction to give the product 99.  These transformations 
complement the classical Ferrier II carbocyclisation reaction, which requires exo-
glycosidic cleavage to release the glycan.38
37
  However, in contrast to the Ferrier reaction, 
in the TIBAL-promoted rearrangement, a glycan is retained due to the initial endo-
glycosidic cleavage.  
 
 
  
 
Later, Sinaÿ and co-workers used a TIBAL-promoted rearrangement for the synthesis of 
(1→3), (1→4) and (1→6) ether-linked pseudodisaccharides.39,40   
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1.3.1.1    Synthesis of (1→3) ether-linked pseudodisaccharides through a TIBAL 
reductive rearrangement 
 
For the synthesis of (1→4) pseudodisaccharides 108a and 108b, D-maltose 100 was 
refluxed with acetic anhydride and sodium acetate to give the peracetylated product, 
followed by glycosylation with thiophenol and then deacetylation to afford exclusively 
phenyl 1-thio-β-maltoside 101 in 68% yield from 100.  Reaction of 101 with 
benzaldehyde dimethyl acetal in mildly acidic DMF selectively gave benzylidene-
protected thioglycoside 102 in 48% yield, followed by perbenzylation with benzyl 
bromide and sodium hydride in DMF to afford 103 in 55% yield (Scheme 17).39 
 
Treatment of 103 with lithium aluminium hydride and aluminium chloride in 
DCM/diethyl ether resulted in the regioselective ring opening of the benzylidene to 
afford 104 in 94% yield.  Trans-glycosylation of 104 with excess methanol promoted by 
N-chlorosuccinimide gave α-methyl maltoside 105 in 68% yield.  Iodination of 105 with 
triphenylphosphine, iodine and imidazole gave iodine substituted product 106 in 93% 
yield.  Refluxing 106 with excess DBU in THF gave the elimination product 107 in 
52% yield (Scheme 17).39 
 
Treatment of 107 with excess TIBAL at 50 oC promoted the reductive rearrangement to 
afford (1→4) ether–linked pseudodisaccharides 108a and 108b as a 2.5:1 mixture of 
diastereomers in 63% yield (Scheme 19).  This moderate diastereoselectivity is 
rationalised by the suggestion that the hydride is delivered from the less hindered β-face 
of the keto intermediate.  
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Partially debenzylated pseudodisaccharides 109a and 109b were also isolated from the 
TIBAL reaction in 26% yield.  This was the result of regioselective O-debenzylation at 
the 2-position.  When the β-anomer of hex-5’-ennomaltoside 112, derived from 110, 
underwent a TIBAL assisted rearrangement, it only afforded the corresponding 
pseudodisaccharides 114 and 115, and no debenzylated product was observed (Scheme 
18).  It was concluded that TIBAL-assisted debenzylation requires a cis 1,2-OR motif 
and that is why α-methylglycoside undergoes debenzylation whereas β-methylglycoside 
does not (for a rationale see Scheme 21).39 
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1.3.1.2   Synthesis of (1→6) ether-linked pseudodisaccharides through a TIBAL 
reductive rearrangement. 
    
Hex-5’-enoisomaltoside 118 was synthesised using iodination/elimination reactions (see 
conversion of 98 to 99) from 116.  Treatment of 118 with excess TIBAL at 50 oC gave 
(1→6) ether-linked pseudodisaccharide 120 in 11% yield as a single diastereomer at C-
5’, and 2-O-debenzylated pseudodisaccharide 121 in 48% yield. Also isolated from this 
reaction was 2-O-debenzylated hex-5’-enoisomaltoside 123 in 13% yield (Scheme 
19).39 
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Similarly, hex-5’-enoisomaltoside 119, derived from β-methyl isomaltoside 117, 
underwent a TIBAL-promoted rearrangement and afforded exclusively (1→6) ether-
linked pseudo-disaccharide 122 in 65% yield as a single diastereomer (Scheme 19).  As 
expected no debenzylated product was observed.39 
 
1.3.1.3   Synthesis of (1→3) ether-linked pseudodisaccharides through a TIBAL 
reductive rearrangement 
 
In 2000, Sinaÿ demonstrated the use of TIBAL-assisted rearrangements to synthesise 
(1→3) ether-linked 5’a-carbadisaccharide 127 from D-maltose.40  Disaccharide 124, 
derived from D-maltose, underwent a TIBAL-promoted reductive rearrangement and an 
oxidation with PCC to give 125.  Treatment of the ketone with Tebbe`s reagent yielded 
the exocylic alkene 126 in 56% yield.  Hydroboration of alkene 120 with borane-THF 
complex and subsequent oxidation with sodium hydroxide/hydrogen peroxide gave the 
desired (1→3) ether-linked 5’a-carbadisaccharide 127 in 48% yield (Scheme 20).40 
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1.3.2 Titanium(IV)-Assisted Rearrangement 
 
Sinaÿ and co-workers have also disclosed the use of a titanium(IV)-promoted 
rearrangement of hex-5’-enoisomaltoside 107 to afford 5a’-carbadisaccharide 128. 
Titanium(IV)-promoted rearrangement of hex-5’-enoisomaltoside 107 requires mild 
reaction conditions, however, it results in very low yield of the product 128 (3%) 
together with the major by-product bis-glycoside 129 (71%) and minor by-product, 
methyl 2,3,5-tri-O-benzyl-α-D-glucopyranoside 130 (7%) (Scheme 21).39,41
 
  Therefore, 
this rearrangement would not be a practical method for making pseudodisaccharides 
unless the methodology is improved significantly.  
 
 
 
It is thought that the mechanism of the reaction involves endo-cleavage of the 
interglycosidic bond followed by intermolecular carbocyclisation to give ketone 128.42  
It is proposed that endo-cleavage is reversible and the carbocyclisation step is 
disfavoured due to the steric demand of the aglycan monosaccharide.43  Alternatively 
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complex A is formed which would undergo regioselective debenzylation and forms the  
tridentate titanium(IV) complex B.  This would undergo either 5-exo-trig cyclisation to 
give the bis-glycoside 129 or exo-cleavage to give aglycon 130 (Scheme 22).39 
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1.3.3 Oxocarbenium Ion-Enol Ether Cyclisation 
 
Mootoo and co-workers have reported a convergent methodology for the synthesis of β-
carbagalactodisaccharide 131 from a central glycan component 134 and the 
corresponding monosaccharide alcohol 135. 44
44
  The key step of the synthesis is the 
formation of the carbasugar moiety via an oxocarbenium ion enol ether cyclisation.   
They envisaged that the esterification of carboxylic acid 134 with a monosaccharide 
alcohol 135, followed by Tebbe olefination of the product would result in enol ether 
133.  Activation of 133 with methyl triflate induces the carbocyclisation to form enol 
ether 132.  Hydroboration–oxidation of 132 would give β-carbagalactodisaccharide 131 
(Scheme 23). ,45
 
 
 
 
 
The central glycan component 141 is synthesised from C-branched pyranoside 137 
which is prepared from D-lyxose 136 in a four step synthesis.46   Debenzylation of 137 
using sodium in ammonia gave lactol 138.  Treatment of 138 with iodosobenzene 
diacetate afforded 1,2-O-isopropylidene acetate 139 as a mixture of stereoisomers.  
Treatment of 139 with thiophenol followed by basic hydrolysis and benzylation of the 
resulting alcohol, gave 140 as a 4:1 isomeric mixture of thioacetals in 70% overall yield 
from 139 (Scheme 24).  
43 
 
 
 
44 
 
Ozonolysis of 140, followed by the sodium chlorite oxidation of the resulting aldehyde 
yielded a mixture of acids 141.  DCC-mediated esterification of acid 141 with manno- 
and gluco-alcohol moieties 142a and 142b resulted in esters 143a and 143b in 80% 
yield in both reactions.  Tebbe olefination of esters 143a and 143b yielded enol ethers 
144a and 144b in 80% and 86% yield respectively.  Activation of 144a and 144b with 
methyl triflate in the presence of 2,6-di-tert-butyl-4-methylpyridine resulted in the 
oxocarbenium ion intermediates 145a and 145b, which after carbocylisation and 
elimination of the resulting carbocation 146a and 146b, resulted in formation of enol 
ethers 147a and 147b in 64% and 75% yield respectively.  Hydroboration of 147a and 
147b afforded protected 5’a-carbadisaccharides 148a and 148b in 72% and 78% yields, 
respectively.  Two step deprotection of 148a and 148b gave the target 5’a-
carbadisaccharides 149a and 149b in 72% overall yield in both cases (Scheme 24).44   
 
1.4 Diels-Alder cycloaddition approach 
 
In 1993, the Stoodley, Larsen et al jointly reported an attractive synthetic methodology 
for making pseudodisaccharides.  Their methodology is based on the Diels-Alder 
cycloadditon between a sugar diene, such as 151 and maleic anhydride 150 to give 
cycloadducts 152 and 153.  The subsequent functionalisation and manipulation of the 
cycloadducts (152 and 153) gave the target pseudodisaccharide 154 (Scheme 25).47
 
 
45 
 
 
 
 
Their strategy relies on the ability to chemically distinguish the two carboxylic acid 
groups of the anhydride functionality in cycloadducts 152 and 153.  This can be 
achieved either by reducing one group and decarboxylating the other, or reducing one 
group followed by decarboxylative amination at the other.  This allows the synthesis of 
pseudodisaccharides with different possible connectivities of the carbasugar moiety to 
the true ‘sugar’ unit (Scheme 26).47,48,49,50
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For example the Diels-Alder cycloaddition between 150 and 151 in benzene gave 152 
and 153 as a 6:1 mixture in favour of the endo-cycloadduct (Scheme 27).47   
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Acidic hydrolysis of the silyl enol ether of the endo-cycloadduct 152 gave the 
corresponding ketone 155.  Treatment of ketone 155 with sodium cyanoborohydride in 
acetic acid was reported to afford lactonic acid 156 in 70% yield after recrystallisation, 
as the major product (see also Scheme 30).  Conversion of compound 156 to the 
corresponding acid chloride using oxalyl chloride followed by treatment with sodium 
azide in anhydrous THF afforded acyl azide 157.  Curtius rearrangement of acyl azide 
157 proceeded with retention of stereochemistry at C-4 and afforded isocyanate 158 in 
98% yield.  A one pot isocyanate and lactone reduction, using excess lithium aluminium 
hydride, followed by acylation gave a low yield of the desired product.  Instead, 
however, selective hydrolysis of isocyanate 158 to the corresponding amine 159, by 
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treating with triethylamine in aqueous THF gave a modest but workable yield of 159 
(35%).  Treatment of 159 with lithium aluminium followed by acetylation gave the 
(1→3) acetal-linked pseudodisaccharide 160 in 82% yield.  Full deprotection of 160 
gave the target pseudodisaccharide 161 in 73% yield (Scheme 28).47 
 
For the synthesis of fully substituted (1→4) pseudodisaccharide s, Stoodley and Larsen 
first utilised allylic oxidation reaction to install a protected hydroxyl functional group at 
C-6 of the cycloadduct 152 (Scheme 29).48  Thus, treatment of 152 with lead (IV) 
acetate in boiling DCM introduced an acetoxy group at C-6 to give 162. Then, treating 
162 with dimethyldioxirane followed by acetic anhydride and catalytic amount of 
perchloric acid installed an acetoxy group at C-4.  Treatment of ketone 163 with sodium 
cyanoborohydride gave exclusively δ-lactonic acid 164.  In contrast to the formation of 
γ-lactone that was observed for 156, intermediate 164 affords δ-lactone 165.  
Decarboxylation at the C-6 of 166 gave the desired product 167 and a sulfide by-
product 168 in 60% and 5% yields, respectively.  Subsequent reduction of 167 with 
lithium aluminium hydride followed by acetylation afforded the protected (1→4) acetal- 
linked pseudodisaccharide 169 (Scheme 29). 48 
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The substituent position on the cyclohexane ring of the cycloadduct influences the 
regioselectivity of the ring opening of the anhydride, when it was treated with sodium 
cyanoborohydride. For instance, when there is no substituent at C-6 and C-4, or there is 
a substituent at C-4 but not on C-6 of the anhydride, treatment with sodium 
cyanoborohydride results in a mixture of γ-and δ-lactone acids.49  For example, 
treatment of 155 in glacial acetic acid with sodium cyanoborohydride resulted in a 83:17 
mixture of γ-and δ-lactone acids 156 and 170 respectively and treatment of 171 in 
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glacial acetic acid with sodium cyanoborohydride resulted in a 75:25 mixture of γ- and 
δ-lactone acids 172 and 173 respectively (Scheme 30).49  In contrast, when there is a 
substituent at both C-4 and C-6 as in 163, treatment with sodium cyanoborohydride 
gives exclusively δ-lactonic acid 165 as shown in Scheme 29.47 
 
 
 
 
Using the same methodologies developed previously and described above, the Stoodley 
and Larsen reported in 2001 the synthesis of (1→3) acetal -linked pseudodisaccharides 
174 and 176, starting from 171 and 175 respectively (Scheme 31).49 
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Another route to the synthesis of (1→3) acetal-linked pseudodisaccharides is the 
decarboxylation of the carboxyl group (b) of the anhydride functionality of 155, and 
reducing that of (a) to the corresponding alcohol (see Scheme 28).  The former can be 
achieved using the Barton decarboxylation reaction.50  To this end, δ-lactonic acid 156 
was treated with acid chloride followed by N-hydroxypyridinethione to yield light 
sensitive thiohydroxamic ester 177 in 92% yield.  Treatment of 177 in the presence of 
tert-butyl thiol (a hydrogen donor) with light from a tungsten filament lamp afforded the 
decarboxylated product 178 in nearly quantitative yield (99%).  Lithium aluminium 
hydride reduction of 178 followed by peracetylation gave the desired a (1→3) 
pseudodisaccharide 179 (Scheme 32).50   It is worth noting that 179 can also be 
considered as (1→1) acetal linked pseudodisaccharide depending on the numbering of 
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the carbasugar unit of the pseudodisaccharide.  A similar approach was adapted to 
prepare compound 183, starting from 180 (Scheme 32).50 
 
 
 
For the synthesis of (1→3) acetal -linked pseudodisaccharides with a hydroxyl 
substituent at C-4 (pseudodisaccharide numbering), the group have used the 
decarboxylation method developed by Barton where the radical produced from the 
decomposition of thiohydroxamic ester is trapped using oxygen.51
50
  Treatment of an 
oxygen-saturated solution of 177 with tert-butyl thiol and dimethylsulfide afforded 
alcohol 184 in 69% yield.  Lithium aluminium hydride reduction of 184 followed by 
acetyl protection gave the desired (1→3) pseudodisaccharide 185.  A similar approach 
was adapted to synthesise compound 188, starting from 186 (Scheme 33).  
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Synthesising pseudodisaccharides through a Diels-Alder cycloaddition of a sugar diene 
and maleic anhydride 150 has its drawbacks; the resulting cycloadducts 152 and 153 
have one extra carbon compared to the target pseudodisaccharide and elimination of the 
extra carbon makes the synthesis longer.  To overcome this problem, Stoodley group 
reported the use of methyl (E)-3-nitroacrylate 192 in the synthesis of 
pseudodisaccharides.52
 
   
 
 
 
Dienophile 192 was prepared from methyl acrylate 189 in a three step synthesis 
(Scheme 34).  Dienophile 192 underwent a smooth Diels-Alder cycloaddition with 
diene 151 to afford a 43:18:30:9 mixture of cycloadducts 193, 194, 195 and 196 (by 
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NMR analysis of the crude product) (Scheme 35).52  Acidic hydrolysis of these 
cycloadducts gave a 42:18:28:12 mixture of ketones 197, 198, 199 and 200.52 
 
 
 
 
The major ketone 197 was isolated and converted into the corresponding (1→3)  acetal-
linked pseudodisaccharide 203.  First, ketone 197 was treated with sodium borohydride 
in methanol at -78 oC to afford the alcohol 201 in 74% yield.  Reduction of the nitro 
group with aluminium amalgam in aqueous methanol followed by acetylation gave the 
hydroxylamine and amine derivatives 202 and 203 in 37% and 26% yield respectively.  
Treatment of the products (202 and 203) with lithium aluminium hydride in THF and 
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acetic anhydride in pyridine gave the target (1→3) acetal-linked pseudodisaccharide 
204 (Scheme 36).52 
 
 
 
 
1.5 Conclusion 
 
Research into pseudodisaccharides is an evolving and expanding area.  As we have seen 
throughout this chapter, there are now a number of different methods for the synthesis 
of pseudodisaccharides. Nevertheless, there is still a need for the development of other 
general and efficient methods, which would give easy access to different connectivity of 
a carbasugar to the “true” sugar component without relying excessively on the use of 
protecting groups. 
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Chapter Two: A New Synthesis of Pseudodisaccharides 
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2.1 Introduction & objectives 
 
In this chapter, we will demonstrate the development of a general preparation of 
pseudodisaccharides through the Diels-Alder cycloaddition between vinyl sugars and 
appropriately substituted pyran-2-ones, to give the corresponding cycloadducts, 
followed by subsequent manipulation of these cycloadducts (Scheme 37). 
 
 
 
 
Compared to the other methods (discussed in chapter 1), we envisaged that 
cycloaddition of a suitably substituted pyran-2-one to a vinylated sugar would be an 
advantageous mean of preparing pseudodisaccharides. First, the Diels-Alder 
cycloadducts of pyran-2-ones are functionally rich and are ideal springboards for the 
synthesis of a diverse range of carbasugar components of a pseudodisaccharide.  In 
addition, cycloadditions can benefit from the induction of chirality by the enantiopure 
vinyl sugar dienophile, to afford the required pseudodisaccharides as single enantiomers. 
Compared with the coupling method, for example, this approach circumvents the need 
to prepare the carbasugar unit in an enantiomerically pure form, thus saving on the 
number of chiral interventions in the synthetic route. 
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In this chapter, we will first introduce the general topic of Diels-Alder cycloaddition 
reactions.  We will then report the preparation of vinyl sugars and pyran-2-ones.  This 
will be followed by the cycloadditions of vinyl sugars and pyran-2-ones and the 
investigations into the regio- and stereoselectivity of the reactions.  Finally we will 
discuss the manipulation of the cycloadducts to afford the target pseudodisaccharides. 
 
2.2 Diels-Alder cycloaddition 
 
2.2.1 General overview 
 
The Diels-Alder (DA) cycloaddition reaction is one of the most important reactions in 
organic chemistry.  In 1906, Albrecht reported the thermal reaction between 
cyclopentadiene and p-benzoquinone.  Although it was not realised at the time, this was 
the first reported example of a [4π+2π] cycloaddition.53  Later, in 1928, Otto Diels and 
Kurt Alder disclosed the cycloaddition reactions of conjugated dienes with a number of 
alkenes.54
54
  Among the reactions they reported, was the cycloaddition reaction between 
cyclopentadiene 205 and maleic anhydride 150 to give cycloadduct 206 (Scheme 38).  
Since then, the Diels-Alder reaction has found countless applications in organic 
chemistry.  In recognition of their pioneering work, Diels and Alder were awarded the 
Nobel Prize for chemistry in 1950. 
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Cycloaddition reactions occur between a diene and a dienophile to form a cycloadduct.  
During the reaction, two new σ-bonds and a new π-bond are formed at the expense of 
the three π-bonds.  The Diels-Alder cycloaddition is formally a concerted pericyclic 
reaction. It is expected that in a DA cycloaddition, the substituent on the diene or 
dienophile would not influence the reaction.  However, in practice this is not the case.  
In particular, both the regio- and stereoselectivity of the reaction can be improved by 
matching the electronic demand of the substituents on the diene and dienophile.  This 
matching of substituents can be done in two ways; therefore the DA cycloadditions can 
be divided into two types. “Normal” electron demand DA cycloadditions are those in 
which the dienophile bears an electron deficient group and the diene bears an electron 
rich group.  In “inverse” electron demand DA cycloadditions, the dienophile bears an 
electron rich group and the diene bears an electron deficient group. It should be noted 
that the term “normal” does not necessarily imply prevalence or typicality of the 
reaction.  It is simply a consequence of those types of DA reaction being historically the 
first to be observed.  Indeed, from a frontier molecular orbital (FMO) point of view, 
both reactions carry the same validity. 
 
The outcome of a DA cycloaddition can be predicted through FMO theory.  FMO 
theory states that the reactions are encouraged when there is a favourable interaction 
between the highest occupied molecular orbital (HOMO) of one component and the 
lowest unoccupied molecular orbital (LUMO) of the other based on their energy 
separation.55
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  Energy separations in a normal electron        Energy separations in an inverse 
  demand cycloaddition.       electron demand 
 
 
In normal electron demand cycloadditions, which involve an electron rich diene and an 
electron deficient dienophile, the HOMO of the diene interacts with the LUMO of the 
dienophile because of its smaller energy gap compared with the HOMO (dienophile)-
LUMO (diene).  In inverse electron demand cycloadditions the LUMO of the diene 
interacts with the HOMO of the dienophile.  In general, an electron donating groups 
(EDG) increase the relative energy of the HOMO by promoting electron density, and an 
electron withdrawing groups (EWG) reduce the relative energy of the LUMO by 
removing the electron density.  Thus, substituting one of the components of the DA 
cycloaddition with an electron withdrawing group, and the other with an electron 
donating group (matching the electronic demands) would significantly facilitate the 
reaction (Scheme 39).   
 
2.2.2 Regioselectivity of Diels-Alder reactions 
 
The cycloaddition of unsymmetrical dienes with unsymmetrical dienophiles should 
result in two regioisomeric cycloadducts.  In practice we normally observe the 
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predominant formation of one.  This is explained by the assumption that the DA 
cycloadditions are asynchronous, which means that in the process leading to the 
formation of the transition state one bond forms faster than the other. The 
asynchronicity of the bond formation is predicted through polarity of the atoms 
involved in this “pre-bonding” arrangement.  For example, the DA cycloaddition 
between methyl acrylate 189 and 1-methoxybuta-1,3-diene 207 results in the 1,2-
substituted cycloadduct 208 as the major product.  This can be explained by the way the 
molecules arrange themselves prior to the formation of the transition state.  The major 
product is derived from the organisation of the molecules in such a way that the 
interactions of partial charges are complementary (Scheme 40).   
 
 
 
 
The asynchronicity in the DA cycloadditions can be shown computationally.  For 
example, our group has previously shown that the transition state leading to the 
formation of the 5-endo-cycloadduct from the reaction between 5-iodopyrone and 
methyl acrylate is very asynchronous (Figure 11).56
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Figure 11 
 
2.2.3 Stereoselectivity of Diels-Alder reaction  
 
DA cycloadditions are also stereoselective.  In many DA reactions the endo-product is 
the major product.  This observation is a corollary to Alder’s endo addition rule, which 
states that the two components arrange themselves in parallel planes in the transition 
state, and the most stable transition state arises from the orientation with the maximum 
accumulation of double bonds.  The formation of the two new σ bonds is a result of the 
primary interactions between the orbitals of the diene and dienophile.  However, there is 
an additional interaction between the π-orbitals of the alkene substituent that lies below 
the diene. These ‘secondary orbital interactions’ energetically contribute to the 
stabilisation of the transition state with the endo-orientation (Scheme 41). 
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Under kinetic conditions, the endo-isomer is formed at a fast rate, as its activation 
energy is lowered due to favourable secondary orbital interactions.  However, under 
thermodynamic conditions (for example prolonged reaction times, higher temperature), 
the exo-isomer may be formed.  Under these conditions the cycloaddition can become 
reversible, which means that the thermodynamically most stable product will dominate.  
Since in the majority of DA cycloadditions (and particularly in the cycloadditions of 
pyran-2-ones), the exo-isomer is sterically less congested than the endo-isomer, it would 
be the most stable and hence the favoured product under thermodynamic conditions.  
Therefore, a degree of care must be taken in the analysis of the outcome of DA 
cycloadditions, particularly those with a longer reaction time.  A good example is the 
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cycloaddition between 1-ethyl-3-methylpyridone 210 and 1-phenyl-1H-pyrrole-2,5-
dione 211, where endo-cycloadduct 212 is formed at a lower temperature rather than the 
exo-cycloadduct 213.  Furthermore, the endo-cycloadduct is converted into the exo-
cycloadduct when heated at a higher temperature (Scheme 42).57
 
  
 
  
 
2.3 Preparation of appropriate dienes and dienophiles 
 
As described in the introduction (section 2.1), we want to develop a general synthetic 
methodology towards pseudodisaccharides, through DA cycloadditions between vinyl 
sugars and pyran-2-ones as the key step (Scheme 43).  Obviously, the alkene dienophile 
component in this reaction is electron rich as the methodology dictates that it would be 
as it is substituted with an oxygen atom.  In order to maximise the efficiency and 
selectivity of the cycloaddition, the diene component must be electron deficient. 
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The electronic demand of unsubstituted pyran-2-one (214, R1 = R2 = H) has not been 
experimentally investigated in detail, because it is highly prone to polymerisation. 
However, 3- and 5- halo substituted pyran-2-ones (214, R1 or R2 = hal) are known to be 
ambident dienes, reacting with electron rich dienophiles including vinyl ethers, as well 
as electron deficient ones.56, 58
 
  Since removal of the halogen in a later step in the 
synthesis is possible, 3- and 5- halo substituted pyran-2-ones are considered as the 
synthetic equivalents of pyran-2-ones in both normal and inverse electron demand 
cycloadditions. Therefore, one approach could involve the use of 3- and 5- halo 
substituted pyran-2-ones as the diene component.  
However, 3- and 5- halo substituted pyran-2-ones are relatively unreactive in DA 
cycloadditions.  Therefore, we felt it was appropriate to also investigate the DA 
cycloadditions of pyran-2-ones substituted with highly electron deficient carbomethoxy 
and carboethoxy substituents in the 3- and 5- positions. Although this approach is more 
likely to afford efficient and selective cycloadditions, the cycloadducts would contain 
one extra carbon atom than required for carbasugar synthesis. Therefore a degradation 
reaction must be carried out at some stage in the chemical manipulation steps that 
follows the cycloaddition.  
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2.3.1 Preparation of Dienophiles (vinyl sugars) 
 
To exemplify the methodology, we decided to use three vinyl sugars. Sugar molecules 
were appropriately protected and then vinylated at three different positions: C-6 
hydroxyl, C-3 hydroxyl and the anomeric hydroxyl. 
 
2.3.1.1 Preparation of 3-vinyl glucofuranose 
 
Anhydrous D-glucose 215 was stirred in excess acetone and concentrated sulphuric acid 
to afford glucose diacetonide 216 (Scheme 44). 59
 
  Under acidic conditions, the 6-
membered pyranose ring is in equilibrium with the open chain and 5-membered ring 
furanose forms.  The furanose form reacts with acetone to give two 5-membered ring 
cyclic acetonides.  The remaining acetonide protection is installed by reaction of the C-5 
and C-6 hyrdroxyl groups of glucose.  
The C-3 hydroxyl of 216 was vinylated using a literature procedure.60  There are several 
methods to vinylate monosaccharides, including using a selenium reagent, 61  the 
Hofmann elimination of N-2-trimethylammonium-ethyl-O-glycoside,62 photochemically 
induced reactions63 and a mercury acetate mediated reaction of isobutyl vinyl ether with 
sugar molecules. 64  Other routes to vinyl sugars employ TMS-triflate promoted 
elimination reactions of mixed acetal glycosides65
60
 and palladium(II) acetate catalysed 
vinylation of monosaccharides.  
 
We have used the palladium(II) acetate catalysed vinylation method developed by 
Schlaf et al.60 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 216 was dissolved in 
excess butyl vinyl ether (BVE) 217 in the presence of 4,7-diphenyl-1,10-phenanthroline 
ligand and palladium(II) acetate in a sealed flask and was stirred at 75 oC for 7 days. 
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The crude reaction mixture was passed through activated charcoal to remove solid 
materials. After removal of the excess BVE, the crude product was purified on 
deactivated silica gel by pre-treating it with petrol/ethyl acetate/triethyl amine (92:6:12) 
as the eluent system, to afford 3-vinyl α-D-1,2:5,6-di-O-isopropylidine glucofuranose 
218 in 88% yield (Scheme 44). 
 
 
 
 
 
A mechanism for the reaction is proposed in Scheme 45. In the reaction, the 4,7-
diphenyl-1,10-phenanthroline ligand co-ordinates to the palladium(II) acetate and 
increases its coupling efficiency. The catalytic transfer vinylation is thought to proceed 
in the oxypalladation-deoxypalladation pathway in which both intra- and intermolecular 
attack of the exchanging alcohol leads to the formation of the palladium alkyl complex 
intermediate.  It can then either generate the product through the rotation of carbon-
carbon double bond followed by deoxypalladation, or go back to the starting alcohol 
(Scheme 45).60  
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2.3.1.2 Preparation of 6-vinyloxy-β-D-glucose-1,2,3,4-tetraacetate 
 
We utilised the method developed by Evans et al 66 to prepare a glucose molecule 
protected at all the hydroxyl groups except the C-6 hyroxyl.  First a mixture of 
anhydrous glucose 215 and trityl chloride in pyridine was refluxed to give the trityl 
protected C-6 hyroxyl.  The reaction proceeds with the formation of the trityl 
carbocation, which is stabilised through delocalisation of the positive charge, followed 
by nucleophilic attack by the oxygen lone pair. The selectivity of the reaction arises 
from the fact that the trityl carbocation exists in a sterically congested propeller shape to 
avoid disfavourable steric interactions (Figure 12).  Therefore the trityl cation reacts 
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with the least sterically demanding hydroxyl group which in this case is the primary C-6 
hyroxyl.   
 
Figure 12 
 
The remaining hydroxyl functions were acetylated in the same reaction pot by treatment 
with acetic anhydride in the presence of base. The two diastereomers (α and β anomers) 
were separated by triturating the crude reaction mixture with ether. The α-isomer is 
soluble in ether whereas the β-isomer is not.  The ether-insoluble residue was then 
recrystallised from hot ethanol, to afford 42% yield of the β-isomer 219 (Scheme 46).   
 
 
 
 
Finally, the C-6 hydroxyl was deprotected by treating 219 with a solution of 
hydrobromic acid in acetic acid to afford 220 in 53% yield (Scheme 48).  Once the C-6 
hydroxyl was free, it was vinylated using the method described above to afford after 
recrystallisation the 6-vinyloxy-β-D-glucose-1,2,3,4-tetraacetate 221 in (45%) yield 
after recrystallisation from petrol (Scheme 47).60 
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2.3.1.3   Preparation of anomerically pure vinyl sugar 
 
A solution of D-mannose 222 in pyridine was treated with benzoyl chloride and 
catalytic amount of DMAP and stirred overnight at room temperature to afford, after 
recrystallisation, pentabenzoate 223 as a single anomer in 72% yield.67
60
  Compound 223 
was selectively deprotected without loss of anomeric purity using ethanolamine to 
afford tetrabenzoate 224 in 50% yield.  The anomeric purity of 224 was established by 
proton and carbon-13 NMR.  The anomeric hydroxyl was subsequently vinylated using 
the methodology described above to afford the corresponding vinyl sugar 225 (Scheme 
48).   
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2.3.2 Synthesis of pyran-2-one 
 
Four 2(H)-pyran-2-one derivatives were chosen as the diene component for the Diels-
Alder cycloaddition with vinyl sugars. One of those chosen was the commercially 
available 3-carbomethoxy-2(H)-pyran-2-one 226. The other three dienes were ethyl 
coumalate 227, 3-bromo-2(H)-pyran-one 228 and 5-bromo-2(H)-pyran-one 229 (Figure 
13).  All the three dienes were prepared from literature procedures.68,69
 
 
 
Figure 13 
 
2.3.2.1 Preparation of ethyl coumalate  
 
A solution of coumalic acid 230 in DCM was treated with 4-dimethylamine pyridine 
(DMAP), dicyclohexylcarbodiimide (DCC) and ethanol, and was stirred for 17 h.69  
After work-up and chromatographic purification the desired ethyl coumalate 227 was 
obtained in 75% yield (Scheme 49).                                              
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2.3.2.2 Preparation of bromo-2(H)-pyran-2-one  
 
3-Bromo-2(H)-pyran-2-one 228 and 5-bromo-2(H)-pyran-2-one 229 were obtained 
from the commercially available 5,6-2dihydro-2(H)-pyran-2-one 231 in the following 
sequence of reactions (Scheme 50).68  First, 5,6-dihydro-2(H)-pyran-2-one 231 in DCM 
was treated with bromine and stirred at room temperature for 8 hours. Then the reaction 
mixture was treated with Et3N and stirred at room temperature for a further 15 h to 
afford 232 in 91% yield.  Then 232 was subjected to radical bromination by treating it 
with NBS 234 and benzoyl peroxide 235 and heating the reaction mixture at 100 oC for 
4 hours to afford 3,5-dibromo-5,6-dihydro-2(H)-pyran-2-one 233 in 67% yield. 
 
 
 
The initiation step involves the breakdown of benzoyl peroxide 235 to form radical 236 
on heating.  Radical 236 reacts with 231 to generate radical 237 and benzoic acid 238.  
The propagation step involves the reaction of N-bromosuccinimide 234 with 237 to 
form 3,5-dibromo-5,6-dihydro-2(H)-pyran-2-one 233 and succinimide radical 239 
(Scheme 51).  The termination step involves all radicals reacting with each other.  
Treatment of 3,5-dibromo-5,6-dihydro-2(H)-pyran-2-one 233 with Et3N results in the 
formation of 3-bromo-2(H)-pyran-2-one 228 as a major product (33%) and 5-bromo-
2(H)-pyran-2-one 229 as a minor one (7%). 
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Initiation: 
 
 
 
Propagation: 
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5-Bromo-2(H)-pyran-2-one 229 can be prepared more efficiently in one step directly 
from 5,6-dihyro-2(H)-pyran-2-one 231 (Scheme 52).  The yield of the reaction was low 
(22%) due to the formation of 3,5-bromo-2(H)-pyran-2-one 241 as a major by-product 
(Scheme 53).70
 
 
. 
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2.4 Diels-Alder Cycloaddition between vinyl sugars and pyran-2-ones 
 
2.4.1 Reaction conditions and selectivities 
 
Once the vinyl sugars and pyran-2-ones were in hand, we investigated their Diels-Alder 
cycloadditions.  Cycloadditions of vinyl sugars with pyran-2-ones were carried out in a 
sealed tube in dichloromethane over a temperature range of 45-100 ºC for 5-7 days. 
Typically, two equivalents of the dienophile were used, although the quantity of the 
dienophile was increased for very slow reactions (Scheme 54).  Outcome of the 
reactions were determined by analysis of the 1H-NMR spectra of the crude reaction 
mixtures (see section 2.4.2). The results of the cycloadditions between vinyl sugars and 
pyran-2-ones are summarised in Table 3.  
 
 
 
 
Since the dienophiles (vinyl sugars) are single enantiomers, the cycloadditions can 
afford 4 possible products. There will be one pair of 5-endo cycloadducts depending on 
which face of the dienophile is presented to the diene. There could also be a pair of exo-
cycloadducts. The four cycloadducts are obtained as single enantiomers, however the 
76 
 
relationship between them is diastereomeric.  For the purposes of this thesis, in order to 
distinguish the diastereofacial stereoisomers from endo and exo isomers, the 
cycloadducts are labelled endo-1 and endo-2, and exo-1 and exo-2. Of course, 
depending on the stereoselectivity of the reaction, not all four possible cycloadducts 
may be actually formed. 
 
 
    Table 3 
a. There were traces of exo product in the reaction mixture but it was not 
possible to measure its abundance. 
 
For example, the cycloaddition of 3-vinyl glucofuranose 218 with 3-carbomethoxy-
2(H)-pyran-2-one 226 was carried out in a sealed tube in dichloromethane at 65 ºC over 
7 days using 2 equivalents of the dienophile (Scheme 55).  Analysis of the crude 
reaction mixture by NMR revealed it to contain a mixture of three cycloadducts in the 
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ratio of 3.4 246a : 2.0 246b : 0.1 246c/d as well as a small quantity of unreacted pyrone 
226.  Following chromatographic separation on silica gel, the endo-configuration for 
cycloadducts 246a and 246b, were established by analysis of the coupling constants in 
the 600 MHz 1H NMR (see later section 2.4.2).71,72
 
  Similarly, the exo-configuration for 
the cycloadducts 246c/d, a mixture of two diastereomers which could not be separated 
by chromatography, was established. 
 
 
 
The absolute configuration of the minor endo-cycloadduct 246b was established 
unequivocally by X-ray crystallography as (1R, 5S) (Figure 14).  The major endo- 
cycloadduct 246a was an oil; however, as can be seen later, the absolute configuration 
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of this isomer was established retrospectively as (1S, 5R) based on X-ray 
crystallography on a derivative (see Figure 19).  
 
 
 
Figure 14: X-ray structure of cycloadduct 246b 
 
To rationalize this modest diastereofacial selectivity, we can assume that the approach 
of the pyrone diene 226 to the vinyl ether 218 is controlled by the steric bulk of the 
sugar’s 5’,6’-O-isopropylidene substituent, rather than the 1’,2’-O-isopropylidene 
substituent.  This is presumably because the former can exert more steric hindrance due 
to possible rotation about C4’-C5’ bond (Figure 15). 
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Figure 15 
 
On the other hand Diels-Alder cycloaddition between 3-vinyl glucofuranose 218 and 
ethyl coumalate 227 afforded 4 cycloadducts (2 endo and 2 exo).  Although we could 
separate the endo- and the exo-isomers from one another, it was not possible to separate 
the diastereofacial diastereomeric pairs, affording a mixture of endo-1 & 2 and a 
mixture of exo-1 & 2 (Scheme 56). 
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The cycloaddition of 6-vinyloxy-β-D-glucose-1,2,3,4-tetraacetate 221 with all four 
pyran-2-ones is stereoselective and only affords the endo-cycloadducts (Table 3).  
However, the cycloaddition lacks diastereofacial selectivity and affords a mixture of 1:1 
endo-1/endo-2 which could not be separated by chromatographic means.  This lack of 
diastereofacial selectivity may be explained by the observation that the reaction centres 
are too far away from the chiral centres of the sugar component.   
 
On the other hand the cycloaddition between O-benzoyl-α-D-mannopyranose 225 and 3-
carbomethoxy-2(H)-pyran-2-one 226 does afford both endo- and exo-cycloadduct.  
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Generally speaking, 5-bromo-2(H)-pyran-2-ones 228 and 3-bromo-2(H)-pyran-2-ones 
229 were not as reactive towards vinyl sugars as 3-carbomethoxy-2(H)-pyran-2-one 226 
and ethyl coumalate 227 and 10 to 20 equivalents of the dienophile was needed for the 
reactions to occur.  However, no cycloaddition reaction was observed between 225 and 
3-bromo or 5-bromo-2(H)-pyran-2-ones even using 20 equivalents of the dienophile, 
higher temperature (>100 oC) and longer reaction time (i.e >10 days). 
 
2.4.2 Determination of the cycloadduct structure 
 
As was discussed in the previous section, ratios of the isomers were determined from 
the analysis of the 1H-NMR of the crude reaction mixtures. In this section, we provide 
the rationale for these assignments. 
 
Through previous studies of the Diels-Alder cycloaddition of pyran-2-ones, our group 
and others71,72,73
 
 have developed a set of empirical rules for the determination of the 
endo- and exo-configuration of the cycloadducts.  These rules involve the comparison of 
both the chemical shifts and the coupling constants of the protons in the bicyclic lactone 
structure.  
The rules are most reliable if both the endo- and exo-isomers are at hand so that a direct 
comparison of the chemical shifts and the coupling constants can be made.  However, 
even if only one of the cycloadducts is present, the empirical rules can fairly reliably 
predict its endo- or exo-configuration. Indeed, through the extensive experience in our 
group of the pyran-2-one cycloadditions, there have only been a handful of cases, where 
it has not been possible to assign the configuration of the cycloadducts. 
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Figure 16 
 
The empirical rules are derived from two observations about the chemical shifts and 
coupling constant in the bicyclic lactone cycloadducts: The first is that the protons in 
the endo-position of the saturated bridge in 2-oxabicyclo[2.2.2]oct-7-en-3-one (protons 
H-5endo and H-6endo) are influenced by the magnetic anisotropy of the C7-C8 double 
bond and therefore resonate at lower frequency than would be expected from their 
connectivity to various atoms and groups. In contrast, protons H-5exo and H-6exo are not 
influenced by the magnetic anisotropy of the C7-C8 double bond and therefore, resonate 
at the chemical shift expected from their connectivity to various atoms or groups. 
 
The second observation is that the coupling constants of the protons at the bridgeheads 
to the protons at the endo-position are usually smaller than those of the protons in the 
exo-position (Figure 16). This is presumably a consequence of the shorted C-O bond in 
the bridging ester and the boat conformation of the ring. This results in an increase in 
the dihedral angle between CH-5endo and CH-6endo with their respective bridgehead CHs 
whilst causing a reduction in the dihedral angle between CH-5exo and CH-6exo with their 
respective bridgehead CHs (Figure 17).  Based on these two observations, we can use 
the following protocol to identify the endo- and exo-isomers. 
 
83 
 
 
 Figure 17: definition of dihedral angle α 
 
There are two possible scenarios.  The first one is when there is no substituent at C-4 of 
the cycloadduct (e.g. a cycloadduct from the reaction of a 5-substituted pyran-2-one) 
and the second one is when there is a substituent at C-4 (e.g. a cycloadduct from the 
reaction of a 3-substituted pyran-2-one) (Figure 18).  In the first case, we look at the 
coupling between H-4 and H-5.  If J4,5 is larger than 2.0-2.5 Hz, then H-5 is in the exo-
face and our cycloadduct is endo.  If J4,5 is smaller than 2.0-2.5 Hz, then H-5 is in the 
endo-face and our cycloadduct is exo.  If both cycloadducts were isolated, then their 
configuration can also be confirmed by the analysis of their chemical shifts.  H-5 in the 
exo cycloadduct has a lower chemical shift than the H-5 in the endo-cycloadduct. 
 
 
Figure 18 
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On the other hand when there is a substituent at C-4, we use a more involved analysis. 
We can first identify the signals for H-1 and the two H-6s. The signal due to H-1 
appears as a multiplet at about 5 to 5.5 ppm. For most cycloadducts there are no other 
major signals in this region and H-1 signal can be easily identified. The signals due to 
the two H-6s are also easily identifiable. They are the only two signals in the 1.5 to 3 
ppm region that have a large gem coupling of about 12-14 Hz.  
 
We then use the coupling between H-1 and each of the H-6’s to distinguish H-6exo from 
H-6endo.  If one of the H-6s has a J1,6 coupling which is larger than 2.0-2.5 Hz, then that 
proton is in fact H-6exo. If one of the H-6s has a J1,6 which is smaller than 2.0-2.5 Hz, 
then that proton is in fact H-6endo.  In addition, H-6endo is also expected to have a lower 
chemical shift than H-6exo. 
 
Once we have identified which signal is H-6endo and which is H-6exo, we use the size of 
their coupling to H-5 to determine H-5s configuration. If H-5 couples to H-6endo by a 
value about 8-10 Hz and to H-6exo by a value about 4-7 Hz, then H-5 and H-6endo are syn 
to each other and H-5 is also in the endo-face, and we have the exo-cycloadduct.  
However, if H-5 couples to H-6exo by a value about 8-10 Hz and to H-6endo by a value 
about 4-7 Hz, then H-5 and H6exo are syn to each other and H-5 is also in the exo-face 
and we have the endo-cycloadduct. 
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2.5 Chemical manipulation of the cycloadducts  
 
 
 
 
 
Once the cycloadducts were in hand, their conversion to the corresponding 
pseudodisaccharides was investigated.  In order to demonstrate the applicability of the 
methodology, we decided to carry out chemical manipulation of cycloadduct 246a to 
gain access to the (3→4) linked pseudodisaccharide 255 (Scheme 57).   
 
However, cycloadducts 246a and 246b contain 8 carbon atoms instead of 7 carbon 
atoms in their corresponding carbasugar unit of the pseudodisaccharide; therefore it was 
necessary to carry out a degradation reaction to eliminate the extra carbon atom.  This 
could be achieved by deallylation followed by decarboxylation of the ring opened 
cycloadduct using palladium (II) acetate.74
 
  Therefore, we first set out to demonstrate 
the applicability of the deallylation/decarboxylation step in these systems. 
Cycloadduct 246a was treated with lithium allyl oxide, prepared from freshly distilled 
allyl alcohol and butyl lithium, resulting in trans-esterification to afford diester 256 in 
81% yield.  The mechanism of this reaction involves nucleophilic attack of the alkoxide 
anion onto the ester carbonyl which results in the ring opening of the lactone molecule 
86 
 
and subsequent protonation of the resulting alkoxide ion after acidic workup (Scheme 
58).  
 
 
 
The one pot deallylation/decarboxylation of 256 was attempted by heating 256 at 100 
oC with palladium(II) acetate, triphenylphosphine, formic acid and triethylamine in a 
sealed tube for 18 h to afford unsaturated ester 261 as a crystalline compound in 63% 
yield (Scheme 59).  
 
 
 
 
In this reaction, palladium metal coordinates the allyl group in diester 256 causing 
deallylation of 256 to generate carboxylate 258 and palladium complex 257.  This is 
followed by decarboxylation of 258 to give 259.  Then acidic work up of 259 resulted 
the desired ester 260 and allyl formate 261 as well as regenerating the palladium (II) 
acetate catalyst 262 (Scheme 60). 
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At this stage, the structure of compound 260 was confirmed  by X-ray crystallography 
(Figure 19).  Since, compound 255 had originated from major endo-cycloadduct 246a , 
it was now possible to confirm the absolute configuration of 246a as (1S, 5R).  
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Figure 19: X-ray structure of compound 260 
 
Treatment of 260 in toluene with excess DIBAL-H at -78 oC then afforded allylic 
alcohol 263 in 88% yield (Scheme 61).  Normally treatment of an ester group with 
DIBAL-H at low temperature furnishes the corresponding aldehyde.  But, using excess 
DIBAL-H and a longer reaction time, as in this case, affords the corresponding 
alcohol.74 
 
 
 
 
Finally, we undertook the stepwise deprotection of the two acetonides in 263, leading to 
the formation of 264 initially and then to the fully deprotected pseudodisaccharide 255.  
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Treatment of 263 with 90% acetic acid at room temperature for 18 h resulted in the 
removal of 5’,6’-O-isopropylidene substituent of the sugar to give 264 in 90% isolated 
yield (Scheme 62).  However, leaving the reaction for longer failed to remove the 1’,2’-
O-isopropylidene.   
 
 
 
 
It is known that the 5’,6’-O-isopropylidene substituent is easily removed than the 1’,2’-
O-isopropylidene substituent.75 This is generally attributed to entropic factors since in 
the former there is rotation about C4’-C5’ bond at the oxonium intermediate stage 
(Scheme 63).   
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The removal of 1’,2’-O-isopropylidene substituent was achieved by treating 264 with 
50% aqueous TFA at 0 oC for 30 minutes and then elevating the temperature to room 
temperature for another 30 min. This afforded 255 in 80% yield as a mixture of anomers 
(Scheme 64).  
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Using the same methodology, pseudodisaccharide 268 was prepared starting from the 
minor endo-cycloadduct 246b (Scheme 65). 
 
 
 
 
We next attempted to dihydroxylate 246a at the C7-C8 double bond by treating 246a in 
acetone/water with osmium tetraoxide and 4-methylmorpholine N-oxide and stirred for 
24 h.  The reaction was quenched by addition of reducing agent aqueous sodium 
bisulfite followed by extraction (Scheme 66).  The crude product was obtained as a 
crystalline compound.  1H and 13C NMR on this material confirmed the disappearance 
of the signals due to the C7-C8 double bond and the likely introduction of new 
substituents at (now saturated) C7 and C8.  However, mass spectrometry failed to give 
the expected molecular ion and was inconclusive as to whether hydroxyl functions were 
present in the molecule.  We tried to protect the dihydroxyl groups with acetonide group 
and the starting material decomposed.  We also attempted to ring open the cycloadduct 
92 
 
and the starting material also decomposed.  Also the compound in hand was very 
unstable and decomposed if it was left to stand in solution at room temperature.  
Therefore, we could not unequivocally assign the structure 269 to this compound. 
 
 
 
 
2.6 Cycloaddition-cycloreversion reactions of Pyran-2-one 
 
We saw in the previous section that 2(H)-pyran-2-ones undergo cycloadditions with 
vinyl sugars to initially afford functionally rich, bridged bicyclic lactone cycloadducts. 
We also demonstrated that the cycloadducts are useful springboards for the synthesis of 
pseudodisaccharides.   
 
During our investigation of the Diels-Alder cycloaddition of 2(H)-pyran-2-ones with a 
vinylated sugar, we noticed a significant role played by the temperature of the reaction.  
For example, when the 3-vinyl glucofuranose 218 and 3-carbomethoxy-2(H)-pyran-2-
one 226 were heated at 65 °C in a sealed tube for 7 days, it afforded cycloducts 246a, 
246b and 246c/d as discussed earlier.  However, upon increasing the temperature to 80 
oC, significant quantities of a second product, as a mixture of diastereomers 270a and 
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270b, was also obtained.  At 100 °C, the reaction quickly and efficiently afforded 
compounds 270a and 270b (Scheme 67). 
 
 
 
 
2(H)-Pyran-2-ones, such as 226, enjoy aromatic resonance stabilisation (Figure 20).76  
This aromatic stabilisation, estimated to be about 35-40 kJ/mol, contributes to the 
activation energy for the cycloadditions of 2(H)-pyran-2-ones.  If forcing conditions are 
used in the cycloaddition reactions, cycloadducts may undergo two possible further 
reactions.  One is the reversion to the starting 2(H)-pyran-2-one. This pathway results in 
a regain of aromatic resonance stabilisation energy and has been generally accepted that 
it is the favoured fate of the pyran-2-one cycloadducts at higher temperature. If this was 
the case, the cycloaddition becomes reversible. As discussed in section (2.2.3), under 
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reversible conditions, thermodynamically more stable exo-cycloadducts predominate. 
Indeed, the formation of exo-cycloadducts in pyran-2-one cycloadditions can be 
attributed mainly to this pathway as was shown by Susherina (Scheme 42).57  The other 
pathway is the loss of bridging carbon dioxide in a retro Diels-Alder reaction.  This 
affords the corresponding cyclohexadienes which are considered very reactive and 
either aromatize to afford benzenes,71,77,78 or undergo cycloaddition with any excess 
dienophile present in the reaction mixture79
 
 (Scheme 68).  This is in fact also a common 
reaction pathway and has been a very useful method for the synthesis of benzenes, 
although the methodology has not found significant application in the synthesis of non-
aromatic six-membered rings, presumably due to the difficulty in controlling the 
synthesis of highly reactive cyclohexadiene intermediate.  
 
Figure 20 
 
 
 
 
Therefore after careful review of the spectroscopic data of compounds 270a and 270b, it 
was much unexpected when they were revealed to be indeed cyclohexadienes obtained 
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from the loss of bridging carbon dioxide.  The structure of compound 270a was 
subsequently confirmed by X-ray crystallography (Figure 21).  This represents the first 
ever example of a crystal structure of a cyclohexadiene from a retrocycloaddition origin.  
Compound 270a appears to be exceptionally stable.  It withstands temperatures of up to 
120 °C, is air stable over a period of months and could be isolated after chromatography 
in multi-gram quantities. 
 
 
Figure 21: X-ray structure of compound 270a 
 
Interestingly, we also observed similar results in the cycloaddition between 6-vinyloxy-
β-D-glucose-1,2,3,4-tetraacetate 221 and 3-carbomethoxy-2(H)-pyran-2-one 226.  
Heating the reaction mixture at 45 oC for 6 days afforded the endo-cycloadducts 245a,b.  
Increasing the temperature to 60 oC afforded a mixture of cycloadducts 250a,b and 
cyclohexadienes 271a,b in 1.2:1 ratio respectively (Scheme 69).  The cyclohexadiene 
271a,b was isolated as a mixture diastereomers.  
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However, we observed that the cycloaddition between ethyl coumalate 227 and 3-vinyl 
glucofuranose 218 at elevated temperature afforded only a small amount of a 
decarboxylated products also as a mixture of two diastereomers 272a,b (Scheme 70).  In 
contrast, the loss of carbon dioxide was not observed in any of the cycloadditions of 
bromopyran-2-ones.  
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Loss of bridging carbon dioxide has been previously reported by a number of groups.80 
For example, Marko et al81
 
 have reported that heating cycloadduct 273 in toluene at 110 
oC overnight causes the loss of bridging carbon dioxide to afford cyclohexadiene 274 
(Scheme 71).   
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The unusual reaction pathway, favouring loss of bridging carbon dioxide rather than 
cycloreversion back to the starting pyran-2-one, prompted us to investigate the reaction 
further.  
 
As discussed earlier, cyclohexadiene 270a and 270a were obtained as a diastereomeric 
mixture. Although cyclohexadiene 270b is an oil, 270a is crystalline and we were able 
to obtain a X-ray crystal structure of this compound to confirm its proposed structure 
and absolute configuration (Figure 19).  The relative configuration of 270a suggests that 
it is derived from the major cycloadduct 246a.  Nevertheless, we confirmed that 270a is 
derived from the major cycloadduct 246a, previously determined as (1S,5R), and 
compound 270b is derived from the minor cycloadduct 246b, previously determined as 
(1R, 5S), by heating each of the cycloadducts independently at 100 oC in sealed tubes 
for 7 days (Scheme 72).  Reformation of the exo-product was not observed during 
conversion of either 246a or 246b. 
  
However, during the loss of bridging carbon dioxide, the information regarding the 
stereochemistry of the C-1 of the cycloadduct is also lost.  This means that 270a can not 
only have originated from the endo 246a, but also exo 246d.  Similarly, 270b can not 
only have originated from the endo 246b, but also exo 246c.  Since the ratio of 
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246a:246b at 65 oC is 1.7:1 whilst the ratio of 270a: 270b is 2.6:1 we cannot rule out 
that some conversion of the endo-cycloadducts to the exo-cycloadduct could have taken 
place prior to the loss of the bridging carbon dioxide. 
 
 
 
 
One of the unexpected observations that we made was that cycloadducts of 218 with 
ethyl coumalate 227 appeared to be less prone to the loss of bridging carbon dioxide 
than those of 218 with 3-carbomethoxy-2(H)-pyran-2-one 226.  To ensure this 
difference was not driven by the steric bulk of the glucofuranose 218, we also 
investigated the rates of decarboxylation of the cycloadducts from 3-carbomethoxy-
2(H)-pyran-2-one 226 and ethyl coumalate 227 with butyl vinyl ether (BVE) 217 
(Scheme 73).  In the first instance, the reactions of 226 and 227 with 217 were carried 
out in a sealed tube at 100 oC and the progress of the reactions was monitored by NMR 
100 
 
at different time intervals.  After 24 h, the reaction between 227 and BVE 217 was 
complete and only cycloadduct 275 was present in the reaction mixture.  On the other 
hand, after 24 h in the reaction between 226 and BVE 217, there was a mixture of 
cycloadduct 277 and decarboxylated product 278 in 1:1 ratio.  After 48 h, there was still 
no decarboxylated product 276 in the reaction of 227 and BVE 217.  All the 
cycloadduct 277 has converted into the decarboxylated product 278 after 48 h in the 
reaction mixture of the cycloaddition between 226 and BVE 217.   We concluded that 
the decarboxylation reaction happens faster when the carboxyl substituent on the pyran-
2-one is in the 3-position. 
 
 
 
 
To gain a better understanding of the variation in the rate of the cycloaddition and those 
for the loss of carbon dioxide from the cycloadducts, we decided to experimentally and 
computationally investigate the reaction. As a preamble to these investigations, we 
isolated and characterised the endo-cycloadducts 275 and 277 in pure form after 
conducting the reaction at lower temperatures. We first investigated the rates of 
cycloadditions for both 3-carbomethoxy-2(H)-pyran-2-one 226 and ethyl coumalate 227 
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with BVE 217 at three different temperatures.  The temperatures were carefully chosen 
so that no decarboxylation could occur. For the cycloadditions of 3-carbomethoxy-2(H)-
pyran-2-one 226 with BVE 217 and the cycloadditions of ethyl coumalate 227 with 
BVE 217 we chose 45, 60 and 75 °C.  The proportion of cycloadduct in each reaction 
was determined from an analysis of the proton NMR and the rate of the conversion was 
determined at each temperature. Using the Arrhenius equation, the enthalpy of 
activation for the cycloadditions were determined (see Appendix I). 
 
The rates of the loss of bridging carbon dioxide from each of the cycloadducts were 
investigated at three different temperatures.  For cycloadduct 277, 80, 98 and 115 °C 
were chosen.  The proportion of cyclohexadiene 278 to cycloadduct 277 was 
determined from the analysis of the proton NMR and the rate of the conversion was 
determined at each temperature.  Using the Arrhenius equation, the activation energy for 
the loss of carbon dioxide was determined (see Appendix I).  For cycloadduct 275, 
temperature range of 130, 145 and 160°C were chosen.  The proportion of 
cyclohexadiene 276 to cycloadduct 275 was determined from the analysis of the proton 
NMR and the rate of the conversion was determined at each temperature.  Using the 
Arrhenius equation, the enthalpy of activation for the loss of carbon dioxide was then 
determined (see Appendix I).  The results of these investigations are shown in (Table 4). 
 
Simultaneously, a computational investigation of the energies of both the transition 
states (TS≠) for the cycloadditions and loss of carbon dioxide in the reactions of 226 and 
227 was carried out.  Calculations were performed using Gaussian09.82  All transition 
structures were initially optimized with AM1, 83  then reoptimized using B3LYP/6-
31G*.84  This DFT method (model chemistry) has been previously shown by us to be a 
reliable method for predicting the regio- and stereoselectivity of the cycloadditions of 4-
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chloro-2(H)-pyran-2-ones.56 Frequency calculations were then carried out with 
B3LYP/6-31G(d) and each transition structure was shown to have only one imaginary 
frequency. Barrier heights were then computed. Constrained optimizations along the 
route of steepest gradient (IRCs) were then carried out in order to prove that the 
transition states found connected the minima of interest. The results of these 
investigations are also shown below (Figure 22 and Table 4). 
 
Table 4  
 Energy (calculated)* ΔEA(experimental) 
cycloaddition of 3-carbomethoxypyran-2-one 
and BVE 
19.1 (1.7) Kcalmol-1 8.4 (2.0) Kcalmol-1 
cycloaddition of ethyl coumalate and BVE 17.4 (0.0) Kcalmol-1 6.4 (0.0) Kcalmol-1 
loss of CO2 from the cycloadduct of 3-
carbamethoxypyran-2one and BVE 
25.9 (0.0) Kcalmol-1 21.5 (0.0) Kcalmol-1 
loss of CO2 from the cycloadduct of ethyl 
coumalate and BVE 
28.7 (2.8) Kcalmol-1 26.3 (4.8) Kcalmol-1 
*At 273K (sum of electronic energy and thermal energy) 
 
 
As can be seen from Table 4, there is a correlation between the experimental and the 
calculated values. According to calculations, cycloaddition of 3-carbomethoxypyran-2-
one and BVE has a 1.7 Kcal/mol higher energy barrier than that for ethyl coumalate and 
BVE. The energy difference was experimentally measured as 2.0 Kcal/mol. Similarly, 
the energy barrier for the loss of carbon dioxide from the cycloadduct of 3-3-
carbomethoxy-2(H)-pyran-2-one and BVE is calculated to be 2.8 Kcal/mol lower than 
that for the cycloadduct of ethyl coumalate and BVE whilst the activation energy 
difference is experimentally measured as 4.8 Kcal/mol. Furthermore, both 
computational and experimental results show that ethyl coumalate 227 is more reactive 
towards cycloadditions than 3-carbomethoxy-2(H)-pyran-2-one 226; and that the 
cycloadducts derived from the former are less susceptible to the loss of carbon dioxide 
than the latter.  
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Figure 22 
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2.6.1 Chemical Manipulation of Cyclohexadiene derivative 
 
Until now, the loss of the bridging carbon dioxide from the cycloadducts, although apt 
for the synthesis of aromatics, had been considered highly disadvantageous for the 
synthesis of non-aromatic carbocycles, including carbasugars.  It clearly removes 
stereochemical information from the cycloadduct and affords supposedly an unstable 
cyclohexadiene, which may undergo further reactions. However, the exceptional 
stability of compound 270a prompted investigatations into whether this cyclohexadiene 
can also be manipulated to form a carbasugar. 
 
Although considerable steric information is lost during the retro DA cycloaddition, one 
clear advantage of using compound 270a is that there would be no need to carry out a 
decarboxylation step in the synthesis.  At the same time, it was hoped that chirality of 
the pendant sugar moiety would allow re-introduction of the lost stereochemical 
features into the molecule. 
 
 
 
 
Therefore, once the identity of compound 270a was established, the next step was to 
carry out its conversion to the corresponding pseudodisaccharide 279 (Scheme 74).  
There were two options: either epoxidation of the C-1/C-2 double bond functionality 
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and further manipulation of the product, or dihydroxylation of the C-1/C-2 double bond 
functionality. 
 
Treatment of cyclohexadiene 270a in DCM/water (3:1 ratio) with mCPBA afforded a 
mixture of epoxides 280a and 2806b in a ratio of (2.7:1).  Epoxide 280a was isolated in 
63% yield whereas 280b was isolated in 24% yield (Scheme 75).85
 
   
 
 
 
The absolute configuration of the major stereoisomer 280a was confirmed by X-ray 
crystallography (Figure 23).  Presumably, this diastereoselectivity suggests that 
epoxidation is significantly controlled by intermolecular H-bonding between the peracid 
and an oxygen atom in one of the many ether linkages contained in the sugar moiety 
(Figure 24).  
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Figure 23: x-ray structure of epoxide 280a 
 
 
Figure 24 
 
Treatment of epoxide 280a in (DME/ethanol/water, 2:1:1 ratio) with sodium azide and 
ammonium chloride at room temperature for 24 hours resulted in regioselective epoxide 
opening to afford azide 281 in 85% yield (Scheme 76 ).86
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Similarly, treatment of minor epoxide 280b with sodium azide under similar conditions 
afforded the corresponding azide 282 in 79% yield (Scheme 77).  Raising the 
temperature of the reaction to 45 oC improved the reaction yield to 89%.  
 
 
 
 
The remaining steps involve reduction of the azide and the α,β-unsaturated ester and 
removal of the acetonide protecting groups.  It was first attempted to convert  azide 281 
to the corresponding amine.  It was decided to initially investigate selective reduction of 
the azide using triphenylphosphine and water.87
 
  (For a mechanism see Scheme 81).  
Thus, a solution of azide 281 in DCM was treated with triphenylphosphine and stirred at 
room temperature for 6 hours before the reaction was quenched with water.  However, 
no desired product was detected.  The reaction was repeated at reflux but still no 
product was detected after quenching with water.  Finally, azide 281 was dissolved in 
THF/water (10:0.1 ratio) and refluxed for 5 hours and again no reaction was observed.   
 
It was concluded that the lack of reactivity of 281 toward triphenylphosphine may be a 
result of a facile elimination of azide under the reaction condition. Therefore, it was 
decided to protect the hydroxyl group at C-2 of the cyclohexene/carbasugar ring.   
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Treatment of azide 281 in DCM with imidazole and TBDMSCl afforded the 
corresponding silylether 283 in 79% yield (Scheme 78).   
 
 
 
 
Interestingly, the formation of the silylether led to some significant changes in coupling 
constants in the 1H NMR spectrum (Table 5).  These changes were attributed to a 
comformational change in the cyclohexene ring prompted by the bulky tert-
butyldimethylsilyl group (Scheme 79).  
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Table 5 
Compound:    J4,3ax  J4,3aq  J3eq,3ax  J2,3ax  J2,3eq J1,2 
     281 1.55  3.50  15.46  3.44  2.50       -
    
     283         3.50   9.23  12.72  3.78  12.2      8.25
     
 
 
 
 
 
Refluxing silylether azide 283 in THF/water (10:0.1 ratio) and triphenylphospine 285 
for 5 hours indeed afforded corresponding amine 284 in very good yield (90%) (Scheme 
80). In this reaction the azide reacts with triphenylphosphine 285 to generate 
phosphazide 286, which will lose nitrogen to form iminophosphorane 287.  Then the 
reaction of water with iminophosphorane 287 gives the corresponding amine 284 and 
triphenylphosphine oxide 288 (Scheme 81).    
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Conversion of the ester in 284 to the corresponding allyl alcohol was attempted by 
treating 284 in dry toluene with DIBAL-H with stirring at -78 oC for 5 hours.  TLC 
analysis showed that the starting material was consumed, however no desired product 
could be isolated.  It is thought that the ester group was first reduced to the 
corresponding aldehyde 289, which consequently reacted with the amine functional 
group causing polymerisation (Scheme 82). 
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It was decided to alter the sequence of the reactions. Treatment of 283 with DIBAL-H at 
-78 oC afforded the corresponding alcohol 290 in 82% yield without reacting with the 
azide functional group (Scheme 83).   Although the lack of reactivity of the azide with 
DIBAL-H was surprising, it is not without precedence.88
 
  
 
 
 
Then azide 290 was reduced using palladium on charcoal (10% weight) to afford the 
corresponding amine 291 in quantitative yield (Scheme 84).  
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Once the protected pseudodisaccharide 291 was in hand, a stepwise deprotection of the 
acetonide and silyl ether protecting groups was carried out by first treating 291 with 
90% acetic acid and stirring at room temperature for 18 hours.  The acetonide protecting 
group was not affected even after a longer period of time (30 hours). Normally 
acetonide groups at C-5’ and C-6’ are easier to remove and 90% acetic acid should have 
been sufficient to remove it.  A one-pot deprotection was attempted by treating 291 with 
TFA/THF/water (3:1:0.1) ratio and stirred at room temperature for 24 hours. The crude 
1H NMR of the product revealed that all the protecting groups (acetonide and silyl ether) 
had been removed.  Low resolution mass spectroscopy also confirmed that the product 
was indeed the target pseudodisaccharide 279. However, due to the polarity of the 
compound, its chromatographic purification was unsuccessful.  It was attempted to 
acetylate isolated product 279 by treating with acetic anhydride, pyridine and DMAP, 
however no product could be isolated after chromatographic purification.   
 
It was then decided to alter the sequence of the reactions and carry out the deprotection 
of the azide 290 followed by reduction. Since the azide functionality is less polar, it was 
hoped this may help in the purification process.  It was planned to carry out a stepwise 
deprotection by first removing the acetonide group at C-5’ and C-6’ and the silyl ether 
protecting group by treating 290 with a mixture of acetic acid/water/TFA (9:1:0.5) and 
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stirring at room temperature for 4 hours.  Indeed the acetonide group at C-5’and C-6’ 
was successfully removed but the silyl ether was still intact. The crude product was 
purified by flash chromatography to afford 292 in 92% yield (Scheme 85).  It was then 
attempted to remove the remaining protecting groups by treating with acetic 
acid/water/TFA (7:2:1) but unfortunately, no product could be isolated. 
 
 
 
 
2.6.1.1 Palladium on carbon reduction of Azide 281 
 
The palladium catalysed reduction of azide/alcohol 281 initially gave the corresponding 
amine 293 but unfortunately amine 293 was very unstable and quickly underwent 
further reaction. After chromatography, only the sugar part of the molecule was 
recovered, which was presumably obtained via an elimination reaction (Scheme 86).   
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Similarly when azide/alcohol 282 was hydrogenated in the presence of palladium on 
charcoal, no product could be isolated.  It was assumed that sugar elimination happened 
in this case. 
 
On the other hand when the silyl ether protected azide 283 was hydrogenated, the 
corresponding amine 294 was obtained in quantitative yield (Scheme 87). 
 
 
 
 
The difference in the two reactions may be an extension of the observed conformational 
“flip” which was observed as a result of the conversion of the alcohol function in 281 to 
silyl ether 283 (Scheme 79). 
 
2.6.1.2 Click Reaction 
 
The azide function is not only a precursor to the amine function but has a diverse and 
rich chemistry in its own right.  In particular, the azide function is shown to be an 
excellent group for linking different moieties via a “click” reaction.  Brief investigations 
into the reaction of azide 283 with phenyl acetylene 295 by means of “click” chemistry.  
Heating 283 with phenyl acetylene 295 at 80 oC in the presence of copper(II) sulfate and 
sodium ascorbate in tert-butyl alcohol and water afforded triazole 296 in 99% yield 
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(Scheme 88).  Although there was not time to further investigate the reaction, it is hoped 
that at a later stage, this reaction can be used to attach this pseudodisaccharide to other 
molecules including other sugars, fluorescent probes etc 
 
 
 
 
2.7 Conclusion 
 
It has been shown that appropriately substituted pyran-2-ones undergo a facile reaction 
with vinylated sugars and that the cycloaddition can be used as the basis of a method to 
prepare carbasugar-“true” sugar pseudodisaccharides.  In this method, a free hydroxyl 
function of a “true” sugar is derivatised to enable attachment of a carbasugar.  
Stereoselective transformations allow the synthesis of a range of configurations at the 
newly constructed carbasugar moiety. Investigations into the 
cycloaddition/cycloreversion reactions of pyran-2-ones were carried out as well 
exploration into its use in the synthesis of pseudodisaccharides. 
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Chapter Three: Inhibitors of Golgi α-Mannosidase II 
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3.1 Introduction 
 
3.1.1 What is Cancer? 
 
Cancer is the second deadliest disease in the developed world. 89  Cancer has been 
known to practitioners of medicine since antiquity. However its prevalence has only 
been recognised as infectious diseases, which used to kill humans in large numbers, are 
being eradicated due to advances in medical science and hygiene.90
 
 
Cancer is a complex disease both in terms of its etiology and prognosis.91  Roughly 
speaking, cancer can be defined as uncontrolled cell division (proliferation),92 but in 
fact rapid cell division on its own does not constitute cancer.  All cells are genetically 
programmed to differentiate and proliferate at some stage in their growth.93  Indeed cell 
division occurs in nearly all organs and is essential for maintenance of all eukaryotic life.  
All cells are also genetically programmed to self-destruct if they are damaged, surplus 
to requirement, or put together in a way that they can not perform their function.94  This 
process is known as ‘programmed cell death’ or PCD, the most prevalent mechanism of 
which is apoptosis.95
 
 
In cancer, a cell’s normal life cycle is interrupted at one or more stages of its growth.  
This can be manifested in rapid and uncontrolled cell growth or a lack of PCD, or 
both.96
 
  This means that there can be multiple causes for cancer development. 
There are two kinds of tumours, benign and malignant.90  In benign tumour cell growth 
is localised.  Benign tumours are only dangerous if they damage the tissue they are 
growing in by their mass effect or using too much energy.90 They are usually treated by 
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surgical intervention or radiotherapy, unless they are inaccessible.89  For example, a 
tumour near the cerebellum is almost always fatal.  In malignant tumour, diseased cells 
either attack healthy cells in the tissue they reside in, or invade those in other tissues.90 
The migration is known as metastasis and is a key event in the pathology of cancer.  
Cells can change from benign to malignant or vice versa (which is known as 
remission).89 
 
3.1.2 Causes of Cancer 
 
The search for the causes of cancer goes back for centuries.  Scientists used to hold 
different opinions about the real cause of cancer.  It is now widely agreed that there are 
many factors that contribute to cancer.  These factors include genetics, smoking, diet, 
infectious agents (bacteria and virus) and the environment.97
 
 
From a biological point view, cancer results from either a genetic mutation or a 
mistranslation of the cell’s genetic code.89  It is important to note that the damage to the 
cell usually manifests in more than one way.  In other words a single ‘wrong’ protein 
may or may not cause cancer, but usually more than one kind of ‘wrong’ protein is 
produced and the cell may be damaged in more than one way.  If PCD mechanisms are 
not interrupted, the cell dies and cancer does not arise.  However, if PCD is not 
operating the cell will continue to exist and divide.  In some cancers, the process of the 
cell division may also be accelerated concurrently. 
 
The causes of cancer are also varied.90  Although genetic mutation can be spontaneous, 
there are a number of mechanisms in the cell for its repair.  Any agent that damages 
deoxyribonucleic acid (DNA)98 can cause cancer but external agents such as viruses, 
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bacteria, radiation and carcinogenic chemicals can also initiate cancer by causing a 
mistranslation of the DNA message.90,97 
 
3.1.3 Strategies for Combating Cancer 
 
Cancer is treated in a number of different ways depending on the type of cancer, its 
tendency to spread and its location in the body.89  If the tumour is accessible, then 
surgery is an option.90  Radiotherapy is an alternative treatment and is used as a means 
of local control.   
 
Chemotherapeutic agents are another option and are mainly designed to damage the 
cell’s replication process; this can be done by intervention in a number of biological 
processes.99
90
  The majority of chemotherapeutic agents currently used in the clinic either 
target DNA or inhibit the enzymes involved in DNA synthesis and repair.  There is 
another type of chemotherapy which affects signal transduction.  Instead of direct attack 
of the DNA, new generations of anti-cancer drug affect the signals which regulate or 
promote growth factors and their receptors and cell cycle.  There are other strategies 
employed for combating the disease, these include affecting proteolytic enzyme activity, 
cell adhesion and angiogenesis in order to slow down cancer disease progression, or 
conjugating chemotherapeutic agents to tumour cell recognising antibodies.90 
  
 
There is a disadvantage in the use of chemotherapeutic agents.  Cancer cells are not the 
only cells which are dividing and growing.  Other cells in the body proliferate; 
especially bone marrow, epithelial cells in the gut and skin and hair follicles.  
Chemotherapy will affect these cells and consequently cause unwanted side effects of 
nausea, vomiting, hair loss and bone marrow suppression.89 
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Another limiting factor of therapeutic agents is the ability of some tumour cells to 
develop resistance mechanisms against cancer drugs.  They do so, either by releasing 
enzymes which will reverse the cytotoxic and cytostatic effect of the drug or by 
pumping the drug agents out of the tumour cell.100
 
 
To reduce side effects and cell resistance to chemotherapeutic agents, it has become 
important to search for new drugs which will have high selectivity in terms of targeting 
cancerous cells, thereby affecting normal cells less. 
 
One of the ways to achieve that goal is to inhibit the enzymes that edit cell surface 
glycoproteins.100 
  
3.2 Glycoprotein 
 
The cell is the smallest structure of the body and the fundamental unit of life.  The 
surface of all cells is a complex landscape containing many molecules which are 
responsible for the interaction between the cell and its environment.  One such group of 
molecules are glycoproteins.  Cell surface glycoproteins consist of a cell-surface-
embedded protein covalently bound to a polysaccharide projected outside the cell into 
the extra-cellular matrix (Figure 25).101  
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Figure 25: Cell Surface Membrane (Picture taken from http://kentsimmons.uwinnipeg.ca/cm 
1504/plasmamembrane.htm) 
 
There are two kinds of glycoproteins depending on the location of the covalent linkage 
between the protein and polysaccharide.  In O-linked glycoproteins, the polysaccharide 
is covalently bonded at its anomeric position to a serine or tyrosine residue of the cell-
surface protein102.  Blood group determinant antigens on the red blood cells are of this 
type.103
102
  In N-linked glycoproteins, the linkage is through the nitrogen of an asparagine 
residue.15  Interestingly, in all eukaryotic cells, although there is a great variety in the 
polysaccharide component of all cell surface glycoproteins, they all contain a preserved 
core of five carbohydrate units at their polysaccharide component.  
 
A detailed study of the biosynthesis of cell surface glycoproteins over the past 20 years 
has shown that all of them are made by addition/cleavage of carbohydrate units to that 
core.  The glycosylation mechanisms (addition of sugars) of the two classes of 
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glycoproteins are different. 104
                                                   
  We are interested in the synthesis of N-linked 
glycoproteins and we will explore it in more detail. 
Asparagine-linked (N-linked) glycoprotein biosynthesis is a complex process, occurring 
in the membranes of the secretory pathways of the endoplasmic reticulum, Golgi 
apparatus, trans-Golgi network and transport vesicles between these organelles.105
105
  The 
protein backbone is first synthesised on ribosomes and is then glycosylated. The 
synthesis starts with oligosaccharide maturation which occurs in four stages.   The 
first stage happens on the cytoplasmic phase of the endoplasmic reticulum and involves 
the synthesis of a lipid-linked precursor oligosaccharide.106
105
  The second stage involves 
the transfer of the lipid-linked precursor to a newly synthesised peptide forming a 
linkage to an Asn residue.   Trimming N-glycans occur in the third stage and involve 
the removal of a variable number of mannose and three glucose residues.  At this stage, 
α-glucosidase and α-mannosidase remove four of the original nine mannose units to 
generate Man5GlcNAc2-N which is then added to GlcNAc to create the 
GlcNAcMan3GlcNAc2-N intermediate.107 The final step of the maturation process is the 
extension and branching of the oligosaccharide, which results in the final glycosylated 
structure which is transported to destinations such as the cytoplasm, lysosomes and 
plasma membrane.108 105  The glycoprotein glycosylation is best illustrated in Figure 26.   
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Figure 26: N-linked glycoprotein processing. (Picture taken from Biochim. Biophys. Acta, 2002, 
1573, 225-235). 
 
 
3.2.1 Glycolysis Mechanism 
 
General enzymatic hydrolysis of the glycosidic bond normally takes place via an acid-
base reaction which requires a nucleophile and a proton acceptor.109  There are two 
possible stereochemical outcomes for the hydrolysis of such a bond: retention and 
inversion of configuration (Scheme 89).110
110
  In the transition state, an oxocarbenium ion 
is formed which is held in between two carboxylic acids at the active site of the 
enzyme.   In retention glycosidases (Path a), the hydrolysis occurs via a double 
displacement mechanism where the two carboxylic acids are located 5.5 Å apart.  In 
contrast, in the inverting transition (Path b), the two carboxylic acid residues are 10.5 Ǻ 
apart and the reaction proceeds via a single displacement mechanism.110 
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The mechanistic understanding of the details of glycosidase-mediated hydrolysis is 
important for the discovery and development of stronger and more selective inhibitors 
that would have therapeutic potential. 111
7
   Relenza 297, a sialidase inhibitor for 
treatment of influenza, and acarbose 10, an α-amalyse inhibitor for control of blood 
glucose, are examples of glycosidase inhibitor based therapeutic agents developed in 
recent years (Figure 27). ,110 
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Figure 27 
 
3.3 Golgi α-Mannosidase II Inhibition as a Cancer Therapy 
 
One of the important enzymes in late stage glycoprotein processing is Golgi α-
mannosidase II (GMII).112  The enzyme is involved in the catalytic process of trimming 
two mannose residues from intermediate 298 to give glycoprotein precursor 299 
(Scheme 92) 113 .  In cancerous cells, altered distribution of glycoprotein (increased 
branching) is observed and is associated with disease progression and metastasis.114
113
  
The inhibition of α-mannosidase II is a potential anti-cancer strategy. ,115 
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Processing α-mannosidases can be divided into two classes, each with distinct 
biochemical properties.116  Class I α-mannosidases, inverting glycosidases, cleave only 
α-1,2-mannose residues.117
117
  They are inhibited by pyranose mannosaccharide analogues 
such as 1-deoxymannojirimycin 300.   Class II α-mannosidases, retaining glycosidases, 
cleave α-1,2-, α-1,3-, and α-1,6-mannose residues.  They are inhibited by furanose 
analogues such as swainsonine 301 (Figure 28).   Since α-mannosidase II is a 
retaining enzyme, the hydrolysis it catalyses will occur via a double displacement 
mechanism.  
 
 
Figure 28 
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Swainsonine 300 is an indolizidine alkaloid natural product found in North American 
plants of genus Astragalus, Australian swainsona canscens and the fungus Rhizoctonia 
leguminicola. 118
113
  As inhibitors of α-mannosidase II it has a potential anticancer 
chemotherapeutic application. ,118 
 
Figure 29: The effect of swainsonine on cells. (Picture taken from Biochim. Biophys. Acta, 
2002, 1573, 225-235). 
 
 
Swainsonine was originally used in research as a means to investigate and determine 
whether alterations in N-linked oligosaccharide structures affect the function or 
intracellular processing of glycoproteins in biological systems.119  It was shown that 
when a swainsonine solution is injected into a cultured medium of animal cells, N-
linked oligosaccharides produced have a hybrid structure instead of a complex one, an 
observation which is consistent with mannosidase II enzyme inhibition120 (Figure 29).  
In other words, swainsonine inhibits α-mannosidase II, but not α-mannosidase I, and 
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protein glycosylation proceeds up to the formation of Man5GlcNAc2, after which the 
pathway is diverted to form hybrid-type N-glycans.112 
 
Swainsonine 301 has been synthesised through a number of different routes.121   An 
exemplar synthesis of swainsonine from α-furyl amide 302 is shown in Scheme 91.122
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Swainsonine had shown several advantages over other glycosylase inhibitors, including 
low preclinical toxicity.112 In vivo studies on swainsonine 301 were carried out on mice 
and showed that it reduces metastasis, solid tumour growth and enhances antitumour 
immune response in mice.123
105
  Specifically, it stimulates natural killer cells, lymphokine 
activated killer cells and anti-tumour activity of macrophages.   In a phase II clinical 
trial study in patients with advanced malignancies, administration of swainsonine 
reduced tumour growth and metastasis is observed.112,123 Swainsonine also showed low 
toxicity in humans in early trials.105 
 
However, swainsonine has been subsequently associated with serious side effects, 
namely its co-inhibition of lysosomal mannosidase II, which causes the accumulation of 
mannose in tissues100,112,113 For this reason, it became important to search for more 
selective α-mannosidase II inhibitors.100 
 
Good α-mannosidase II inhibitors must satisfy a number of conditions in order to 
become potential drugs.  These conditions include, low toxicity, enzyme specificity and 
membrane permeability.124
 
  Inhibitors are made membrane permeable by introducing 
lipophilic groups to inhibitor molecules. 
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Figure 30 
 
Pearson and co-workers have reported swainsonine analogues with interesting 
inhibitory properties.113  Since swainsonine does not discriminate between GM II and 
lysosomal α-mannosidase II, they tried to make selective inhibitors which would inhibit 
GM II but not lysosomal α-mannosidase II.113  Their hypothesis was based upon adding 
a sugar or sugar-like molecule to swainsonine 301 at C(3), thereby yielding a selective 
Golgi mannosidase II inhibitor.  They suggested that the GM II catalysed hydrolysis 
transition state involves mannosyl cation 313 and the C(3) position of swainsonine 301 
would correspond to the anomeric carbon of 313 (Figure 30).113  Indeed, some of the 
analogues they have developed exceeded swainsonine in their ability to inhibit jack 
bean α-mannosidase II.  For example, analogues 314 and 315 gave IC50’s of 50 and 70 
nM respectively compared to compound 301 which gave (400 nM).113 
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Swainsonine analogues 314 and 315 are synthesised from D-ribose 316 as shown in 
Scheme 92.113,125
 
 
Other α-mannosidase inhibitors include mannostatin 320126, salacinol 321127, D-glycon-
δ-lactams such as 322128, compound 323129, five-membered ring amino sugar 324130, 5-
thio-D-glycopyranosylamines 325 131  and α-D-glucopyranosyl-(13)-1-
deoxymannojirimycin 326 (Figure 31).132,133
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Figure 31 
 
3.4 Conclusion 
 
The search for selective GM II inhibitors is an evolving and promising area of cancer 
research.  Obtaining exact information about glycosidase mechanisms will help 
scientists in designing potent inhibitors.   
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3.5 Results & Discussions 
 
3.5.1 Objectives 
 
 
 
 
Figure 32 
 
Our approach in the search for new inhibitors of Golgi α-mannosidase II is based on the 
synthesis of 6-aminosubstituted mannose derivatives 327 (Figure 32) and determination 
of their inhibitory potential towards commercially available jack bean α-mannosidase II.  
The design of 327 as an inhibitor is based on two principles. Firstly, by using a non-
anomeric linkage in 327, the molecule can bind to the enzyme but not be turned over, 
thus acting as an inhibitor. Secondly, by replacing a nitrogen atom for the oxygen atom 
at the exocyclic anomeric position, we hoped for an increase in binding of 327 to the 
enzyme since the proposed mechanism for the cleavage by GMII (Scheme 91) requires 
protonation of this heteroatom. Since the nitrogen atom is a more basic atom than 
oxygen, 327 should interact more strongly with the enzyme. Since the R group in 327 is 
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supposed to mimic a sugar, we proposed that the most suitable groups would be 
cyclohexyl or benzyl groups with hydroxyl or methoxy substituents, e.g. 328 and 329. 
 
 
 
 
The original retrosynthetic analysis of compound 328/329 is shown in Scheme 93. We 
envisaged that 328/329 can be prepared via a reductive amination of protected aldehyde 
331 and an amine 330. Aldehyde 331 in turn can be prepared from the protected 
mannose derivative 333 which can be easily prepared from commercially available 
methylmannopyranoside 334. 
 
3.5.2 Synthesis of 6-substituted mannose derivatives134
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We started our synthesis with commercially available α-D-methylmannopyranoside 334.  
The primary hydroxyl group in α-D-methylmannopyranoside can be protected 
selectively since it is more reactive than the rest of hydroxyls on steric grounds.  This 
was achieved by treating 334 with TBDMSCl in pyridine, in the presence of a catalytic 
amount of DMAP to afford 52% yield of product 335 (Scheme 94).  DMAP is a 
nucleophilic catalyst as it displaces the chloride in the TBDMSCl to give 336 in situ.  
DMAP is a better leaving group than a chloride ion as it forms a neutral species once it 
is eliminated.  The full mechanism of the reaction is shown in Scheme 95. 
 
 
 
 
The remaining hydroxyl groups in compound 335 were protected with benzyl groups.  
This was achieved by treating the 6-silyloxy mannoside 335 with sodium hydride in 
DMF with a catalytic amount of TBAI before the addition of BnBr.  The iodide in TBAI 
is a nucleophilic catalyst as it will replace the bromide in benzyl bromide to give benzyl 
iodide, which is a better alkylating agent compared to benzyl bromide as iodide is a 
better leaving group than bromide.  The benzylation proceeds with deprotonation of the 
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hydroxyl groups to generate alkoxides which in turn act as nucleophiles to attack benzyl 
iodide as shown in the Scheme 97.  
 
 
 
 
 
 
 
The fully protected mannoside 337 was desilylated under mildly acidic conditions in 
MeOH to give primary alcohol 333 (Scheme 98).  The mechanism of the hydrolysis 
proceeds via protonation of the oxygen on C-6, followed by nucleophilic attack of water 
on silicon to displace the protonated primary alcohol.  The final step of the reaction is 
loss of a proton to give silyl product 338 (Scheme 99). 
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We next attempted to oxidise the primary alcohol in 333, by treating with pyridinium 
chlorochromate (PCC) in DCM as reported in the literature.134  Unfortunately no 
product could be isolated.  This prompted us to use other methods for oxidising primary 
alcohols to aldehydes, e.g. the Swern oxidation.  In the course of this method, the 
primary alcohol was treated with oxalyl chloride in DCM, followed by DMSO and 
triethylamine.  However, this method also did not yield any product. 
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For this reason, we decided to revise our strategy and we came up with a new route to 
synthesise our target molecules.  The new retrosynthetic analysis is shown in (Scheme 
100). 
 
We converted primary alcohol 333 to tosylate 341 by treating 333 in pyridine with tosyl 
chloride to afford 341 in 88% yield.  Heating 341 with sodium azide at 90 ºC for 4 
hours afforded azide 342 in good yield (97%).  Azide 342 was then reduced to the 
corresponding amine in 72% yield (Scheme 101).   
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Primary amine 339 was then coupled with a number of aryl aldehydes and 
cyclohexanone derivatives.  First the amine, together with the corresponding aldehyde 
or ketone was heated under reflux for 24 hours and then the resulting imine was reduced 
using sodium borohydride (Scheme 102).   The results are summarised in Table 6. 
 
 
 
 
The benzyl protecting groups of compound 343 were removed by catalytic 
hydrogenation over palladium on charcoal in methanol over 3 days to afford 351 
(Scheme 103).   
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Table 6: Coupling amine 339 with aldehyde/ketone  
 
Entry Aldehyde/ketone Product Yield (%) 
 
 
1 
 
  
 
 
56 
 
 
2 
 
  
 
 
89 
 
 
 
3 
 
 
 
 
 
83 
 
 
4 
 
 
 
 
 
 
61 
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However, when compound 344 was hydrogenated using palladium on charcoal in 
methanol overnight, amine 339 was re-formed.  Surprisingly, instead of cleavage of the 
O-benzyl groups, hydrogenation preferentially removed the N-benzyl group (Scheme 
104). 
 
 
 
 
This prompted us to rethink our synthesis strategy again.  We decided this time to work 
with unprotected sugars, since protecting and then de-protecting sugars is a long method 
and sometimes not reliable as we have experienced. 
 
We started our synthesis with α-D-methylmannopyranoside 334 and tosylated the 6-
hydroxyl group with tosyl chloride, followed by nucleophilic attack with sodium azide 
to furnish 6-azido mannose 353 in 96% yield.  6-Azido mannose 353 was then reduced 
to the corresponding amine 354 in 72% yield (Scheme 105).135
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We then carried out a series of reductive aminations between 6-amino mannose 354 and 
a number of aryl aldehydes and cyclohexanone derivatives.  First the amine and 
aldehyde or ketone were heated under reflux for 24 hours and then reduced using excess 
sodium borohydride to yield the desired product 355 (Scheme 106).  The results are 
summarised in Table 7 
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Table 7: Coupling amine 354 with aldehyde/ketone  
 
Entry Aldehyde/ketone Product Yield (%) 
 
 
1 
 
  
 
 
63 
 
 
2 
 
 
 
 
 
59 
 
 
3 
 
 
 
 
 
53 
 
 
4 
 
  
 
 
49 
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3.5.3  Biological activity 
 
 The compounds were screened in an in vitro enzyme inhibition assay against Jack bean 
α-mannosidase II using a protocol supplied by Vasalla. In this test, inhibition of the 
enzyme is measured as a reduction in the rate of hydrolysis of p-nitrophenyl-α-D-
mannopyranoside in the presence of the inhibitor. Unfortunately, all compounds were 
found to lack inhibitory action. Detailed procedure of the assay is provided in the 
experimental section. 
3.5.4 Conclusion  
 
We have successfully synthesized 5 target molecules as potential inhibitors of GM II.  
We evaluated their inhibition against jack bean α-mannosidase, and the compounds 
were not active.    
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Chapter Four: 6-Anhydro-(1,2,3-triazolo)sugars as  
inhibitors of glucokinase 
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4.1 Introduction 
 
4.1.1 Glycolysis 
 
Glucose 215 is the major source of energy for almost all organisms.  In the human body, 
glucose is the only source of energy for the brain and red blood cells.  Every cell in the 
body is able to generate adenosine triphosphate (ATP) from glycolysis, a sequence of 
reactions that converts glucose to pyruvate.  If this process is anaerobic (i.e. occurring in 
the presence of low or zero levels of oxygen), the product of glycolysis, pyruvate, is 
further processed to lactate (in higher animals) or ethanol (in yeast).  Under aerobic 
conditions on the other hand, pyruvate can be completely oxidised to carbon dioxide via 
tricarboxylic acid TCA (Kreb’s) cycle releasing even more ATP. 
 
The glycolysis process takes place in three stages.136
 
 
Stage 1: Conversion of glucose into fructose-1,6-bisphosphate 
 
This process consists of three steps: in the first step, glucose is phosphorylated to give 
glucose-6-phosphate (G6P) 360.  This reaction is mediated by the enzyme hexokinase.  
Glucose 6-phosphate 360 is both a product and an inhibitor of hexokinase which means 
its cellular accumulation is prevented under normal conditions. The second step 
involves isomerisation of glucose 6-phosphate 360 into fructose 6-phosphate 361 by the 
action of phosphoglucose isomerase.  The final step is the phosphorylation of fructose 
6-phosphate 361 to yield fructose-1,6-bisphosphate 362.  Although energy will be 
generated in later stages of glycolysis, reactions in this first stage consume energy 
particularly the first and third steps (Scheme 107).136,137
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Stage 2: Cleavage of fructose-1,6-bisphosphate to two triose phosphates 
 
Fructose 1,6-bisphosphate 362 is cleaved into glyceraldehydes-3-phosphate 363 and 
dihydroxyacetone phosphate 364 (Scheme 108).  The two products are isomers; one is 
an aldehyde while the other is a ketone.  They are readily interconverted by triose 
phosphate isomerase.136,137 
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Stage 3: Energy harvesting 
 
This stage consists of a series of steps in which ATP is generated.  Glyceraldehyde 3-
phosphate 364 is converted into 1,3-bisphosphoglycerate 365 by the action of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  2 molecules of ATP are 
generated from ADP when 1,3-bisphosphoglycerate 365 is converted into 3-
phosphoglycerate 366.  This reaction is catalysed by phosphoglycerate kinase (PGK).  
A further 2 molecules of ATP are released when two molecules of 1,3-
biphosphoglycerate are converted into two molecules of pyruvate 369 (Scheme 109).  
Overall, glycolysis generates a net 2 moles of ATP (as well as 2 moles of NADH and 2 
moles of pyruvate) per mole of glucose 215.136,137 
 
 
 
 
Pyruvate 369 is the end product of glycolysis and is converted to acetyl–CoA by 
pyruvate dehydrogenase before it enters the TCA cycle. 138   During this stage of 
metabolism, each mole of pyruvate generates a further 4 moles of NADH, a mole of 
GTP and a mole of FADH2. 
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In general glycolysis is a well regulated pathway due to the necessity to respond to 
conditions inside and outside of the cell.139
 
 
4.1.2 Lactate metabolism 
 
Lactate is generated from pyruvate when there is a great need for energy but the amount 
of oxygen in the cells is limited and so further oxidation of pyruvate to carbon dioxide 
is not possible.  This process which releases a further small amount of ATP is catalysed 
by lactate dehydrogenase (LDH).139  Lactate metabolism is common in muscle cells 
during strenuous exercise when the demand for energy is very high.  The resulting 
lactate is transported out of the cell and into the blood to highly aerobic tissues such as 
the heart, where lactate is either converted back to glucose or catabolised further 
through aerobic respiration. 
 
4.1.3 Cancer and Glycolysis 
 
An increase in metabolic activity is associated with fast growing cancer cells.  Since the 
microenvironment around many tumour cells is oxygen deficient (hypoxic), non-aerobic 
metabolic pathways become very important to cancer cells as a means of producing the 
energy they need to survive and grow.  
 
Cells in embryonic development and those in exercising muscles experience hypoxia 
because the demand exceeds the supply of oxygen via the cardiovascular system.  In 
cancer, tumour cells out-grow the vascular systems that would supply them with oxygen.  
To gain enough energy to survive and replicate, cancer cells inside hypoxic tumours 
make glycolysis more efficient by the action of a transcription factor known as hypoxic 
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inducible transcription factor (HIF-1).140
 
  Formed when oxygen is not present in the cell 
environment, HIF-1 increases the expression of glucose transporters and glycolytic 
enzymes.  In this way, the cell can get most of its energy from the anaerobic glycolytic 
pathway.  
For example, HIF-1 induces pyruvate dehydrogenase kinase-1 (PDK1)141 which inhibits 
pyruvate dehydrogenase by phosphorylation.142  This in turn blocks the pyruvate entry 
into mitochondrial metabolism and hence promotes anaerobic metabolism towards 
lactate.143
 
  The resulting lactate is released into the extracellular space and regenerates 
NAD+ for continued glycolysis under anaerobic conditions.  
Since tumour cells survive and grow under hypoxic conditions, there are several studies 
investigating how suppression of glycolytic pathway enzymes will affect tumour growth.  
Fantin et al investigated the effect of LDH-A suppression on cancer cell growth, 
metabolism and tumourigenicity.144
144
  When LDH-A is suppressed (using expression of 
short hairpin RNAs complementary to LDH-A) in neu-initiated mammary epithelial cell 
lines, oxidative phosphorylation is enhanced to compensate for the lack of anaerobic 
metabolism.   They also noticed a decrease in tumourigenic and proliferative potential 
of the cancer cells.144 
 
There are two explanations for these observations: first, oxidative phosphorylation alone 
cannot adequately sustain the metabolic demands of cancer cells, and secondly, 
glycolytic metabolites are used for the synthesis of fatty acids and non-essential amino 
acids necessary for cell growth.144,145  Therefore suppression of glycolysis results in 
reduced growth and tumourigenicity of cancer cells.  
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4.2 Aims of the project 
 
We are synthesising a series of 6-triazole glucose and mannose derivatives as mimics of 
glucose-6-phosphate (G6P) by employing click chemistry. 
 
4.3 Click chemistry  
 
4.3.1  Introduction 
 
Sharpless and co-workers have described a group of reactions that selectively form 
heteroatom links called ‘click reactions’.146
146
  In order for a reaction to be useful in this 
context, it must be modular, high yielding, wide in scope, generate only inoffensive by-
products and must have a thermodynamic driving force greater than 20 kcal/mol.  
 
Reactions designated as click chemistry include: cycloaddition reactions (especially 
hetero-Diels-Alder reactions), nucleophilic ring opening reactions (such as opening of 
epoxides and aziridines), addition to ‘carbon-carbon’ multiple bonds and carbonyl 
chemistry of the non-aldol type.146 
 
4.3.2 Copper(I) catalysed azide-alkyne cycloaddition 
 
The best click reaction to date is the CuI-catalysed Huisgen 1,3-dipolar cycloadditon of 
azides and alkynes which affords 1,2,3-triazoles. This CuI-catalysed reaction was 
reported independently in 2002 by two groups (Sharpless and Madel).147,148  Since then, 
it has quickly found many applications in chemistry, biology and material sciences.  It 
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has been used for the synthesis of biologically active molecules, 149  for selective 
labelling of modified bacterial cell walls150 and the synthesis of dendrimers.151
 
  
Uncatalysed alkyne-azide cycloadition is a slow process, normally requiring elevated 
temperature and the product is a mixture of 1,4- and 1,5-regioisomers.  For example, the 
thermal reaction between benzyl azide 370 and phenyl propargyl ether 371 gave both 
isomers in a ratio of 1:1.6 in favour of the 1,4 regioisomer 373 (scheme 110).  When the 
same reaction was carried out under click conditions, 1,4-regioisomer 373 was formed 
exclusively (Scheme 111).147 
 
 
 
 
 
 
 
The use of a variety of solvents was reported, including ethanol or tert-butanol and even 
water without an organic co-solvent.  The catalyst loading reported is in the range of 
0.25 to 2 mole%.147   
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Table 8: Some examples of CuI-catalysed alkyne-azide couplings from literature.147 
 
Entry Azide Alkyne Product Yield (%) 
 
1  
 
  
 
92 
 
2  
 
  
 
93 
 
3 
 
 
 
  
 
82 
 
4 
 
 
 
 
  
 
84 
 
5 
   
 
91 
 
6 
 
 
 
 
 
88 
 
7 
 
   
 
88 
 
8 
 
   
 
84 
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4.3.3 Sources of copper(I) catalyst 
 
The sources of copper(I) catalyst are varied.  One of these sources is in-situ generation 
of copper(I) from copper(II) sulfate pentahydrate.  This process occurs either by 
reduction or by conproportionation with copper metal.  In the reduction route, sodium 
ascorbate is used as the favoured reducing agent.147,151  The ratio of sodium ascorbate to 
copper used, ranges from 3 to 10 fold.  In biological systems 
tris(caboxyethyl)phosphine is the favoured reducing agent.152
 
  
Oxidation of copper metal is another source of copper(I) catalyst.  This is achieved by 
direct addition of copper turnings to azide-alkyne reactions in alcohol/water solvents.153  
Nanosize Cu0 can be used to accelerate the rate of reaction since use of copper turnings 
in reactions require long reaction times.154
 
   
On the other hand, copper(I) salts, such as copper(I) iodide, CuOTf.C6H6 and 
[Cu(NCCH3)4][PF6], can be used as a copper(I) sources.147  Normally one equivalent of 
base and acetonitrile as a co-solvent are needed.  This method has the disadvantage of 
byproduct generation, in the form of bisacetylenes, 5-hydroxytriazoles and bis-
triazoles.147,148  The use of 2,6-lutidine and DIPEA improves the reaction by minimising  
byproduct formation, and oxygen exclusion further improves the yield and purity of the 
product.147  
4.3.4 Mechanism of copper(I) catalysed azide-alkyne reaction 
 
The proposed mechanism begins with copper(I) insertion into a terminal alkyne (no 
reaction is observed with internal alkynes), and proceeds with stepwise formation of a 
six-membered copper containing species 379 (Scheme 112).153 
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In mechanistic studies, acetonitrile was used as a ligand for the copper complex as well 
as the solvent.  In the reaction, copper(I) acetylene formation starts with coordination of 
alkyne 375 with copper(I) species 374 to displace one of the acetonitrile ligands 
(Scheme 113).153  In acetonitrile, this step is endothermic by 0.6 kcal/mol.  But, in 
aqueous solutions, the displacement process is exothermic by 11.7 kcal/mol.153  This is 
consistent with experimental observations of rate acceleration in aqueous medium.  The 
initial coordination of copper and alkyne to form a π complex lowers the pKa of the 
alkyne C-H 382 by up to 9.8 units.153  
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After formation of the copper acetylene complex, the azide displaces one ligand and 
binds with copper to generate intermediate 378.153  This process is slightly exothermic, 
and is followed by nucleophilic attack of the distal nitrogen of the azide at C(4) of the 
acetylene, generating six membered copper(III) metallacycle 379.153 This is followed by 
ring contraction which is facilitated by transannular association of N(1) lone pair of 
electrons with Cu π* orbital.  Transformation of 379 to 380 is fast due to the low energy 
barrier.  Proteolysis of triazolyl-copper derivative 380 forms product 381 and hence 
regenerates the catalyst.153 
 
4.3.5 One-pot multi-step synthesis of triazole linked glycoconjugates 
 
Due to the perceived dangers of handling organic azides, in situ generation of azides 
enhances the appeal of the copper(I) catalysed azide-alkyne reaction.  Wang and co-
workers reported the one-pot synthesis of triazole substituted glycoconjugates from an 
unprotected monosaccharide. 155
155
  In this one-pot synthesis, four transformations are 
achieved without isolating any intermediates.  The process begins with acetate 
protection of the sugar followed by brominolysis and subsequent azide displacement 
and cycloaddition to afford the desired triazole product in good yield (Scheme 114).  
 
 
 
 
With protected D-glucose and D-galactose as starting materials, the reaction furnished 
the expected products smoothly at room temperature overnight.  Due to the steric 
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hindrance of the 3-substituent of D-mannose, the rate of the reaction is slow and 
elevated temperature is needed to obtain the desired triazole product from that sugar.155 
 
4.3.6 Limitations of CuI-catalysed alkyne-azide reactions 
 
CuI-catalysed alkyne-azide coupling usually generates the desired triazole in an efficient 
and reliable way.  How ever some research groups have reported reactions with low 
yield due to byproduct formation, or generation of unexpected products.148,156  In the 
case of reactions with low yield, alkyne homocoupling is a possible cause.  Alkyne 
homocoupling is a known reaction which is also catalysed by CuI species and small, 
unhindered amines promote this conversion through stabilisation of intermediates of 
alkyne homocoupling 384 and 385 (Scheme 115).157
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On the other hand, Chang and co-workers reported unexpected high yield of compound 
389 from a three component coupling of alkyne 295, azide 387 and amine 388 under 
click conditions (Scheme 116).156  In the absence of CuI no reaction took place 
indicating the important role of the copper(I) catalyst.   
 
 
 
 
There are two possible pathways for this reaction.  The first possible pathway (A) is the 
formation of ketenimine intermediate 391 from copper acetylene and azide coupling, 
followed by amination across the C=N bond and finally tautomerisation to form the 
imidine 389.156  The second pathway (B) involves formation of triazole intermediate 
392, followed by Dimroth rearrangement via α-diazoimine and finally reaction with 
amine generates  imidine 389 (Scheme 117).156 
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4.4 Retro-synthetic analysis of the target molecule 
 
The first step of glycolysis is the phosphorylation of glucose to form glucose-6-
phosphate (G-6-P).  This reaction is catalysed by the hexokinase enzyme (Scheme 118).  
Glucose 6-phosphate is both a product and an inhibitor of hexokinase.  We are trying to 
design molecules which can mimic G-6-P, so they can inhibit the activity of hexokinase.   
The molecules we have designed have the triazole functional group substituted at the 6 
position on mannose and glucose compounds 393.  Triazole-substituted molecules have 
been used before as inhibitors of phosphatase.   Seto and co-workers have designed 
triazole substituted compounds as protein tyrosine phosphatase inhibitors.158
 
   We have 
synthesised the target molecules by making azide sugars (mannose and glucose) and 
subsequent cycloadition of azide and alkyne to generate the desired triazole.  The 
retrosynthetic analysis of compound 393 is shown in Scheme 118.   
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4.4.1 Synthesis of sugar azides (mannose and glucose) 
 
We started our synthesis with commercially available α-D-methylmannopyranoside 334 
and α-D-methylglucopyranoside 394.  The 6-hydroxyl group of the saccharide (glucose 
and mannose) was tosylated with tosyl chloride.  The tosylate was then treated with 
sodium azide to furnish 6-azido saccharides 353 and 396 in good yields (Scheme 119).   
 
 
 
 
4.4.1.1 Thermal coupling of Azide and Alkyne 
 
Azide 353 and methyl propiolate 397 were heated under reflux in methanol for 24 h and 
afforded a mixture of 1,4- and 1,5-regioisomers of the corresponding triazoles 398 and 
399 in a 1:3.7 ratio (Scheme 120).   
 
 
161 
 
 
 
 
However, when propargyl alcohol 400 or phenyl acetylene 295 were heated with azide 
353, no product was isolated.   Therefore, we decided to use the copper(I) catalysed 
alkyne-azide coupling to obtain the desired products. 
 
4.4.1.2 CuI-catalysed Alkyne-Azide coupling 
 
Although a number of copper(I) sources are available, we used copper(II) sulphate 
pentahydrate, where copper(I) is generated in situ when copper sulfate is reduced by 
sodium ascorbate.  The catalyst loading was 1 mol%.  Our solvent of choice was tert-
butyl alcohol with water as the co-solvent in a 1:1 ratio. 
 
The reaction between 6-azido mannose 353 and propargyl alcohol 400 proceeded to 
completion in 40 h at room temperature (Scheme 121).  However, the reaction with 
phenyl acetylene 295 was very slow.  Carrying out the NMR of the crude reaction 
mixture after 60 hours indicated that much of the starting material was left unreacted.  
162 
 
When the reaction temperature was elevated to 80 oC, the reaction went to completion 
in 15 hours.  Subsequently, in order to increase the rate of the reaction, all azide-alkyne 
coupling reactions were carried out at 80 oC over 15 hours (Scheme 122).    
 
 
 
 
The results of the cycloaddition reactions are summarised in Tables 9 and 10.  The 
coupling of 6-azido mannose and methyl propiolate under click conditions gave only 
one regioisomer (1,4-isomer), which confirms the regioselectivity of this reaction.  
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Table 9: Results of CuI-catalysed 6-azido mannose and alkyne coupling 
Entry Alkyne Product Yield (%) 
 
 
1 
 
 
 
 
 
 
70 
 
 
2 
 
 
 
 
 
 
58 
 
 
3 
 
 
  
 
 
45 
 
 
 
 
4 
 
 
 
 
 
 
76 
 
 
5 
 
 
  
 
 
56 
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Table 10: Results of CuI-catalysed 6-azido glucose and alkyne coupling 
 
Entry Alkyne Product Yield (%) 
 
 
1 
 
 
 
 
 
 
69 
 
 
 
2 
 
 
  
 
 
 
84 
 
 
3 
 
 
  
 
 
34 
 
 
 
4 
 
 
  
 
 
 
67 
 
 
 
 
165 
 
4.4.2 Biological activities 
 
The compounds were screen in an in vitro cell survival assay using colorectal HCT116 
p53+/+ (both p53 alleles intact) and HCT116 p53-/- (both p53 alleles disrupted) to asses 
their cytotoxic poteantial but were found to be inactive. Detailed procedure is provided 
in the experimental section. 
 
4.4.3 Conclusion 
 
We have successfully synthesised 6-substituted triazole sugar molecules using click 
chemistry.  Biological assay of these molecules showed that they were inactive. 
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Chapter Five: Experimental 
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5.1 General Experimental 
 
Most commercially available reagents were used as received without additional 
purification.  A minority of compounds were additionally purified and dried according 
to accepted procedures.  Products were typically purified by column chromatography 
using Merck 9385 silica gel 60 (40-63 μm). Analytical thin layer chromatography (TLC) 
was conducted on Merck silica gel 60 F254 glass backed plates. Visualisation of the 
reaction components was accomplished by illumination under short wavelength (254 
nm) ultraviolet light or using basic potassium permanganate (KMnO4) stain. 
 
Proton Nuclear Magnetic Resonance spectra (1H NMR) were recorded in CDCl3 and 
MeOD using spectrometers operating at 360, 600 MHz. Carbon Nuclear Magnetic 
Resonance (13C NMR) were performed on the same instruments operating at 101 and 
150 MHz respectively. Chemical shifts are relative to an internal standard 
(tetramethylsilane, δ = 0.0) and are reported in ppm.  Assignments of the NMR spectra 
were confirmed by COSY, DEPT and HMQC.  Sodium chloride plates were used to run 
the IR spectra. Solids were run as a dispersion in nujol or by grinding with potassium 
bromide powder, and oils were run neat as a thin film. Electrospray ionisation (ESI) 
technique was used for low resolution and high resolution mass spectroscopy. 
Petroleum ether (petrol) refers to the 60-80 ˚C boiling point fraction.  Optical rotations 
were measured with a Perkin Elmer polarimeter (Model 341). 
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1,2,:5,6-Di-O-isopropylidene-α-D-glucofuranose 216 
 
 
 
Sulphuric acid (98%, 16 mL) was added dropwise over 15 mins to a vigorously stirred 
solution of alpha D-glucose (20 g, 0.111 mmol) in acetone (400 mL) at 0 oC.  Sulfuric 
acid (98%, 16 mL) was added dropwise over 15 minutes.  After the addition was 
complete the reaction was stirred vigorously for 5 hours whilst allowing the temperature 
to rise gradually to room temperature.  The reaction mixture was cooled in an ice bath 
and 50% sodium hydroxide solution (30 mL) was added dropwise.  A small amount of 
solid sodium bicarbonate was added to maintain the solution at near neutral pH.  The 
solution was stirred overnight, filtered and concentrated under reduced pressure to a 
thick oil.  The oil was dissolved in chloroform and washed with water (2 x 100 mL).  
The aqueous layer was extracted with chloroform (3 x 70 mL).  The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure.  The crude 
solid was recrystallised from cyclohexane to give the title compound 216 (14.13 g, 49%) 
as white crystals. 
 
mp: 109-110 oC (Lit., 110 oC)59 
 
[α] 20D = -13.3
 (1.35, CHCl3), (Lit., -13.5)59       
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IR: (thin film) 3434, 2987, 2952, 2936, 2807, 2904, 1458, 1423, 1376, 1319, 1287, 1249, 
1223 cm-1.  
 
1H NMR (CDCl3, 600 MHz): δ 1.28 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.41 (s, 3H, CH3), 
1.47 (s, 3H, CH3), 3.97 (dd, 1H, J = 5.2, 8.6 Hz, H-6), 4.02 (dd, 1H, J = 2.8, 7.7 Hz, H-
4),  4.13 (dd, 1H, J = 6.3, 8.6 Hz, H-6), 4.28-4.33 (m, 2H, H-3, H-5), 4.49 (d, 1H, J = 
3.6 Hz, H-2), 5.90 (d, 1H, J = 3.6 Hz, H-1). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.23 (CH3), 26.25 (CH3), 26.85 (CH3), 26.91 (CH3), 
67.70 (C-6), 73.34 (C-5), 75.06 (C-3), 81.22 (C-4), 85.16 (C-2), 105.31 (C-1), 109.70 
(Me2C), 111.89 (Me2C). 
 
LRMS (ESI+): 283.2 [M+Na]+.  
 
HRMS (ESI) calcd for C12H24O6N [M+NH4]+: 278.1598; Found: 278.1606. 
 
3-Vinyl-α-D-1,2,:5,6-di-O-isopropylidene glucofuranose 218 
 
 
 
A mixture of Pd(OAc)2 (314 mg, 1.40 mmol) and 4,7-diphenyl-1,10-phenanthroline 
(641 mg, 1.93 mmol) in BVE (10 mL) was stirred for 5 minutes at room temperature 
under an argon atmosphere.  A solution of compound 216 (12.83 g, 49 mmol) in BVE 
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(270 mL) was added via a cannula to the mixture which was then stirred for 7 days at 75 
oC under an argon atmosphere.  The reaction was cooled to room temperature and 
passed through a column of activated charcoal with petrol/EtOAc (1:1) to remove the 
catalyst. The crude product was purified by flash chromatography eluting with 
petrol/EtOAc (15:1) by deactivating the silica gel with Et3N (2 mL), to give the title 
compound 218 (12.4 g, 88%) as a pale yellow oil. 
 
[α] 20D  = -25.7
 (16.9, CHCl3).  
     
  
 
IR: (thin film) 2988, 2938, 2895, 1638, 1621, 1457, 1374, 1328 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.30 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.42 (s, 3H, CH3), 
1.50 (s, 3H, CH3), 4.02 (dd, 1H, J = 5.2, 8.6 Hz, H-6), 4.08 (dd, 1H, J = 6.2, 8.6 Hz, H-
6), 4.14 (dd, 1H, J = 2.3, 6.7 Hz, H-8), 4.18 (dd, 1H, J = 2.9, 7.7 Hz, H-4), 4.30 (m 1H, 
H-5), 4.34 (d, 1H, J = 2.9 Hz, H-3), 4.38 (dd, 1H, J = 2.3, 14.3 Hz, H-8), 4.58 (d, 1H, J 
= 3.8 Hz, H-2), 5.87 (d, 1H, J = 3.8 Hz, H-1), 6.38 (dd, 1H, J = 7.6, 14.3 Hz, H-7). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.31 (CH3), 26.24 (CH3), 26.75 (CH3), 26.88 (CH3), 
67.08 (C-6), 72.15 (C-5), 80.38 (C-3, C-4), 82.1 (C-2), 89.43 (C-8), 105.15 (C-1), 
109.14 (Me2C), 111.91 (Me2C), 150.05 (C-7). 
 
LRMS (ESI+): 287.3 [M+H]+. 
 
HRMS (ESI) calcd for C14H23O6 [M+H]+: 287.1489; Found: 287.1492. 
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6-Trityl-β-D-glucose-1,2,3,4-tetraacetate 219 
 
 
 
A mixture of D-glucose (15.2g, 84.5 mmol), trityl chloride (24.2 g, 86.8 mmol), and 
anhydrous pyridine (65 mL) was heated until a solution was obtained. Without cooling, 
acetic acid (45 mL) was added and the mixture was left to cool and stand for 18 h.  The 
reaction mixture was poured slowly into ice water (1 L), to which acetic acid (500 mL) 
was added, and the resulting mixture was stirred mechanically for 2 hrs.  The precipitate 
was filtered, and washed with cold water and dried.  The solid was suspended in ether 
(60 mL).  The insoluble material was collected, dried and then recrystallised from hot 
95% aqueous ethanol to give the title compound 219 (20.9 g, 42%) as fine needles. 
 
mp: 166-167 °C (Lit., 166–166.5 °C)66 
 
[α] 20D  = +44.4
 (c 4.74, CHCl3), (Lit., +44.8)66 
 
IR: (KBr): 3024, 2943, 1757, 1432, 1223, 1078, 1039, 901, 757 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.72 (s, 3H, CH3), 1.99 (s, 3H, CH3), 2.04 (s, 3H, CH3), 
2.15 (s, 3H, CH3), 3.05 (dd, 1H, J = 4.1, 10.5 Hz, H-6), 3.33 (dd, J = 2.1, 10.5 Hz, H-6), 
3.68 (m, 1H, H-5), 5.17 (m, 2H, H-2, H-3), 5.26 (m, 1H, H-4), 5.71 (dd, 1H, J = 3.2, 1.5 
Hz, H-1), 7.22 (m, 3H, Ar-H), 7.26 (m, 6H, Ar-H), 7.41 (d, 6H, J = 11.5 Hz, Ar-H). 
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13C NMR (CDCl3, 150.9 MHz): δ 20.54 (CH3), 20.71 (CH3), 20.75 (CH3), 20.98 (CH3), 
61.71 (C-6), 68.37 (C-4), 70.61 (C-3), 73.23 (C-2), 74.13 (C-5), 86.72 (OCPh3), 92.01 
(C-1), 127.11 (Ar-CH), 127.88 (Ar-CH), 128.80 (Ar-CH), 143.56 (Ar-C), 169.04 (C=O), 
169.09 (C=O), 169.46 (C=O), 170.37 (C=O). 
 
LRMS (ESI+): 613.4 [M+Na]+. 
 
HRMS (ESI) calcd for C33H38O10N [M+NH4]+: 608.2490 ; Found: 608.2490. 
 
β-D-Glucose-1,2,3,4-tetraacetate 220 
 
 
 
Compound 219 (20.3 g, 34.4 mmol) and acetic acid (100 mL) were heated until a 
solution was obtained.  The solution was cooled to 10 oC, and a solution of hydrogen 
bromide in acetic acid (8.2 mL) was added, and the mixture was shaken for 45 seconds.  
The mixture was immediately filtered to remove the trityl bromide formed, and the 
filtrate is poured immediately into cold water (500 mL).  The product was extracted 
with chloroform (200 mL) and washed with ice water (4 x 50 mL) and dried over 
anhydrous sodium sulphate.  The chloroform was evaporated under reduced pressure.  
The resulting syrup was covered with anhydrous ether to induce crystallisation.  The 
crude product was removed by filteration and dissolved in the minimum amount of 
chloroform, followed by slow, careful addition of diethyl ether until crystallisation 
began, to give the title compound 220 (6.28 g, 53%) as a white crystalline solid. 
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mp: 127-128 °C, (Lit., 128–129 °C)66 
 
[α] 20D  = +10.8
 (c  4.13, CHCl3), (Lit., +12.1)66 
 
IR: (KBr) 3475, 3060, 2938, 2871, 1751, 1492, 1449, 1366, 1224, 1072, 980 cm-1 
 
1H NMR (CDCl3, 600 MHz): δ 2.01 (s, 3H, CH3), 2.02 (s, 3H, CH3), 2.06 (s, 3H, CH3), 
2.10 (s, 3H, CH3), 2.28 (br s, 1H, OH), 3.56 (dd, 1H, J = 4.0, 12.5 Hz, H-6), 3.65 (ddd, 
1H, J = 1.7, 4.0, 6.0 Hz, H-5), 3.77 (dd, 1H, J = 6.0, 12.5 Hz, H-6), 5.06-5.12 (m, 2H, 
H-2 and H-4), 5.28-5.31 (m, 1H, H-3), 5.71 (d, 1H, J = 8.2, H-1). 
 
13C NMR (CDCl3, 150.9 MHz): δ 20.72 (CH3), 20.75 (CH3), 20.78 (CH3), 20.96 (CH3), 
60.93 (C-6), 68.28 (C-4), 70.50 (C-3), 72.71 (C-2), 75.01 (C-5), 91.83 (C-1), 169.24 
(C=O), 169.44 (C=O), 170.26 (C=O), 170.46 (C=O). 
 
LRMS (ESI+): 371.3 [M+Na]+. 
 
HRMS (ESI) calcd for C14H20O10Na [M+Na]+: 371.0949; Found: 371.0949.  
 
 
 
 
 
 
 
 
174 
 
6-Vinyloxy-β-D-glucose-1,2,3,4-tetraacetate 221 
 
 
 
 
A mixture of Pd(OAc)2 (88 mg, 0.39 mmol) and 4,7-diphenyl-1,10-phenanthroline (180 
mg, 0.54 mmol) in BVE (10 mL) was stirred for 5 minutes at room temperature. A 
solution of compound 220 (3.60 g, 10.3 mmol) in BVE (65 mL) was added via cannula 
to this mixture, which was then stirred for 7 days at 75 oC under an argon atmosphere.  
The reaction mixture was cooled to room temperature and was passed through column 
of activated charcoal eluting with petrol/EtOAc (1:1) to remove the catalyst.  The 
product was concentrated under reduced pressure and recrystallised from petrol to 
afford the title compound 221 (1.74g, 45%) as a white solid. 
  
mp: 101-103 °C 
 
[α] 20D  = 12.7
 (c 6.02, CHCl3). 
 
IR: (KBr): 2958, 2954, 1761, 1625, 1372, 1223, 1079, 1039, 901 cm-1 
 
1H NMR (CDCl3, 600 MHz): δ 2.01 (s, 3H, CH3), 2.02 (s, 3H, CH3), 2.03 (s, 3H, CH3), 
2.10 (s, 3H, CH3), 3.75 (dd, 1H, J = 4.6, 11.2 Hz, H-6), 3.81 (dd, 1H, J = 2.6, 11.2 Hz, 
H-6), 3.86-3.89 (m, 1H, H-5), 4.03 (dd, 1H, J = 2.4, 6.7 Hz, H-8 cis), 4.15 (dd, 1H, J = 
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2.4, 14.3 Hz, H-8 trans), 5.12-5.19 (m, 2H, H-2, H-4), 5.26 (t, 1H, J = 9.5 Hz, H-3), 
5.73 (d, 1H, J = 8.3, H-1), 6.44 (dd, 1H, J = 6.7, 14.3 Hz, H-7). 
 
13C NMR (CDCl3, 150.9 MHz): δ 20.66 (CH3), 20.71 (CH3), 20.92 (CH3), 31.04 (CH3), 
65.92 (C-6), 68.52 (C-4), 70.35 (C-2), 72.93 (C-3), 73.07 (C-5), 87.36 (C-8), 91.78 (C-
1), 151.38 (C-7), 169.04 (C=O), 169.09 (C=O), 169.46 (C=O), 170.37 (C=O). 
 
LRMS (ESI+): 392.1 [M+NH4]+. 
 
HRMS (ESI) calcd for C16H26O10N1 [M+NH4]+: 392.1551; Found: 392.1558. 
 
1,2,3,4,6-Penta-O-benzoyl-α-D-mannopyranose 223 
 
 
 
D-Mannose (2.0 g, 11.1 mmol) and a catalytic DMAP were dissolved in pyridine (12 
mL) and cooled to 0 oC.  Benzoyl chloride (9.6 mL, 82.5 mmol) was added dropwise 
and the mixture was stirred overnight at room temperature. The reaction mixture was 
concentrated under reduced pressure. The residue was dissolved in DCM (200 mL) and 
H2O (40 mL) was added carefully with cooling and vigorous stirring to decompose 
excess benzoyl chloride. The product was extracted with DCM, the organic phase was 
washed with brine (40 mL), sat. NaHCO3 (2 × 40 mL), and brine (40 mL), dried over 
anhydrous MgSO4 and concentrated under reduced preaure.  The crude product was 
dissolved in a mixture of acetone–methanol (1:1, ca. 20 mL), and left overnight.  The 
solution was then diluted with methanol (10 mL), left for 2 h, further diluted with 
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methanol (20 mL) and left for two days at 4 oC.  The precipitated crystals were collected 
by filtration, washed with a small amount of methanol and dried in air to give the title 
compound 223 (5.56 g, 72%) as a white solid.  
 
mp: 151–152 oC (Lit., 152-153 oC)159
 
 
[α] 20D  = -22.1
 (c 2.09, CHCl3), (Lit., -18.6)159 
 
IR: (KBr): 3064, 3034, 2973, 2913, 2890, 1725, 1602, 1453, 1266, 1178, 1086, 1026, 
995 cm-1 
 
1H NMR (CDCl3, 600 MHz): δ 4.49 (dd, 1H, J = 3.6, 12.2 Hz, H-6), 4.56 (dt, 1H, J = 
10.1, 2.5 Hz, H-5), 4.69 (dd, 1H, J = 2.4, 12.2 Hz, H-6), 5.90-5.91 (m, 1H, H-2), 6.06 
(dd, 1H, J = 3.3, 10.1 Hz, H-3), 6.28 (t, 1H, J = 10.1 Hz, H-4), 6.62 (s, 1H, H-1), 7.27-
7.69 (m, 15H, Ar-H), 7.84-8.20 (m, 10H, Ar-H), 
 
13C NMR (CDCl3, 150.9 MHz): 62.45 (C-6), 66.26 (C-4), 69.54 (C-2), 70.11 (C-3), 
71.30 (C-5), 91.48 (C-1), 128.56-129.13 (Ar-C, Ar-CH), 128.97 (Ar-CH), 129.92 (Ar-
CH), 129.97 (Ar-CH), 130.11 (Ar-CH), 130.31 (Ar-CH), 133.22 (Ar-CH), 133.56 (Ar-
CH), 133.71 (Ar-CH), 133.83 (Ar-CH), 134.24 (Ar-CH), 163.96 (C=O), 165.27 (C=O), 
165.41 (C=O), 165.85 (C=O), 166.18 (C=O). 
 
LRMS (ESI+): 723 [M+Na]+. 
 
HRMS (ESI) calcd for C41H36O11N [M+NH4]+: 718.2283; Found: 718.2286. 
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2,3,4,6-Tetra-O-benzoyl-α-D-mannopyranose 224 
 
 
            
Ethanolamine (1.14 mL, 15.76 mmol) was added dropwise to a solution of compound 
223 (12.1 g, 17.30 mmol) in dry THF (100 mL) and.  The solution was stirred overnight, 
during which time a white precipitate formed. The precipitate was removed by 
filteration, and the filtrate was stripped of solvent under reduced pressure. The crude 
product was purified by flash chromatography eluting with petroleum ether/EtOAc (3:1) 
to give the title compound 224 (5.1 g, 50%) as a white foam. 
 
[α] 20D  = -83.5
 (c 0.4, CHCl3), (Lit., -81.0)160
 
 
IR: (KBr): 3501, 3067, 2957, 1726, 1602, 1452, 1269, 1179, 1107, 1069, 1025, 969 cm-
1. 
 
1H NMR (CDCl3, 600 MHz): δ 3.58 (br s, 1H, OH), 4.45 (dd, 1H, J = 3.6, 12.2 Hz, H-6), 
4.68 (dt, 1H, J = 10.0, 2.9 Hz, H-5), 4.77 (dd, 1H, J = 2.4, 12.2 Hz, H-6), 5.54 (s, 1H, 
H-1), 5.74-5.75 (m, 1H, H-2), 6.01 (dd, 1H, J = 3.3, 10.3 Hz, H-3), 6.18 (t, 1H, J = 10.1 
Hz, H-4), 7.27-7.59 (m, 12H, Ar-H), 7.84-8.13 (m, 8H, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): 62.83 (C-6), 66.96 (C-4), 69.04 (C-5), 69.86 (C-3), 
70.93 (C-2), 91.48 (C-1), 128.44 (Ar-CH), 128.59 (2 x Ar-CH), 128.70 (Ar-CH), 128.80 
(Ar-C), 129.12 (Ar-C), 129.20 (Ar-C), 129.40 (Ar-C), 129.89 (Ar-CH), 129.95 (2 x Ar-
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CH), 129.97 (Ar-CH), 133.23 (Ar-CH), 133.32 (Ar-CH), 133.57 (Ar-CH), 133.59 (Ar-
CH), 165.61 (2 x C=O), 165.69 (C=O), 166.46 (C=O). 
 
LRMS (ESI+): 619 [M+Na]+. 
 
HRMS (ESI) calcd for C34H32O10N [M+NH4]+: 614.2021; Found: 614.2018. 
 
1-Vinyl-2,3,4,6-tetra-O-benzoyl-α-D-mannopyranose 225 
 
 
 
A mixture of Pd(OAc)2 (194 mg, 0.864 mmol) and 4,7-diphenyl-1,10-phenanthroline 
(323 mg, 97.1 mmol) in BVE (10 mL) was stirred for 5 minutes at room temperature.  
Compound 224 (3.60 g, 10.3 mmol) was dissolved in BVE (170 mL) and injected into 
the reaction mixture which was then stirred for 7 days at 75 oC in an argon atmosphere.  
The reaction mixture was cooled to room temperature and was passed through a column 
of activated charcoal eluting with petrol/EtOAc (1:1) to remove the catalyst.  The 
product was concentrated under reduced pressure and purified by flash chromatography 
eluting with petroleum ether/EtOAc (3:1) to give the title compound 225 (3.6 g, 46%) 
as a yellow oil. 
 
[α] 20D  = -37.1
 (c 7.00, CHCl3). 
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IR: (thin film) 3066, 2959, 2935, 2872, 1730, 1646, 1602, 1268, 1103, 1070, 1027, 978 
cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 4.36 (dd, 1H, J = 2.1, 6.5 Hz, H-8), 4.43-4.4.48 (m, 2H, 
H-5, H-6), 4.70 (d, 1H, J = 11.5 Hz, H-6), 4.79 (dd, 1H, J = 2.1, 14.1 Hz, H-8), 5.45 (s, 
1H, H-1), 5.78 (dd, 1H, J = 1.9, 3.4 Hz, H-2), 5.97 (dd, 1H, J = 3.4, 10.1 Hz, H-3), 6.16 
(t, 1H, J = 10.1 Hz, H-4), 6.49 (dd, 1H, J = 6.5, 14.1 Hz, H-7), 7.27-7.62 (m, 12H, Ar-
H), 7.84-8.12 (m, 8H, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): 62.66 (C-6), 66.61 (C-4), 69.53 (C-5), 69.89 (C-3), 
69.93 (C-2), 93.90 (C-7), 96.39 (C-1), 128.46 (Ar-CH), 128.57 (Ar-CH), 128.60 (Ar-
CH), 128.70 (Ar-C), 128.76 (Ar-CH), 128.99 (Ar-C), 129.08 (Ar-C), 129.24 (Ar-C), 
129.89 (2 x Ar-CH), 129.96 (Ar-CH), 130.01 (Ar-CH), 133.21 (Ar-CH), 133.39 (Ar-
CH), 133.64 (Ar-CH), 133.72 (Ar-CH), 147.58 (C-8), 165.44 (C=O), 165.54 (C=O), 
166.60 (C=O), 166.26 (C=O).  
 
LRMS (ESI+): 645 [M+Na]+. 
 
HRMS (ESI) calcd for C36H34O10N [M+NH4]+: 640.2177; Found: 640.2173. 
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Ethyl coumalate 227 
 
 
 
4-Dimethylaminopyridine (1.17 g, 9.58 mmol) was added to a stirred solution of 
coumalic acid (6.77 g, 48.3 mmol) in DCM (2.50 mL) and stirred for 15 min at room 
temperature.  Ethanol (14 mL) and dicyclohexyl carbodiimide (9.9 g, 48 mmol) were 
added and the reaction mixture stirred for 18 hours.  The solvent was removed under 
reduced pressure and the residue was dissolved in EtOAc (200 mL) and filtered through 
a bed of celiteTM.  The solvents were removed under reduced pressure and the crude 
product was purified by flash chromatography eluting with petroleum ether/EtOAc (2:1) 
to give the title compound (6.1 g, 75%) as a yellow solid. 
 
mp: 42-43 oC (Lit, 43 oC)69 
 
IR: (KBr) 3088, 2986, 2940, 1757, 1722, 1555, 1469, 1432, 1370, 1296, 1238, 1086, 
1019, 948 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.35 (t, 3H, J = 7.2 Hz, H-9), 4.33 (q, 2H, J = 7.2 Hz, H-
8), 6.33 (dt, 1H, J = 9.8, 1.0 Hz, H-3), 7.79 (dd, 1H, J = 2.6, 9.8 Hz, H-4), 8.29-8.30 (dd, 
J = 1.0, 2.6 Hz, H-6). 
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13C NMR (CDCl3, 150.9 MHz): δ 14.33 (C-9), 61.76 (C-8), 112. 31 (C-5), 115.34 (C-3), 
141.87 (C-4), 158.14 (C-6), 160.06 (C=O), 163.07 (C=O). 
 
LRMS (ESI+): 169.1 [M+H]+. 
 
HRMS (ESI) calcd for C8H9O4 [M+H]+: 169.9495; Found: 169.0495. 
 
3-Bromo-2(H)-pyran-2-one 228 & 5-bromo-2(H)-pyran-2-one 229 
 
 
 
Triethylamine (4.3 mL) was added dropwise to a stirred solution of 3,5-dibromo-5,6-
dihydro-2H-pyran-2-one161
 
 (6.27 g, 24.51 mmol) in DCM (110 mL) and the reaction 
mixture stirred for 24 hours.  The reaction mixture was washed with water (3 x 100 mL).  
The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure.  The crude product was purified by flash chromatography eluting with 
petroleum ether/EtOAc (10:1) to give the title compound 229 (300 mg, 7%) as a light 
brown solid and the title compound 228 (1.39 g, 33%) as a tan solid. 
3-Bromo-2(H)-pyran-2-one 228 
 
IR: (KBr) 3098, 1730, 1622, 1530, 1322, 1236, 1092, 973 cm-1 
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1H NMR (CDCl3, 600 MHz): δ 6.16 (dd, 1H, J = 5.0, 7.0 Hz, H-5), 7.33 (dd, 1H, J = 1.7, 
5.0 Hz, H-6), 7.70 (dd, 1.7, 7.0 Hz, H-4). 
 
13C NMR (CDCl3, 150.9 MHz): δ 106.67 (C-5), 112.89 (C-3), 144.19 (C-4), 151.07 (C-
6), 158.32 (C=O). 
 
LRMS (ESI+): 175.0 [M+H]+. 
 
HRMS (ESI) calcd for C5H4O279Br [M+H]+: 174.9386; Found: 174.9386. 
 
5-Bromo-2(H)-pyran-2-one 229 
 
IR: (KBr) 3073, 1744, 1606, 1531, 1322, 1220, 1156, 1126, 1040, 938, 830 cm-1 
 
1H NMR (CDCl3, 600 MHz): δ 6.29 (d, 1H, J = 10.0 Hz, H-3), 7.33 (dd, 1H, J = 2.7, 
10.0 Hz, H-4), 7.58 (d, 2.7 Hz, H-6). 
 
13C NMR (CDCl3, 150.9 MHz): δ 100.93 (C-5), 117.72 (C-3), 146.13 (C-4), 149.81 (C-
6), 159.61 (C=O). 
 
LRMS (ESI+): 175.0 [M+H]+.  
 
HRMS (ESI) calcd for C5H3O279Br [M+H]+: 173.9311; Found: 173.9313. 
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Cycloaddition between 218 & 226 
A solution of compound 218 (8.39 g, 29.32 mmol, 2 eq.) and compound 226 (2.26 g, 
14.66 mmol, 1 eq.) in DCM (2 mL) was heated for 7 days at 65 oC in a sealed tube.  The 
reaction mixture was cooled to room temperature and the solvent was removed under 
reduced pressure. The crude product was purified by flash chromatography on silica gel 
(pre-washed with petrol/EtOAc/Et3N (92:6:12)), eluting with petroleum ether/EtOAc 
(15:1, then 8:1, then 5:1) to give 5-endo cycloadduct 246a (2.97 g, 43%) as a pale 
yellow oil, 5-endo cycloadduct 246b (1.56 g, 24%) as a white crystalline solid, and a 
mixture of 5-exo cycloadducts 246c/d (4.6:1, 204 mg, 3%) as a yellow oil. 
 
5-Endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-3-oxo-2-oxa-
bicyclo[2.2.2]oct-8-ene-4-carboxylic acid methyl ester 246a 
 
 
 
[α] 20D  = -14.1
 (c 8.00, CHCl3).  
     
  
 
IR: (thin film) 2988, 2939, 2897, 1766, 1619, 1439, 1373, 1248, 1284, 1218, 1119, 1077 
cm-1. 
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1H NMR (CDCl3): δ 1.29 (s, 3H, CH3), 1.31 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.47 (s, 3H, 
CH3), 1.92 (dt, 1H, J = 13.8, 1.7 Hz, H-6), 2.59 (ddd, 1H, J = 3.6, 7.2, 13.8 Hz, H-6), 
3.87 (m, 1H, H-6’), 3.91 (m, 1H, H-4’) 3.93 (s, 3H, OCH3), 3.99-4.00 (m, 1H, H-3’), 
4.01-4.04 (m, 2H, H-5’, H-6’) 4.59 (m, 2H, H-2’, H-5), 5.27 (ddd, 1H, J = 1.7, 3.6, 5.2 
Hz, H-1), 5.73 (d, 1H, J = 3.8 Hz, H-1’), 6.60 (dd, 1H, J = 5.2, 7.7 Hz, H-7), 6.71 (d, 1H, 
J = 7.7 Hz, H-8). 
 
13C NMR (CDCl3): δ 25.48 (CH3), 26.27 (CH3), 26.88 (CH3), 26.91 (CH3), 34.68 (C-6), 
53.22 (OCH3), 61.48 (C-4), 67.67 (C-6’), 71.91 (C-5’), 72.20 (C-5), 74.24 (C-1), 80.66 
(C-4’), 80.92 (C-3’), 81.93 (C-2’), 105.51 (C-1’), 109.69 (Me2C), 112.17 (Me2C), 
129.60 (C-8), 130.76 (C-7), 167.45 (C=O), 168.35 (C=O). 
 
LRMS (ESI+): 463.2 [M+Na]+. 
 
HRMS (ESI) calcd for C21H29O10 [M+H]+: 441.1755; Found: 441.1757. 
 
5-Endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-3-oxo-2-oxa-
bicyclo[2.2.2]oct-8-ene-4-carboxylic acid methyl ester 246b 
 
 
 
mp: 147-149 oC 
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[α] 20D   = -13.5
 (c 11.3, CHCl3). 
 
IR: (KBr) 2988, 2925, 2855, 1760, 1738, 1615, 1459, 1440, 1377, 1356 cm-1. 
 
1H NMR (CDCl3): δ 1.30 (s, 3H, CH3), 1.35 (s, 3H, CH3), 1.40 (s, 3H, CH3), 1.66 (s, 
3H, CH3), 1.91 (dt, 1H, J = 14.1, 1.7 Hz, H-6), 2.76 (ddd, 1H, J = 3.6, 7.9, 13.9 Hz, H-
6), 3.87 (dd, 1H, J = 5.7, 8.4 Hz, H-6’), 3.93 (s, 3H, OCH3), 4.00 (m, 2H, H-4’, H-6’), 
4.07 (dd, 1H, J = 5.8, 13.8 Hz, H-5’), 4.18 (d, 1H, J = 2.9 Hz, H-3’), 4.38 (d, 1H, J = 
3.6 Hz, H-2’), 4.65 (d, 1H, J = 7.4 Hz, H-5), 5.25 (ddd, 1H, J = 1.7, 3.4, 6.7 Hz, H-1), 
5.76 (d, 1H, J = 3.6 Hz, H-1’), 6.62 (dd, 1H, J = 2.2, 7.7 Hz, H-7), 6.75 (d, 1H, J = 1.2, 
7.7 Hz, H-8). 
 
13C NMR (CDCl3): δ 25.31 (CH3), 26.34 (CH3), 26.88 (CH3), 26.90 (CH3), 37.32 (C-6), 
53.14 (OCH3), 61.67 (C-4), 67.37 (C-6’), 71.93 (C-5’), 72.07 (C-5), 73.91 (C-1), 81.13 
(C-4’), 82.70 (C-3’) 82.89 (C-2’), 105.03 (C-1’), 109.20 (Me2C), 112. 28 (Me2C), 
129.96 (C-8), 130.73 (C-7), 167.20 (C=O), 168.45 (C=O). 
 
LRMS (ESI+): 463.2 [M+Na]+. 
 
HRMS (ESI) calcd for C21H32NO10 [M+NH4]+: 458.2021 ; Found: 458.2020. 
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5-Exo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-3-oxo-2-oxa-
bicyclo[2.2.2]oct-8-ene-4-carboxylic acid methyl ester 246c/d 
 
 
 
IR: (thin film) 2989, 1743, 1439, 1626, 1439, 1369, 1218, 1077, 1019 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.32 (s, 3H, CH3), 1.32 (s, 3H, CH3), 1.40 (s, 3H, CH3), 
1.49 (s, 3H, CH3), 2.1 (dd, 1H, J =  8.4, 13.6 Hz, H-6), 2.32 (ddd, 1H, J = 2.2, 4.0, 13.6 
Hz, H-6), 3.90-3.91 (m, 1H, H-6’), 3.92 (s, 3H, OCH3),  4.03 (dd, 1H, J = 3.1, 8.6 Hz, 
H-4’), 4.06-4.08 (m, 2H, H-3’, H-6’), 4.11-4.4.15 (m, 1H, H-5’), 4.30 (dd, 1H, J = 2.1, 
8.4 Hz, H-5), 4.78 (d, 1H,  J = 3.6 Hz, H-2’), 5.23-5.24 (m, 1H, H-1), 5.84 (d, 1H, J = 
3.6 Hz, H-1’), 6.36 (dd, 1H, J = 2.2, 7.7 Hz, H-8), 6.75 (d, 1H, J = 1.2, 7.7 Hz, H-7). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.46 (CH3), 26. 46 (CH3), 27.03 (CH3), 27.07 (CH3), 
34.64 (C-6), 53.23 (OCH3), 60.12 (C-4),  67.87 (C-6’), 72.46(C-5’), 73.59 (C-5),  73.89 
(C-1), 81.26 (C-4’), 82.17 (C-3’)  82.42 (C-2’), 105.68 (C-1’), 109.13 (Me2C), 111.96 
(Me2C), 130.5 (C-8), 134.70 (C-7), 166.66 (C=O), 168.58 (C=O). 
 
LRMS (ESI+): 463 [M+Na]+. 
 
HRMS(EI) calcd for C21H32O10N [M+NH4]+: 458.2021; Found: 458.2024.  
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Cycloaddition between 218 & 227 
 
 
A solution of compound 218 (1.98 g, 6.92 mmol, 2 eq.) and ethyl coumalate 227 (581 
mg, 3.46 mmol, 1 eq.)  in DCM (2 mL) was heated for 6 days at 100 oC in a sealed tube.  
The reaction mixture was cooled to room temperature and the solvent was removed 
under reduced pressure. The crude product was purified by flash chromatography on 
silica gel (pre-washed with petrol/EtOAc/Et3N (92:6:12)), eluting with petroleum 
ether/EtOAc (8:1 and 6:1)  to give a mixture of 5-endo-1/5-endo-2 cycloadducts 247a/b 
(1.22 g, 78%), as a pale yellow oil, a mixture of 5-exo-1/5-exo-2 cycloadducts 247c/d 
(162 mg, 10%) as a pale yellow oil and a mixture of diastereomers 272a/b (159 mg, 
11%) as a pale yellow oil. 
 
5-Endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-3-oxo-2-oxa-
bicyclo[2.2.2]oct-8-ene-7-carboxylic acid ethyl ester 247a 
 
IR: (thin film) 2987, 2938, 1767, 1717, 1637, 1456, 1379, 1300, 1258, 1216, 1080, 960 
cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.31 (br s, 3H, OCH2CH3 ), 1.33 (s, 3H, CH3), 1.37 (s, 
3H, CH3), 1.39 (s, 3H, CH3), 1.49 (s, 3H, CH3), 1.82 (dt, 1H, J = 14.3, 1.4 Hz, H-6), 
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2.57 (ddd, 1H, J = 3.8, 7.6, 14.3 Hz, H-6), 3.90 (dd, 1H J = 5.0, 8.4 Hz, H-6’), 3.92 (d, 
1H, J = 2.9 Hz, H-4’), 3.96-3.98 (m, 1H, H-6’), 3.99-4.01 (m, 1H, H-3’), 4.02-4.06 (m, 
1H, H-4), 4.22-4.26 (m, 3H, OCH2CH3, H-5’), 4.32-4.34 (m, 1H, H-5), 4.43 (d, 1H, J = 
3.6 Hz, H-2’), 5.71-5.72 (m, H-1), 5.83 (d, 1H, J = 3.6 Hz, H-1’), 7.23 (dd, 1H, J = 1.4, 
6.2 Hz, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 14.29 (OCH2CH3), 25.19 (CH3), 26. 31 (CH3), 26.84 
(CH3), 26.98 (CH3), 34.10 (C-6), 48.55 (C-4), 61.48 (OCH2CH3), 67.84 (C-6’), 71.36 
(C-5’), 72.08 (C-5), 73.38 (C-1), 80.69 (C-4’), 81.18 (C-3’), 83.11 (C-2’), 105.50 (C-1’), 
109.31 (Me2C), 112.29 (Me2C), 136.44 (C-8), 137.92 (C-7), 162.01 (C=O), 170.23 
(C=O). 
 
5-Endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-3-oxo-2-oxa-
bicyclo[2.2.2]oct-8-ene-7-carboxylic acid ethyl ester 247b 
 
1H NMR (CDCl3, 600 MHz): δ 1.30 (br s, 3H, OCH2CH3 ), 1.31 (s, 3H, CH3), 1.39 (s, 
3H, CH3), 1.44 (s, 3H, CH3), 1.48 (s, 3H, CH3), 1.59 (dt, 1H, J = 1.4, 14.3 Hz, H-6), 
2.68 (ddd, 1H, J = 3.8, 7.9, 14.3 Hz, H-6), 3.95 (dd, 1H, J = 4.6, 8.3 Hz, H-6’), 3.97-
4.00 (m, 2H, H-3’, H-4’), 4.08 (dd, 1H, J = 6.2, 8.3 Hz, H-6’), 4.16 (dd, 1H, J = 3.3, 6.2 
Hz, H-4), 4.23-4.26 (m, 3H, OCH2CH3, H-5’), 4.32-4.33 (m, 1H, H-5), 4.42 (d, 1H, J = 
3.8 Hz, H-2’), 5.68-5.69 (m, 1H, H-1), 5.80 (d, 1H, J = 3.8 Hz, H-1’), 7.26-7.27 (m, 1H, 
H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 14.28 (OCH2CH3), 25.34 (CH3), 26.27 (CH3), 26.87 
(CH3), 26.90 (CH3), 35.37 (C-6), 46.91 (C-4), 61.44 (OCH2CH3), 67.80 (C-6’), 70.87 
(C-5’), 71.74 (C-5), 73.27 (C-1), 80.66 (C-4’), 80.96 (C-3’), 83.02 (C-2’), 105.42 (C-1’), 
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109.55 (Me2C), 112.36 (Me2C), 135.92 (C-8), 138.89 (C-7), 162.20 (C=O), 170.40 
(C=O). 
 
LRMS (ESI+): 477.0 (MNa+). 
 
HRMS (ESI) calcd for C22H34O10N [M+NH4]+: 472.2177; Found: 472.2173. 
 
5-Exo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-3-oxo-2-oxa-
bicyclo[2.2.2]oct-8-ene-7-carboxylic acid ethyl ester 247c/d 
 
 
 
IR: (thin film) 2988, 2939, 1769, 1717, 1637, 1456, 1374, 1252, 1087, 1020, 957 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.30 (overlapping s, 6H, OCH2CH3, CH3), 1.31 (s, 3H, 
CH3), 1.39 (s, 3H, CH3), 1.48 (s, 3H, CH3), 2.13-2.15 (m, 2H, H-6, H-6), 3.93-3.95 (m, 
2H, H-4, H-6’), 3.98 (d, 1H, J = 2.1 Hz, H-3’), 4.02 (dd, 1H, J =  2.9, 8.6 Hz, H-4’), 
4.08-4.15 (m, 3H, H-5, H-5’, H-6’), 4.25 (q, 2H, J = 7.2 Hz, OCH2CH3), 4.62 (d, 1H, J 
= 3.6 Hz, H-2’), 5.63-5.64 (m, H-1), 5.83 (d, 1H, J = 3.6 Hz, H-1’), 7.21-7.22 (d, 1H, J 
= 2.4 Hz, H-8). 
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13C NMR (CDCl3, 150.9 MHz): δ 14.28 (OCH2CH3), 25.46 (CH3), 26. 36 (CH3), 26.97 
(CH3), 27.01 (CH3), 33.61 (C-6), 48.27 (C-4), 61.65 (OCH2CH3), 67.88 (C-6’), 72.52 
(C-5’), 73.53 (C-1), 74.61 (C-5), 81.30 (C-4’), 81.97 (C-3’), 83.69 (C-2’), 105.62 (C-1’), 
109.27 (Me2C), 112.15 (Me2C), 137.32 (C-8), 138.86 (C-7), 161.98 (C=O), 169.92 
(C=O). 
 
LRMS (ESI+): 477.2 [M+Na]+.  
 
HRMS (ESI) calcd for C22H34O10N [M+NH4]+: 472.2177; Found: 472.2174. 
 
2-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-cyclohexa-3,5-dienecarboxylic 
acid ethyl ester 272a/b 
 
 
 
IR: (thin film) 2986, 2938, 1721, 1454, 1357, 1250, 1217, 1163, 1075, 1022, 960 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.28 (br s, 3H, OCH2CH3), 1.32 (s, 3H, CH3), 1.39 (s, 
3H, CH3), 1.40 (s, 3H, CH3), 1.47 (s, 3H, CH3), 2.50 (ddd, 1H, J = 3.1, 7.6, 19.6 Hz, H-
1), 2.79 (dt, 1H, J = 19.6, 5.0 Hz, H-1), 3.93 (dd, 1H, J = 6.0, 8.6 Hz, H-6’), 4.00 (dd, 
1H, J = 2.9, 9.5 Hz, H-4’), 4.03-4.08 (m, 2H, H-3’, H-6’), 4.17-4.19 (m, 1H, H-2), 4.20-
4.21 (m, 1H, H-5’), 4.22-4.23 (m, 2H, OCH2CH3), 4.45 (d, 1H, J = 3.6 Hz, H-2’), 5.82 
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(d, 1H, J = 3.6 Hz, H-1’), 6.04 (dd, 1H, J = 4.6, 9.8 Hz, H-3), 6.62 (d, 1H, J = 9.8 Hz, 
H-4), 6.97-7.00 (m, 1H, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 14.35 (OCH2CH3), 25.51 (CH3), 26. 37 (CH3), 26.94 
(2 x CH3), 29.94 (C-1), 60.74 (OCH2CH3), 67.69 (C-6’), 69.89 (C-5’), 72.31 (C-2), 
80.05 (C-4’), 81.42 (C-3’), 84.10 (C-2’), 105.44 (C-1’), 109.08 (Me2C), 111.93 (Me2C), 
124.86 (C-4), 125.08 (C-3), 136.37 (C-5a), 159.70 (C-5), 165.33 (C=O). 
 
LRMS (ESI+): 428.2 [M+NH4]+.  
 
HRMS (ESI) calcd for C21H34O8N [M+NH4]+: 428.2279; Found: 428.2274. 
 
 
Cycloaddition between 218 & 228 
 
 
A solution of compound 218 (2.13 g, 7.44 mmol, 20 eq.) and compound 228 (65.1 mg, 
0.372 mmol, 1 eq) in DCM (1 mL) and a few drops of Et3N was heated for 6 days at 
100 oC in a sealed tube.  The reaction mixture was cooled to room temperature and the 
solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N (92:6:12)), eluting 
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with petroleum ether/EtOAc (10:1) to give 5-endo-cycloadduct 248a (65 mg, 38%), as a 
yellow oil and 5-endo-cycloadduct 248b (52 mg, 30%) as a yellow oil. 
 
IR: (thin film) 2989, 2938, 1763, 1620, 1439, 1374, 1284, 1217, 1077, 1023, 959 cm-1. 
 
4-Bromo-5-endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-2-oxa-
bicyclo[2.2.2]oct-8-en-3-one 248a 
 
1H NMR (CDCl3, 600 MHz): δ 1.29 (s, 3H, CH3), 1.31 (s, 3H, CH3), 1.38 (s, 3H, CH3), 
1.47 (s, 3H, CH3), 1.91 (dt, 1H, J = 13.9, 1.7 Hz, H-6), 2.58 (ddd, 1H, J = 3.6, 7.4, 13.9 
Hz, H-6), 3.87-3.88 (m, 1H, H-6’), 3.91 (d, 1H, J = 2.8 Hz, H-4’), 3.98-4.04 (m, 3H, H-
3’, H-5’, H-6’), 4.57-4.58 (m, 1H, H-5), 4.58 (d, 1H, J = 3.6 Hz, H-2’), 5.29-5.31 (m, 
1H, H-1), 5.74 (d, 1H, J = 3.6 Hz, H-1’), 6.60 (dd, 1H, J = 5.0, 7.7 Hz, H-7), 6.71 (d, 
1H, J = 7.7 Hz, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.55 (CH3), 26.32 (CH3), 26.94 (CH3), 26.96 (CH3), 
34.74 (C-6), 61.54 (C-4), 67.67 (C-6’), 71.91 (C-5’), 72.20 (C-5), 74.24 (C-1), 80.74 
(C-4’), 80.98 (C-3’), 82.00 (C-2’), 105.57 (C-1’), 1109.17 (Me2C), 112.31 (Me2C), 
129.67 (C-8), 130.80 (C-7), 167.52 (C=O). 
 
LRMS (ESI+): 463.0 [M+H]+.  
 
HRMS (ESI) calcd for C19H29O8N79Br [M+NH4]+: 478.1071; Found: 478.1075. 
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4-Bromo-5-endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-2-oxa-
bicyclo[2.2.2]oct-8-en-3-one 248b 
 
IR: (thin film) 2989, 2958, 2932, 1767, 1634, 1457, 1374, 1165, 1082, 1029   cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.29 (s, 3H, CH3), 1.32 (s, 3H, CH3), 1.37 (s, 3H, CH3), 
1.42 (s, 3H, CH3), 1.81 (dt, 1H, J = 13.8, 1.7 Hz, H-6), 2.76 (ddd, 1H, J = 2.4, 7.7, 13.8 
Hz, H-6), 3.93 (dd, 1H, J = 6.2, 8.4 Hz, H-6’), 4.04 (dd, 1H, J = 6.5, 8.4 Hz, H-6’), 4.10 
(m, 1H, H-5’), 4.22 (dd, 1H, J = 2.6, 6.9 Hz, H-4’), 4.24 (dt, 1H, J = 1.2, 7.7 Hz, H-5), 
4.28 (d, 1H, J = 3.1 Hz, H-3’), 4.36 (d, 1H, J = 3.6 Hz, H-2’), 5.24 (ddd, 1H, J = 1.7, 
3.6, 6.9 Hz, H-1), 5.86 (d, 1H, J = 3.8 Hz, H-1’), 6.44 (m, 1H, H-7), 6.49 (m, 1H, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.48 (CH3), 26.27 (CH3), 26.88 (CH3), 26.91 (CH3), 
34.68 (C-6), 61.48 (C-4), 67.74 (C-6’), 71.98 (C-5’), 72.26 (C-5), 74.30 (C-1), 80.66 
(C-4’), 80.92 (C-3’), 81.93 (C-2’), 105.51 (C-1’), 109.69 (Me2C), 112.17 (Me2C), 
129.60 (C-8), 130.76 (C-7), 167.45 (C=O). 
 
LRMS (ESI+): 463.0 [M+H]+.  
 
HRMS (ESI) calcd for C19H29O8N79Br [M+NH4]+: 478.1071; Found: 478.1070. 
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Cycloaddition between 218 & 229 
 
 
 
A solution of compound 218 (1.10 g, 3.84 mmol, 10 eq.) and compound 229 (67 mg, 
0.384 mmol, 1 eq.) in DCM (1 mL) and a few drops of Et3N was heated for 6 days at 
100 oC in a sealed tube.  The reaction mixture was cooled to room temperature and the 
solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N (92:6:12)), eluting 
with petroleum ether/EtOAc (8:1) to give a mixture of 5-endo-1/5-endo-2/5-exo-1 
cycloadducts 249a/b/c (157 mg, 89%) as a yellow oil. 
 
7-Bromo-5-endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-2-oxa-
bicyclo[2.2.2]oct-8-en-3-one 249a 
 
IR: (thin film) 2988, 2937, 2899, 1768, 1618, 1456, 1374, 1215, 1163, 1082, 1022, 913 
cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.29 (s, 3H, CH3), 1.37 (s, 3H, CH3), 1.42 (s, 3H, CH3), 
1.48, (s, 3H, CH3), 1.74 (d, 1H, J = 14.3 Hz, H-6), 2.61 (ddd, 1H, J = 3.8, 7.9, 14.3 Hz, 
H-6), 3.91 (d, 1H, J = 2.9 Hz, H-4’), 3.92 (dd, 1H, J = 2.9 Hz, 8.9 Hz, H-6’), 3.95-3.98 
(m, 3H, H-4, H-3’, H-6’), 4.06-4.10 (m, 1H, H-5’), 4.15-4.18 (m, 1H, H-5), 4.44 (d, 1H, 
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J = 3.6 Hz, H-2’), 5.09-5.10 (m, 1H, H-1), 5.82 (d, 1H, J = 3.6 Hz, H-1’), 6.49 (dd, 1H, 
J = 2.2, 6.4 Hz, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.51 (CH3), 26.29 (CH3), 26.83 (CH3), 27.01 (CH3), 
35.53 (C-6), 47.87 (C-4), 67.73 (C-6’), 70.43 (C-5’), 71.80 (C-5), 80.37 (C-4’), 80.51 
(C-1), 80.89 (C-3’), 83.00 (C-2’), 105.41 (C-1’), 109.48 (Me2C), 112.31 (Me2C), 119.92 
(C-7), 128.43 (C-8), 169.94 (C=O). 
 
7-Bromo-5-endo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-2-oxa-
bicyclo[2.2.2]oct-8-en-3-one 249b 
 
1H NMR (CDCl3, 600 MHz): δ 1.30 (s, 3H, CH3), 1.32 (s, 3H, CH3), 1.39 (s, 3H, CH3), 
1.48, (s, 3H, CH3), 1.96 (d, 1H, J = 14.3 Hz, H-6), 2.51 (ddd, 1H, J = 3.8, 7.6, 14.3 Hz, 
H-6), 3.85 (dd, 1H, J = 3.3, 6.4 Hz, H-4), 3.95-3.98 (m, 3H, H-3’, H-4’, H-6’), 4.06-
4.10 (m, 2H, H-5’, H-6’), 4.22-4.24 (m, 1H, H-5), 4.41 (d, 1H, J = 3.8 Hz, H-2’), 5.11-
5.12 (m, 1H, H-1), 5.84 (d, 1H, J = 3.8 Hz, H-1’), 6.47 (dd, 1H, J = 2.2, 6.4 Hz, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.46 (CH3), 26.29 (CH3), 26.86 (CH3), 26.93 (CH3), 
34.40 (C-6), 49.47 (C-4), 67.73 (C-6’), 70.95 (C-5’), 72.01 (C-5), 80.51 (C-1), 80.58 
(C-4’), 81.20 (C-3’), 83.12 (C-2’), 105.48 (C-1’), 109.38 (Me2C), 112.25 (Me2C), 
120.59 (C-7), 127.75 (C-8), 169.77 (C=O). 
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7-Bromo-5-exo-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-2-oxa-
bicyclo[2.2.2]oct-8-en-3-one 249c 
 
1H NMR (CDCl3, 600 MHz): δ 1.31 (s, 3H, CH3), 1.32 (s, 3H, CH3), 1.39 (s, 3H, CH3), 
1.48, (s, 3H, CH3), 2.08 (dt, 1H, J = 14.1, 3.3 Hz, H-6), 2.26-2.32 (m, 1H, H-6), 3.79 
(dd, 1H, J = 3.1, 6.9 Hz, H-4), 3.95-3.98 (m, 3H, H-3’, H-4’, H-6’), 4.06-4.10 (m, 2H, 
H-5’, H-6’), 4.22-4.24 (m, 1H, H-5), 4.58 (d, 1H, J = 3.6 Hz, H-2’), 5.05-5.06 (m, 1H, 
H-1), 5.81 (d, 1H, J = 3.6 Hz, H-1’), 6.46 (dd, 1H, J = 2.6, 6.4 Hz, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.51 (CH3), 26.33 (CH3), 26.83 (CH3), 27.01 (CH3), 
33.62 (C-6), 49.05 (C-4), 67.83 (C-6’), 71.46 (C-5’), 72.47 (C-5), 80.51 (C-1), 81.58 
(C-4’), 81.23 (C-3’), 83.61 (C-2’), 105.57 (C-1’), 109.24 (Me2C), 112.11 (Me2C), 
123.86 (C-7), 127.30 (C-8), 169.41 (C=O). 
 
LRMS (ESI+): 480.0 [M+NH4]+.  
 
HRMS (ESI) calcd for C19H29O8N79Br [M+NH4]+: 478.1071; found: 478.1069. 
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Cycloaddition between 221 & 226 
 
 
 
A solution of compound 221 (906 mg, 2.42 mmol, 2 eq.) and compound 226 (187 mg, 
1.21 mmol, 1 eq.) in DCM (1 mL) was heated for 6 days at 45 oC in a sealed tube.  The 
reaction mixture was cooled to room temperature and the solvent was removed under 
reduced pressure.  The crude product was purified by flash chromatography on silica gel 
(pre-washed with petrol/EtOAc/Et3N (92:6:12)), eluting with petroleum ether/EtOAc 
(5:1) to give a mixture of 5-endo-1/5-endo-2 cycloadducts 250a/b (351 mg, 55%) as a 
yellow oil. 
 
5-Endo-(β-D-glucose-1’,2’,3’,4’-tetraacetate)-3-oxo-2-oxa-bicyclo[2.2.2]oct-8-ene-4-
carboxylic acid methyl ester 250a 
 
IR: (thin film) 2955, 2944, 1757, 1437, 1368, 1222, 1077, 1038, 981 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.67 (dt, 1H, J = 14.3, 1.72 H-6), 1.99 (s, 3H, CH3), 
2.00 (s, 3H, CH3), 2.02 (s, 3H, CH3), 2.03 (s, 3H, CH3, 2.56 (ddd, 1H, J = 3.6, 7.7, 14.3 
Hz, H-6), 3.52 (dd, 1H, J = 5.7, 11.9 Hz, H-6’), 3.59-3.61 (m, 1H, H-6’), 3.63-3.66 (m, 
1H, H-5’), 3.93 (s, 3H, OCH3), 4.42 (dt, 1H, J = 7.6, 1.2 Hz, H-5), 4.95 (t, 1H, J = 9.5 
Hz, H-4’), 5.06 (t, 1H J = 8.3 Hz, H-2’), 5.18 (t, 1H, J = 9.5 Hz, H-3’), 5.22-5.24 (m, 
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1H, H-1), 5.63 (d, 1H, J = 8.3 Hz, H-1’), 6.61 (dd, 1H, J = 5.2, 7.7 Hz, H-7), 6.74 (dt, 
1H, J = 7.7, 1.3 Hz, H-8).  
 
13C NMR (CDCl3, 150.9 MHz): δ 20.70 (CH3), 20.75 (CH3), 20.79 (CH3), 20.96 (CH3), 
36.00 (C-6), 53.24 (OCH3), 61.73 (C-4) 68.27 (C-4’), 69.42 (C-6’), 70.23 (C-2’), 72.95 
(C-3’), 74.31 (C-1), 74.55 (C-5’), 74.63 (C-5), 91.67 (C-1’), 129.64 (C-8), 130.87 (C-7), 
167.66 (C=O), 168.72 (C=O), 169.36 (C=O), 169.42 (C=O), 169.47 (C=O), 170.24 
(C=O). 
 
5-Endo-(β-D-glucose-1’,2’,3’,4’-tetraacetate)-3-oxo-2-oxa-bicyclo[2.2.2]oct-8-ene-4-
carboxylic acid methyl ester 250b 
 
1H NMR (CDCl3, 600 MHz): δ 1.72 (dt, 1H, J = 1.72, 14.09 H-6), 1.99 (s, 3H, CH3CO), 
2.00 (s, 3H, CH3CO), 2.03 (s, 3H, CH3CO), 2.04 (s, 3H, CH3CO), 2.60 (ddd, 1H, J = 
3.6, 7.7, 14.09 Hz, H-6), 3.47 (dd, 1H, J = 5.5, 11.7 Hz, H-6’), 3.57-3.61 (m, 1H, H-6’), 
3.63-3.66 (m, 1H, H-5’), 3.91 (s, 3H, OCH3), 4.42 (dt, 1H, J = 1.2, 7.6 Hz, H-5), 4.99 (t, 
1H, J = 9.45 Hz, H-4’), 5.08-509 (m, 1H, H-2’), 5.18 (t, 1H, J = 9.5 Hz, H-3’), 5.22-
5.24 (m, 1H, H-1), 5.62 (d, 1H, J = 8.3 Hz, H-1’), 6.60 (dd, 1H, J = 5.2, 7.7 Hz, H-7), 
6.70 (dt, 1H, J = 1.2, 7.7 Hz, H-8).  
 
13C NMR (CDCl3, 150.9 MHz): δ 20.70 (CH3), 20.75 (CH3), 20.80 (CH3), 20.86 (CH3), 
35.93 (C-6), 53.15 (OCH3), 62.00 (C-4), 68.17 (C-4’), 69.42 (C-6’), 70.31 (C-2’), 73.13 
(C-3’), 7352 (C-1), 74.00 (C-5), 74.65 (C-5’), 91.81 (C-1’), 129.73 (C-8), 130.83 (C-7), 
167.77 (C=O), 169.15 (C=O), 169.36 (C=O), 169.52 (C=O), 169.58 (C=O), 170.32 
(C=O). 
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LRMS (ESI+): 546.0 [M+NH4]+. 
 
HRMS (ESI) calcd for C23H32O14N [M+NH4]+: 546.1817; Found: 546.1821. 
 
Cycloaddition between 221 & 227 
 
 
 
A solution of compound 221 (0.707 g, 1.89 mmol, 2 eq.) and compound 227 (0.158 g, 
0.944 mmol, 1 eq.) in DCM (1 mL) was heated for 6 days at 80 oC in a sealed tube.  The 
reaction mixture was cooled to room temperature and the solvent was removed under 
reduced pressure.  1H-NMR analysis of the crude reaction mixture indicated the 
presence of two cycloadducts in a 1:1 ratio.  The crude product was purified by flash 
chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N (92:6:12)), eluting 
with petroleum ether/EtOAc (5:1) to give a mixture of 5-endo-1/5-endo-2 cycloadducts 
251a/b (459 mg, 90%) as a yellow oil. 
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5-Endo-(β-D-glucose-1’,2’,3’,4’-tetraacetate)-3-oxo-2-oxa-bicyclo[2.2.2]oct-8-ene-4-
carboxylic acid ethyl ester 251a/b 
 
IR: (thin film) 3025, 2943, 1757, 1638, 1368, 1300, 1219, 1077, 1038, 912 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.23 (t, 3H, J = 7.2 Hz, OCH2CH3 ), 1.61 (dd, 1H, J = 
6.4, 15.0 Hz, H-6), 2.00 (s, 3H, CH3), 2.01 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.03 (s, 3H, 
CH3), (ddd, 1H, J = 4.5, 7.9, 15.0 Hz, H-6), 3.47 (dd, 1H, J = 4.6, 11.6 Hz, H-6’), 3.59-
3.64 (m, 1H, H-6’), 3.69-3.71 (m, 1H, H-5’), 4.04 (dd, 1H, J = 3.3, 16.0 Hz, H-4), 4.06-
4.08 (m, 1H, H-5), 4.27-4.31 (m, 2H, OCH2CH3), 5.00-5.06 (m, 1H, H-4’), 5.07-5.10 
(m, 1H, H-2’), 5.21 (t, 1H, J = 9.5 Hz, H-3’), 5.65 (t, 1H, J = 8.4 Hz, H-1’), 5.67-5.69 
(m, 1H, H-1), 7.17-7.19 (m, 1H, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 14.31 (OCH2CH3), 20.71 (CH3), 20.75 (CH3), 20.77 
(CH3), 20.96 (CH3), 34.82 (C-6), 47.57(C-4), 61.52 (OCH2CH3), 67.60 (C-6’), 68.54 
(C-4’), 70.21 (C-2’), 72.65 (C-5), 72.92 (C-3’), 73.43 (C-1), 74. 09 (C-5’), 91.80 (C-1’), 
136.36 (C-7), 137.80 (C-8), 169.25 (C=O), 169.38 (C=O), 169.41 (C=O), 169.96 (C=O), 
170.25 (C=O), 170.52 (C=O). 
 
LRMS (ESI+): 560.1 [M+NH4]+.  
 
HRMS (ESI) calcd for C24H34O14N [M+NH4]+: 560.1974; Found: 560.1976. 
 
 
 
 
201 
 
Cycloaddition between 221 & 228 
 
 
 
A solution of compound 221 (2.64 g, 7.04 mmol, 20 eq.) and compound 228 (123 mg, 
0.704 mmol, 1 eq.) in DCM (1 mL) and a few drops of Et3N was heated for 6 days at 
100 oC in a sealed tube. The reaction mixture was cooled to room temperature and the 
solvent was removed under reduced pressure.   1H-NMR analysis of the crude reaction 
mixture indicated the presence of two cycloadducts in a 1:1 ratio. The crude product 
was purified by flash chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N 
(92:6:12)), eluting with petroleum ether/EtOAc (5:1) to give a mixture of 5-endo-1/5-
endo-2 cycloadducts 252a/b (96 mg, 25%) as a yellow oil. 
 
4-Bro-5-endo-(β-D-glucose-1’,2’,3’,4’-tetraacetate)-2-oxa-bicyclo[2.2.2]oct-8-en-3-one 
250a/b 
 
IR: (thin film) 2940, 1758, 1432, 1368, 1219, 1074, 1038, 907 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.87 (dt, 1H, J = 1.2, 14.1 Hz, H-6), 1.99 (s, 3H, CH3), 
2.02 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.10 (s, 3H, CH3) (ddd, 1H, J = 2.4, 7.9, 14.1 Hz, 
H-6), 3.71 (td, 1H, J = 2.4, 10.0 Hz, H-5’) 3.79 (dd, 1H, J = 2.1, 10.0 Hz, H-6’), 3.95 (d, 
1H, J  = 7.7 Hz, H-5), 3.97 (dd, 1H, J = 3.4, 9.8 Hz, H-6’), 5.06-5.13 (m, 2H, H-2’, H-
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4’), 5.19-5.22 (m, 2H, H-1, H-3’), 5.65 (d, 1H, J = 8.42 Hz, H-1’), 6.41 (d, 1H, J = 7.9 
Hz, H-8), 6.47 (dd, 1H, J = 5.0, 7.9 Hz, H-7). 
 
13C NMR (CDCl3, 150.9 MHz): δ 20.72 (CH3), 20.75 (CH3), 20.99 (CH3), 21.01 (CH3), 
37.57 (C-6), 64.61 (C-4), 68.09 (C-2’), 70.17 (C-4’), 70.22 (C-6’), 72.98 (C-1), 73.23 
(C-3’), 73.94 (C-5’), 77.83 (C-5), 91.86 (C-1’), 130.65 (C-7), 135.49 (C-8), 167.67 
(C=O), 169.13 (C=O), 169.43 (C=O), 170.24 (C=O), 170.34 (C=O). 
 
LRMS (ESI+): 566.0 [M+NH4]+. 
 
HRMS (ESI) calcd for C21H29O12N79Br [M+NH4]+: 566.0868; Found: 566.0859. 
 
Cycloaddition between 221 & 229 
 
 
 
A solution of compound 221 (1.65 g, 4.41 mmol, 10 eq.) and compound 229 (77 mg, 
0.441 mmol, 1 eq.) in DCM (1 mL) and a few drops of Et3N was heated for 6 days at 
100 oC in a sealed tube. The reaction mixture was cooled to room temperature and the 
solvent was removed under reduced pressure.   1H-NMR analysis of the crude reaction 
mixture indicated the presence of two cycloadducts in a 1:1 ratio. The crude product 
was purified by flash chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N 
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(92:6:12)), eluting with petroleum ether/EtOAc (4:1) to give a mixture of 5-endo-1/5-
endo-2 cycloadducts 253a/b (158 mg, 65%) as a yellow oil. 
 
7-Bro-5-endo-(β-D-glucose-1’,2’,3’,4’-tetraacetate)-2-oxa-bicyclo[2.2.2]oct-8-en-3-one 
250a 
 
IR: (thin film) 3022, 2944, 1760, 1433, 1368, 1221, 1161, 1075, 1038, 910 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.73 (dt, 1H, J = 1.4, 14.3 Hz, H-6), 2.02 (CH3), 2.02 
(CH3), 2.03 (CH3), 2.03 (CH3), 2.55 (ddd, 1H, J = 4.0, 7.9, 14.3 Hz, H-6), 3.47 (dd, 1H, 
J = 4.8, 11.3 Hz, H-6’), 3.60 (dd, 1H, J = 2.8, 6.4 Hz, H-6’), 3.72 (ddd, 1H, J = 2.8, 5.0, 
10.0 Hz, H-5’), 3.87 (dd, 1H, J = 3.3, 6.4 Hz, H-4), 3.97-3.99 (m, 1H, H-5), 5.06-5.08 
(m, 1H, H-1), 5.07-5.10 (m, 2H, H-2’, H-4’), 5.21 (t, 1H, J = 9.5 Hz, H-3’), 5.65 (dd, 
1H, J = 8.4, 11.3 Hz, H-1’), 6.41-6.44 (m, 1H, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 20.7 (CH3), 20.81 (CH3), 20.94 (CH3), 21.18 (CH3), 
35.05 (C-6), 48.44 (C-4), 67.84 (C-6’), 68.52 (C-1), 70.23 (C-4’), 72.30 (C-5), 72.87 
(C-3’), 74.10 (C-5’), 80.55 (C-2’), 91.78 (C-1’), 120.46 (C-7), 127.58 (C-8), 169.24 
(C=O), 169.37 (C=O), 169.48 (C=O), 170.01 (C=O), 170.24 (C=O). 
 
7-Bro-5-endo-(β-D-glucose-1’,2’,3’,4’-tetraacetate)-2-oxa-bicyclo[2.2.2]oct-8-en-3-one 
250b 
 
1H NMR (CDCl3, 600 MHz): δ 1.75 (dt, 1H, J = 1.4, 14.3 Hz, H-6),  2.02 (CH3), 2.02 
(CH3), 2.03 (CH3), 2.03 (CH3), 2.55 (ddd, 1H, J = 4.0, 7.9, 14.3 Hz, H-6), 3.47 (dd, 1H, 
J = 4.8, 11.3 Hz, H-6’), 3.60 (dd, 1H, J = 2.8, 6.4 Hz, H-6’), 3.72 (ddd, 1H, J = 2.8, 5.0, 
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10.0 Hz, H-5’), 3.84 (dd, 1H, J = 3.3, 6.4 Hz, H-4), 3.97-3.99 (m, 1H, H-5), 5.04 (m, 1H, 
H-1), 5.07-5.10 (m, 2H, H-2’, H-4’), 5.21 (t, 1H, J = 9.5 Hz, H-3’), 5.65 (dd, 1H, J = 
8.4, 11.3 Hz, H-1’), 6.41-6.44 (m, 1H, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 20.68 (CH3), 20.79 (CH3), 20.94 (CH3), 21.18 (CH3), 
35.22 (C-6), 48.44 (C-4), 68.00 (C-6’), 68.55 (C-1), 70.19 (C-4’), 72.18 (C-5), 72.89 
(C-3’), 73.89 (C-5’), 80.55 (C-2’), 91.74 (C-1’), 120.46 (C-7), 127.64 (C-8), 169.24 
(C=O), 169.34 (C=O), 169.45 (C=O), 170.05 (C=O), 170.24 (C=O). 
LRMS (ESI+): 571.2 [M+Na]+.  
 
HRMS (ESI) calcd for C21H29O12N79Br [M+NH4]+: 566.0868; Found: 566.0857. 
 
Cycloaddition between 225 & 227 
 
A solution of compound 225 (705 mg, 1.13 mmol, 2 eq.) and compound 227 (95.2 mg, 
0.567 mmol, 1 eq.) in DCM (1 mL) was heated for 6 days at 100 oC in a sealed tube.  
The reaction mixture was cooled to room temperature and the solvent was removed 
under reduced pressure.  1H-NMR analysis of the unpurified reaction mixture indicated 
the presence of two cycloadducts in a 6:1.9:1 ratio.  The crude product was purified by 
flash chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N (92:6:12)), 
eluting with petroleum ether/EtOAc (6:1) to give a give a mixture of 5-endo-1/5-endo-2 
cycloadducts 254a/b (334 mg, 75%) as a yellow oil and and 5-exo-1 cycloadduct 254c 
(67 mg, 15%) as a yellow oil. 
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5-Endo-(2’,3’,4’,6’-tetra-O-benzoyl-α-D-mannopyranose)-3-oxo-2-oxa-
bicyclo[2.2.2]oct-8-ene-7-carboxylic acid ethyl ester 254a/b 
 
 
 
IR: (thin film) 3065, 3028, 2984, 1765, 1727, 1638, 1450, 1265, 1105, 1069, 1029, 978 
cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.40 (t, 3H, J = 7.1 Hz, CH3CH2O), 1.87 (dt, 1H, J = 1.7, 
14.4 Hz, H-6), 2.75 (ddd, 1H, J = 3.8, 8.1, 14.3 Hz, H-6), 4.18 (dd, 1H, J = 3.4, 6.2 Hz, 
H-4), 4.29 (ddd, 1H, J = 2.75, 4.8, 10.0 Hz, H-5’), 4.32-4.40 (m, 2H, MeCH2O), 4.49 
(dd, 1H, J = 5.0, 12.2 Hz, H-6’), 4.57 (d, 1H, J = 6.2 Hz, H-5), 4.67 (dd, 1H, J = 2.6, 
12.2 Hz, H-6’), 5.23 (s, 1H, H-1’), 5.56 (dd, 1H, J = 1.7, 3.3 Hz, H-2’), 5.75-5.76 (m, 
2H, H-1, H-3’), 6.05 (t, 1H, J = 10.1 Hz, H-4’), 7.32 (d, 1H, J = 6.0 Hz, H-8), 7.36 (t, 
2H, J = 7.6 Hz, Ar-H), 7.39-7.45 (m, H, Ar-H), 7.52 (t, 1H, J = 7.2 Hz, Ar-H), 7.58 (t, 
1H, J = 7.2 Hz, Ar-H), 7.62 (t, 1H, J = 7.2 Hz, Ar-H), 7.81 (d, 2H, J = 8.1 Hz, Ar-H), 
7.81 (d, 2H, J = 8.1 Hz, Ar-H), 7.94 (d, 2H, J = 8.3 Hz, Ar-H), 8.04-8.06 (m, 4H, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): 14.32 (CH3CH2O), 34.96 (C-6), 46.81(C-4), 61.77 
(CH3CH2O), 62.87 (C-6’), 66.84 (C-4’), 68.46 (C-5), 69.62 (C-3’), 69.81 (C-5’), 70.27 
(C-2’), 73.22 (C-1), 96.05 (C-1’), 128.52 (Ar-CH), 128.62 (Ar-CH), 128.71 (Ar-CH), 
128.75 (Ar-C), 128.84 (Ar-CH, C-7), 128.91 (Ar-C), 129.07 (Ar-C), 129.67 (Ar-C), 
129.77 (Ar-CH), 129.85 (Ar-CH), 129.96 (Ar-CH), 130.01 (Ar-CH), 133.44 (Ar-CH), 
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133.53 (Ar-CH), 133.73 (Ar-CH), 133.90 (Ar-CH), 137.12 (C-8), 162.15 (C=O), 165.55 
(C=O), 165.62 (C=O), 165.64 (C=O), 166.18 (C=O), 169.61 (C=O). 
 
LRMS (ESI+): 813.0 [M+Na]+. 
 
HRMS (ESI) calcd for C44H42O14N [M+NH4]+: 808.2600; Found: 808.2592. 
 
5-Exo-(2’,3’,4’,6’-tetra-O-benzoyl-α-D-mannopyranose)-3-oxo-2-oxa-bicyclo[2.2.2]oct-
8-ene-7-carboxylic acid ethyl ester 254c 
 
 
 
IR: (thin film) 3068, 2959, 2928, 1769, 1727, 1602, 1450, 1265, 1103, 1070, 1027, 912 
cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.32 (t, 3H, J = 7.1 Hz, CH3CH2O), 2.24 (ddd, 1H, J = 
1.7, 9.11, 14.3 Hz, H-6), 2.37 (dt, 1H, J =  3.3, 14.3 Hz, H-6), 4.05 (dd, 1H, J = 3.1, 6.7 
Hz, H-4), 4.27 (q, 2H, J = 7.2 Hz, OCH2CH3), 3.31 (dt, 1H, J = 9.1, 3.1 Hz, H-5), 4.36-
4.39 (m, 1H, H-5’), 4.45 (dd, 1H, J = 3.8, 12.2 Hz, H-6’), 4.76 (dd, 1H, J = 2.6, 12.2 Hz, 
H-6’), 5.31 (d, 1H, J = 1.4 Hz, H-1’), 5.66 (dd, 1H, J = 1.9, 3.3 Hz, H-2’), 5.67-5.69 (m, 
1H, H-1), 5.87 (dd, 1H, J = 3.3 , 10.1 Hz, H-3’), 6.08 (t, 1H, J = 10.1 Hz, H-4’), 7.21 
(dd, 1H, J = 2.2, 6.7 Hz, H-8), 7.37 (t, 4H, J = 7.6 Hz, Ar-H), 7.41-7.43 (m, 4H, Ar-H), 
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7.50-7.53 (m, 1H, Ar-H), 7.56-7.62 (m, 3H Ar-H), 7.83 (m, 3H, Ar-H), 7.96 (dd, 2H, J 
= 1.2, 8.4 Hz, Ar-H), 8.05-8.06 (m, 3H, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): 14.32 (CH3CH2O), 34.61 (C-6), 46.97(C-4), 61.71 
(CH3CH2O), 62.84 (C-6’), 66.97 (C-4’), 69.05 (C-5), 69.86 (C-3’), 69.91 (C-5’), 70.55 
(C-2’), 73.28 (C-1), 96.37 (C-1’), 128.44 (Ar-CH), 128.60 (Ar-CH, C-7), 128.62 (Ar-
CH), 128.71 (Ar-CH), 128.76 (Ar-C), 128.13 (Ar-C), 129.21 (Ar-C), 129.42 (Ar-C), 
129.89 (Ar-CH), 129.95 (Ar-CH), 129.98 (Ar-CH), 130.08 (Ar-CH), 133.23 (Ar-CH), 
133.32 (Ar-CH), 133.59 (Ar-CH), 133.70 (Ar-CH), 137.08 (C-8), 165.39 (C=O), 165.60 
(C=O), 165.62 (C=O), 165.68 (C=O), 166.21 (C=O), 166.45 (C=O). 
 
LRMS (ESI+): 813 [M+Na]+. 
 
HRMS (ESI) calcd for C44H42O14N [M+NH4]+: 808.2600; Found: 808.2599. 
 
3’-(2-Hydroxy-5-hydroxymethyl-cyclohex-5-enyloxy)-glucose 255 
 
 
 
Compound 264 (96 mg, 0.277 mmol) was dissolved in 90% aq. trifluoroacetic acid (10 
mL) at 0 oC and stirred for 30 minutes at 0 oC. The reaction mixture was brought to 
room temperature and stirred for another 30 minutes. The solvent was evaporated under 
reduced pressure. The crude product was purified by flash chromatography eluting with 
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DCM/MeOH (3:1, 2:1) to give an anomeric mixture of the title compound 255 (68 mg, 
80 %) as a colourless oil. 
 
[α]D  = 28.6 (c 0.53, MeOH). 
 
IR: (thin film) 3416, 2890, 1682, 1439, 1206, 1143, 1038, 844, 804 cm-1. 
 
1H NMR (MeOD, 600 MHz): δ 1.51-1.56 (m, 1H, H-3), 1.91 (dd, 1H, J = 8.8, 17.4 Hz, 
H-1), 2.35-2.39 (m, 2H, H-1, H-3), 3.21-3.31 (m, 2H, H-4’ and H-5’), 3.46 (dd, 1H, J = 
3.6, 5.8 Hz, β-anomer H-2’), 3.53-3.7 (2H, m, H-6’), 3.75-3.83 (m, 2H, H-3’ and H-2), 
4.01-4.05 (m, 2H, H-6), 4.27-4.31 (m, 1H, H-4), 4.45-4.48 (m,  2H, β-anomer H1’ & α-
anomer H-2’), 5.08 (d, 1H, J = 3.6 Hz, α-anomer H-1’), 5.67 (m, 1H, H-5a). 
 
13C NMR (MeOD, 150.9 MHz): δ 34.01 (C-3), 36.36 & 36.48 (C-1), 61.49 & 61.62 (C-
6’), 63.43 (C-2), 63.60 & 63.76 (C-6), 69.03 & 69.11 (C-4’), 72.00 & 73.66 (C-2’), 
74.54 & 74.83 (C-4), 76.09 & 76.86 (C-5’), 81.13 & 84.31 (C-3’), 92.61& 96.62 (C-1’), 
123.69 & 123.77 (C-5a), 137.83 & 137.88 (C-5). 
 
LRMS (ESI+): 329.1 [M+Na]+. 
 
HRMS (ESI) calcd for C13H26NO8 [M+NH4]+: 324.1658; Found: 324.1660. 
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(2R, 4R, 5R)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-2-hydroxy-
cyclohex-5a-ene-5,5-dicarboxylic acid allyl ester methyl ester 256 
 
 
 
A solution of lithium prop-2-en-1-olate was freshly prepared by adding n-BuLi (1.06 
mL, 1.06 mmol) dropwise to allyl alcohol (30 mL) at -78 oC under a nitrogen 
atmosphere.  After the addition was complete the solution was warmed to room 
temperature and stirred for 30 minutes. The solution was cooled to 0 oC and was then 
added dropwise to a solution of compound 246a (1.16 g, 2.6 mmol) in allyl alcohol (20 
mL) maintained at 0 oC under a nitrogen atmosphere. The reaction mixture was stirred 
for 2 h at 0 oC and then quenched with saturated aq. NH4Cl and extracted with DCM (4 
x 80 mL). The combined organic extracts were dried over MgSO4 and concentrated 
under reduced pressure. The crude product was purified by flash chromatography 
eluting with petrol/EtOAc (3:1) to give the title compound 256 (1.07 g, 82%) as a pale 
yellow oil. 
 
[α] 20D  = -80.3
 (c 3.63, CHCl3) 
 
IR: (thin film) 3477, 2988, 2940, 2898, 1740, 1650, 1452, 1374, 1247, 1215, 1165, 1119, 
1074, 1022 cm-1. 
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1H NMR (CDCl3, 600 MHz): δ 1.30 (s, 3H, CH3), 1.32 (s, 3H, CH3), 1.40 (s, 3H, CH3), 
1.48 (s, 3H, CH3), 1.79 (ddd, 1H, J = 1.5, 10.0, 14.0 Hz, H-3), 2.57 (dt, 1H, J = 14.0, 
4.6 Hz, H-3), 3.73 (s, 3H, OCH3), 3.86 (dd, 1H, J = 5.9, 8.8 Hz, H-6’), 4.00 (dd, 1H, J = 
6.0, 8.8 Hz, H-6’), 4.06-4.07 (m, 1H, H-3’), 4.08-4.09 (m, 1H, H-5’), 4.10-4.12 (m, 1H, 
H-4’), 4.50-4.52 (m, 1H, H-4), 4.57-4.59 (m, 2H, H-2, H-7), 4.60 (d, 1H, J = 3.7 Hz, H-
2’), 4.64 (ddd, 1H, J = 1.4, 5.5, 13.4 Hz, H-7), 5.26 (dd, 1H, J = 1.4, 10.5 Hz, H-9), 5.28 
(dt, 1H, J = 1.4, J = 17.2 Hz, H-9), 5.70 (d, 1H, J = 3.7 Hz, H-1’), 5.84 (ddd, 1H, J = 5.5, 
10.5, 17.2 Hz, H-8), 5.94 (d, 1H, J = 10.3 Hz, H-1), 6.02 (d, 1H, J = 10.3 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz):  δ 25.47 (CH3), 26.27 (CH3), 26.84 (CH3), 26.88 (CH3), 
32.00 (C-3), 52.84 (OCH3), 59.19 (C-5), 63.37(C-5’), 66.43 (C-7), 67.42 (C-6’), 72.22 
(C-4), 74.02 (C-2), 79.02 (C-4’), 80.92 (C-3’), 80.96 (C-2’), 105.32 (C-1’), 109.07 
(Me2C), 111.91 (Me2C), 118.90 (C-9), 122.68 (C-1), 131.19 (C-8), 134.52 (C-5a), 
167.62 (C=O), 169.22 (C=O). 
LRMS (ESI+): 521.3 [M+Na]+. 
 
HRMS (ESI) calcd for C24H38NO11 [M+NH4]+: 516.2439 ; Found: 516.2439. 
 
(2S,4R)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-2-hydroxy-cyclohex-5-
ene-carboxylic acid  methyl ester 261 
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A mixture of compound 256 (150 mg, 0.301 mmol), formic acid (9.1 μL), Et3N (5.4 μL), 
PPh3 (3.95 mg, 15 μmol), and Pd(OAc)2 (0.79 mg, 3.52 x 10-3 mmol) in dioxane (1 mL) 
was heated at 100 oC for 18 hours in a sealed tube. The reaction mixture was stripped of 
solvent and volatiles under reduced pressure and 1 M hydrochloric acid (1 mL) was 
added.  This mixture was extracted with DCM (3 x 20 mL) and the combined organic 
layers were washed with saturated aq. NaHCO3, dried over MgSO4 and concentrated 
under reduced pressure. The crude product was purified by flash chromatography 
eluting with petrol/EtOAc (5:1) to give the title compound 261 (79 mg, 63%) as a white 
crystalline solid. 
 
mp: 135-136 oC 
 
[α] 20D  = -8.5
 (c 0.96, CHCl3). 
 
IR: (KBr) 3499, 3434, 2992, 2926, 1710, 1447, 1374, 1264, 1209, 1163, 1072 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.32 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.38 (d, 1H, J = 
13.2 Hz, H-3), 1.41 (s, 3H, CH3), 1.48 (s, 3H, CH3), 2.09 (ddd, 1H, J = 2.2, 9.8, 19.1 Hz, 
H-1), 2.35 (d, 1H, J = 13.2 Hz H-3), 2.65 (dt, 1H, J = 19.1, 5.5 Hz, H-1), 3.72 (s, 3H, 
OCH3), 3.94 (dd, 1H, J = 5.5, 8.6 Hz, H-6’), 4.04-4.07 (m, 3H, H-3’, H-4’, H-6’), 4.08-
4.11 (m, 1H, H-5’), 4.21-4.25 (m, 1H, H-4), 4.49 (m, 1H, H-2), 4.93 (d, 1H, J = 3.8 Hz, 
H-2’), 5.78 (d, 1H, J = 3.8 Hz, H-1’), 7.02 (dd, 1H, J = 2.41 5.5 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.51 (CH3), 26.43 (CH3), 26.98 (CH3), 27.04 (CH3), 
35.10 (C-3), 35.43 (C-1), 51.82 (OCH3), 67.84 (C-6’), 70.75 (C-4), 72.47(C-5’), 80.32 
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(C-4’), 81.17 (C-3’), 82.25 (C-2’), 105.61 (C-1’), 109.12 (Me2C), 111.86 (Me2C), 
129.59 (C-5), 142.08 (C-5a), 166.17 (C=O). 
 
LRMS (ESI+): 437.2 [M+Na]+. 
 
HRMS (ESI) calcd for C20H34NO9 [M+NH4]+: 432.2228 ; Found: 432.2227. 
 
(2S,4R)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-5-hydroxymethyl-
cyclohex-5-en-2-ol 263 
 
 
 
iBu2Al-H (2.9 mL of a 1 M solution in hexane, 2.9 mmol, 6.3 eq.) was added dropwise 
to a solution of compound 261 (19 mg, 0.461 mmol) in dry toluene (2 mL) maintained 
at -78 oC under a dry nitrogen atmosphere. The reaction was monitored by TLC. After 3 
hours the reaction mixture was quenched at -78 oC by addition of a 1 M solution of 
potassium sodium tartrate (5 mL) and then EtOAc (15 mL). The reaction mixture was 
warmed to room temperature and stirred for 30 minutes. The organic layer was 
separated and the aqueous phase was extracted with EtOAc (4 x 40 mL). The combined 
organic extracts were dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography eluting with petrol/EtOAc (2:1) to 
give the title compound 263 (156 mg, 88 %) as a pale yellow oil. 
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[α] 20D  = 3.3
 (c 1.45, CHCl3). 
 
IR: (thin film) 3402, 2988, 2932, 1454, 1375, 1334, 1218, 1163, 1072, 1017 cm-1. 
 
1H NMR (CDCl3): δ 1.31 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.41 (s, 3H, CH3), 1.48 (s, 3H, 
CH3), 1.53-1.58 (m, 1H, H-3), 1.97 (dd, 1H, J = 8.9, 17.5 Hz, H-1), 2.22 (dt, 1H, J = 
13.2, 4.5 Hz, H-3), 2.44 (dt, 1H, J = 5.2, 17.5 Hz, H-1), 3.94 (dd, 1H, J = 5.7, 8.6 Hz, 
H-6’), 4.03-4.05 (m, 3H, H-4, H-4’ H-6’), 4.06-4.09 (m, 3H, H-3’, H-6, H-6), 4.21 (m, 
1H, H-2), 4.26 (dd, 1H, J = 5.8, 13.9 Hz, H-5’), 4.62 (d, 1H, J = 3.6 Hz, H-2’), 5.76-
5.77 (m, 1H, H-5a), 5.85 (d, 1H, J = 3.6 Hz, H-1’). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.48 (CH3), 26.40 (CH3), 26.95 (CH3), 26.99 (CH3), 
34.40 (C-1), 35.54 (C-3), 64.30 (C-2), 65.01 (C-6), 67.63 (C-6’), 72.43 (C-4), 72.46 (C-
5’), 79.90 (C-4’), 81.07 (C-3’), 82.75 (C-2’), 105.48 (C-1’), 109.18 (Me2C),111.14 
(Me2C), 126.90 (C-5a), 136.12 (C-5). 
 
LRMS (ESI+): 409.3 [M+Na]+. 
 
HRMS (ESI) calcd for C19H34NO8 [M+NH4]+: 404.2279 ; Found: 404.2277. 
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(2S,4R)-4-(1’,2’-O-isopropylidene-α-D-glucofuranose)-5-hydroxymethyl-cyclohex-5-
en-2-ol 264 
 
 
 
Compound 263 (128mg, 0.331 mmol) was dissolved in 90% aq. AcOH (10 mL) and 
stirred at room temperature for 18 hours.  The reaction mixture was concentrated under 
reduced pressure and the crude residue was purified by flash chromatography eluting 
with DCM/MeOH (20:1→10:1) to give the title compound 264 (103 mg, 90%) as 
colourless crystals. 
 
mp: 151-153 oC 
 
[[α] 20D  = 3.8
 (c 0.77, CHCl3). 
 
IR: (KBr) 3386, 3321, 3248, 2978, 2935, 2882, 1378, 1255, 1225 cm-1. 
 
1H NMR (MeOD): δ 1.30 (CH3), 1.44 (s, 3H, CH3), 1.47 (dd, 1H, J = 4.0, 12.0 Hz, H-3), 
1.91 (dd, 1H, J = 9.6, 17.2 Hz, H-1), 2.27 (d, 1H, J = 13.0 Hz, H-3), 2.37 (dt, 1H, J = 
17.3, 5.2 Hz, H-1), 3.54 (dd, 1H, J = 6.0, 11.5 Hz, H-6’), 3.72 (dd, 1H, J = 2.1, 11.5 Hz, 
H-6’), 3.82-3.83 (m, 1H, H-5’), 3.92-3.96 (m, 2H, H-3’, H-2), 4.05-4.06 (m, 3H, H-4’, 
H-6, H-6), 4.21 (s, 1H, H-4), 4.69 (d, 1H, J = 3.4 Hz, H-2’), 5.74 (d, 1H, J = 4.64 Hz, 
H-5a), 5.81 (d, 1H, J = 2.9 Hz, H-1’). 
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13C NMR (MeOD, 150.9 MHz): δ 25.17 (CH3), 25.78 (CH3), 33.90 (C-1), 35.42 (C-3), 
62.75 (C-6), 63.45 (C-2), 64.14 (C-6’), 68.56 (C-4), 70.99 (C-5’), 79.62 (C-4’), 79.89 
(C-3’), 82.22 (C-2’), 105.30 (C-1’), 111.62 (Me2C), 125.27 (C-5a), 136.69 (C-5). 
 
LRMS (ESI+): 369.0 [M+Na]+. 
 
HRMS (ESI) calcd for C16H30NO8 [M+NH4]+: 464.1966 ; Found: 464.1964. 
 
(2S, 4S, 5S)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-2-hydroxy-
cyclohex-5a-ene-5,5-dicarboxylic acid allyl ester methyl ester 265 
 
 
 
A solution of lithium prop-2-en-1-olate was freshly prepared by adding nBuLi (2.26 mL, 
2.26 mmol) dropwise to allyl alcohol (20 mL) at -78 oC under a dry nitrogen 
atmosphere. After the addition was complete the solution was warmed to room 
temperature and stirred for 30 minutes. This solution was cooled to 0 oC and was then 
added dropwise to a solution of endo cycloadduct 246b (996 mg, 2.26 mmol) in allyl 
alcohol (2 mL) maintained at 0 oC under a nitrogen atmosphere.  The reaction mixture 
was stirred for 2.5 hours at 0 oC and then quenched with saturated aq. NH4Cl and 
extracted with DCM (4 x 80 mL), The combined organic extracts were dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by 
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flash chromatography eluting with petrol/EtOAc (2:1) to give the title compound 265 
(966 mg, 86%) as a pale yellow oil. 
 
[α] 20D  = 44.4
 (c 1.51, CHCl3). 
 
IR: (thin film) 3468, 2988, 2939, 2898, 1738, 1650, 1452, 1374, 1248, 1211, 1165, 1119, 
1074, 1020 cm-1. 
 
1H NMR ((CDCl3, 600 MHz): δ 1.30 (s, 3H, CH3), 1.34 (s, 3H, CH3), 1.40 (s, 3H, CH3), 
1.48 (s, 3H, CH3), 1.91 (ddd, 1H, J = 1.6, 10, 13.9 Hz, H-3), 2.40 (dt, 1H, J = 14.0, 5.3 
Hz, H-3), 3.77 (s, 3H, OCH3), 3.85 (dd, 1H, J = 5.8, 8.6 Hz, H-6’), 3.95 (dd, 1H, J = 5.8, 
8.6 Hz, H-6’), 4.07-4.12 (m, 3H, H-3’, H-4’, H-5’), 4.30-4.33 (m, 1H, H-4), 4.56 (d, 1H, 
J = 3.61 Hz, H-2’), 4.56-4.59 (m, 1H, H-7), 4.61-4.65 (m, 1H, H-7), 4.72-4.23 (m, 1H, 
H-2), 5.23 (dd, 1H, J = 1.2, 10.5 Hz, H-9), 5.28 (dd, 1H, J = 1.2, 17.3 Hz, H-9), 5.83 (d, 
1H, J = 3.6 Hz, H-1’), 5.84 (ddd, 1H, J = 5.7, 10.7, 17.3 Hz, H-8), 5.96 (dd, 1H, J = 1.4, 
10.3 Hz, H-1), 6.03 (d, 1H, J = 10.1 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.41 (CH3), 26.37 (CH3), 26.77 (CH3), 26.90 (CH3), 
35.55 (C-3), 52.88 (OCH3), 59.06 (C-5), 63.78 (C-5’), 66. 41 (C-7), 66.77 (C-6’), 72.35 
(C-4), 75.38 (C-2), 81.18 (C-4’), 81.62 (C-3’), 82.62 (C-2’), 104.95 (C-1’), 108.96 
(Me2C), 112.08 (Me2C), 118.86 (C-9), 123.44 (C-1), 131.22 (C-8), 134.39 (C-5a), 
167.71 (C=O), 168.42 (C=O). 
 
LRMS (ESI+): 521.9 [M+Na]+. 
 
HRMS(EI) calcd for C24H38NO11 [M+NH4]+: 516.2439 ; Found: 516.2439. 
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(2R,4S)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-2-hydroxy-cyclohex-5-
ene-carboxylic acid  methyl ester 266 
 
 
 
A mixture compound 265 (430 mg, 86.3 μmol), formic acid (51 μL), triethylamine (171 
μL), PPh3 (20.5 mg, 78 μmol), and Pd(OAc)2 (4.7 mg, 20.9 μmol) in dioxane (2.3 mL) 
was heated at 100 oC for 19 h in a sealed tube.  The reaction mixture was stripped of 
solvent and volatiles under reduced pressure and 1 M hydrochloric acid (1 mL) was 
added. This mixture was extracted with DCM (3 x 50 mL) and the combined organic 
layers were washed with saturated aq. NaHCO3, dried over MgSO4 and concentrated 
under reduced pressure. The crude product was purified by flash chromatography 
eluting with petrol/EtOAc (2:1) to give the title compound 266 (235 mg, 66%) as a pale 
yellow oil. 
 
[α] 20D  = -60.4
 (c 2.83, CHCl3). 
 
IR: (thin film) 3468, 2989, 2937, 1717, 1438, 1374, 1327, 1254, 1217, 1163, 1076 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.28 (s, 3H, CH3), 1.29 (s, 3H, CH3), 1.36 (s, 3H, CH3), 
1.46 (s, 3H, CH3), 1.60 (dt, 1H, J = 13.0, 3.6 Hz, H-3), 2.06 (ddd, 1H, J = 2.2, 9.3, 19.2 
Hz, H-1), 2.16 (dt, 1H, J = 13.0, 3.3 Hz, H-3), 2.65 (dt, 1H, J = 19.2, 5.3 Hz, H-1), 3.73 
(s, 3H, OCH3), 3.87 (d, 2H, J = 6.4 Hz, H-6’, H-6’), 4.07-4.12 (m, 1H, H-2), 4.16 (dd, 
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1H, J = 3.1, 6.2 Hz, H-4’), 4.20 (q, 1H, J = 6.2 Hz, H-5’), 4.27 (d, 1H, J = 3.1 Hz, H-3’), 
4.55 (d, 1H, J = 3.6 Hz, H-2’), 4.59 (t, 1H, J = 2.8 Hz, H-4), 5.85 (d, 1H, J = 3.6 Hz, H-
1’), 6.96 (dd, 1H, J = 2.6, 5.2 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz):  δ 25.33 (CH3), 26.40 (CH3), 26.71 (CH3), 26.93 (CH3), 
35.30 (C-3), 38.73 (C-1), 51.92 (OCH3), 63.71(C-2), 66.59 (C-6’), 71.68 (C-4), 72.84 
(C-5’), 81.14 (C-4’), 82.24 (C-3’), 83.27 (C-2’), 105.19 (C-1’), 108.60 (Me2C), 111.94 
(Me2C), 130.33 (C-5), 141.36 (C-5a), 166.68 (C=O). 
 
LRMS (ESI+): 437.0 [M+Na]+. 
 
HRMS (ESI) calcd for C20H34O9Na ([M+Na]+: 437.1782; Found: 437.1788. 
 
(2R,4S)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-5-hydroxymethyl-
cyclohex-5-en-2-ol 267 
 
 
 
iBu2Al-H (2.7 mL, of a 1 M solution in hexane, 2.7 mmol, 6.9 eq.) was added dropwise 
to a solution of compound 266 (162 mg, 0.391 mmol) in dry toluene (2 mL) maintained 
at -78 oC under a dry nitrogen atmosphere. The reaction was monitored by TLC. After 3 
hours the reaction mixture was quenched at -78 oC by addition of a 1 M solution of 
potassium sodium tartrate (5 mL) and then EtOAc (10 mL). The reaction mixture was 
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warmed to room temperature and stirred for 30 minutes. The organic layer was 
separated and the aqueous phase was extracted with EtOAc (4 x 40 mL). The combined 
organic extracts were dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography eluting with petrol/EtOAc (1:2) to 
give the title compound 267 (122 mg, 81%) as a pale yellow oil. 
 
 [α] 20D  = -57.6
 (c 1.395, CHCl3). 
 
IR: (thin film) 3414, 2988, 2936, 1454, 1375, 1329, 1217, 1163, 1073, 1020 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.32 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.45 (s, 3H, CH3), 
1.49 (s, 3H, CH3), 1.79 (ddd, 1H, J = 4.3, 10.5, 13.4 Hz, H-3), 2.00 (dd, 1H, J = 8.6, 
16.7 Hz, H-1), 2.19 (dt, 1H, J = 13.4, 3.3 Hz, H-3), 2.44 (dt, 1H, J = 16.7, 5.2 Hz, H-1), 
3.54 (t, 1H, J = 6.9 Hz, OH), 3.94 (dd, 1H, J = 6.9, 12.0 Hz, H-6), 4.06-4.11 (m, 4H, H-
2, H-3’, H-4’, H-6’), 4.15 (dd, 1H, J = 6.2, 8.9 Hz, H-6’), 4.34-4.37 (m, 2H, H-5’, H-6), 
4.39 (t, 1H, J = 3.6 Hz, H-4), 4.57 (d, 1H, J = 3.6 Hz, H-2’), 5.67-5.68 (m, 1H, H-5a), 
5.88 (d, 1H, J = 3.6 Hz, H-1’). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.08 (CH3), 26.45 (CH3), 27.04 (CH3), 27.09 (CH3), 
34.77 (C-1), 37.24 (C-3), 64.27 (C-2), 64.52 (C-6), 67.97 (C-6’), 73.15 (C-5’), 75.12 
(C-4), 81.67 (C-4’), 82.69 (C-3’), 84.84 (C-2’), 105.48 (C-1’), 109.96 (Me2C), 112.10 
(Me2C), 124.98 (C-5a), 137.73 (C-5). 
 
LRMS (ESI+): 409.3 [MNa+]. 
 
HRMS (ESI) calcd for C19H34O8N1 [M+NH4]+: 404.2279 ; Found: 404.2277. 
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3’-(2-Hydroxy-5-hydroxymethyl-cyclohex-5-enyloxy)-glucose 268 
 
 
 
Compound 267 (135 mg, 0.349 mmol) was dissolved in 90% aq. AcOH (10 mL) and 
stirred at room temperature for 17 h. The reaction mixture was concentrated under 
reduced pressure. The crude product was dissolved in TFA/THF/H20 (3:1:0.1, 4.1 mL) 
and stirred at room temperature for 3 h. The solvent was evaporated under reduced 
pressure. The crude product was purified by flash chromatography eluting with 
DCM/MeOH (10:1, 5:1) to give an anomeric mixture of the title compound 268 (74 mg, 
69 %) as a colourless oil. 
 
IR: (thin film) 3433, 22528, 1642, 1447, 1206, 1143, 1039, 843, 807 cm-1.  
 
1H NMR (MeOD, 600 MHz): δ 1.51-1.56 (m, 1H, H-3), 1.89 (dd, 1H, J = 8.8, 17.4 Hz, 
H-1), 2.36-2.39 (m, 2H, H-1, H-3), 3.17-3.31 (m, 2H, H-4’ and H-5’), 3.34-3.46 (m, 1H, 
β-anomer H-2’), 3.58-3.68 (m, 2H, H-6’), 3.73-3.81 (m, 2H, H-3’ and H-2), 4.01-4.07 
(m, 2H, H-6), 4.28-4.30 (m, 1H, H-4), 4.46-4.49 (m, 2H, β-anomer H1’ & α-anomer H-
2’), 5.10 (d, H, J = 3.6 Hz, α-anomer H-1’), 5.67 (m, 1H, H-5a). 
 
13C NMR (MeOD, 150.9 MHz): δ 33.9 & 34.0 (C-3), 36.33 & 36.5 (C-1), 61.21 & 
61.37 (C-6’), 63.44 & 63.72 (C-6), 71.07 (C-4’), 71.6 (C-2’), 73.6 (C-2), 74.63 & 74.81 
(C-4), 76.25 & 76.31 (C-5’), 81.16 & 84.31 (C-3’), 92.94 & 97.13 (C-1’), 123.73 & 
123.89 (C-5a), 137.88 (C-5). 
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LRMS (ESI+): 329.1 [M+Na+]. 
 
HRMS (ESI) calcd for C13H22O8Na [M+Na]+: 329.1207; Found: 329.1213. 
 
(R)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-cyclohexa-1,5-
dienecarboxylic acid methyl ester 270a & 270b 
 
A solution of compound (10.97 g,  38.3 mmol, 2 eq.) and compound 226 (2.95  g,  19.2 
mmol, 1 eq.) in DCM (2 mL) was heated for 7 days at 100 oC in a sealed tube.  The 
reaction mixture was cooled to room temperature and the solvent was removed under 
reduced pressure.  The crude product was purified by flash chromatography on silica gel, 
eluting with petroleum ether/EtOAc (15:1) to give the title compound 270a (5.12 g, 
67%) as white crystalline solid and the title compound 270b (1.9 g, 25%) as pale yellow 
oil. 
 
(R)-4-(1’,2’:5’,6’-Diisopropylidene-α-D-glucofuranose)-cyclohexa-1,5-dienecarboxylic 
acid methyl ester 270a  
 
 
 
mp: 122-124 oC 
 
[α] 20D  = +39.4
 (c 0.337, CHCl3). 
222 
 
IR: (KBr) 2986, 2986, 2937, 2896, 1712, 1576, 1444, 1379, 1337, 1258, 1218, 1069 cm-
1.  
 
1H NMR (CDCl3, 600 MHz): δ 1.32 (s, 6H, CH3), 1.42 (s, 3H, 2 x CH3), 1.49 (s, 3H, 
CH3), 2.31 (dd, 1H, J = 6.5, 19.1 Hz, H-3), 2.95 (dd, 1H, J = 3.6, 19.1 Hz, H-3), 3.79 (s, 
3H, OCH3), 3.89 (dd, 1H, J = 6.2, 8.6 Hz, H-6’), 4.00 (dd, 1H, J = 6.2, 8.6 Hz, H-6’), 
4.04 (d, 1H, J = 3.1 Hz, H-3’), 4.09 (dd, 1H, J = 2.9, 7.7 Hz, H-4’), 4.14 (dd, 1H, J = 
6.2, 12.4 Hz, H-5’), 4.47 (d, 1H, J = 6.4 Hz, H-4), 4.77 (d, 1H, J = 3.6 Hz, H-2’), 5.80 
(d, 1H, J = 3.6 Hz, H-1’), 6.19-6.20 (m, 2H, H-1, H-2), 7.23-7.24 (m, 1H, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.60 (CH3), 26.39 (CH3), 26.81 (CH3), 26.97 (CH3), 
29.11 (C-3), 51.83 (OCH3), 67.38 (C-6’), 67.49 (C-4), 72.19 (C-5’), 79.30 (C-4’), 81.14 
(C-3’), 83.37 (C-2’), 105.49 (C-1’), 108.76 (Me2C), 111.71 (Me2C), 122.73 (C-1), 
125.23 (C-5), 133.27 (C-2), 136.19 (C-5a), 167.14 (C=O). 
LRMS (ESI+):  419 [M+Na]+. 
  
HRMS (ESI) calcd for C20H28O8Na [M+Na]+: 419.1676; Found: 419.1676. 
 
(S)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-cyclohexa-1,5-
dienecarboxylic acid methyl ester 270b 
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[α] 20D  = -15.8
 (c 4.03, CHCl3). 
 
IR: (thin film) 2988, 2937, 2895, 1712, 1574, 1456, 1373, 1256, 1217, 1073, 1022 cm-1.  
 
1H NMR (CDCl3, 600 MHz): δ 1.31 (s, 6H, CH3), 1.32 (s, 3H, CH3), 1.39 (s, 3H, CH3), 
1.48 (s, 3H, CH3), 2.46 (ddd, 1H, J = 2.2, 6.2, 19.3 Hz, H-3), 2.77 (ddd, 1H, J = 1.4, 5.2, 
19.4 Hz, H-3), 3.79 (s, 3H, OCH3), 3.88 (dd, 1H, J = 3.4, 8.6 Hz, H-6’), 3.89 (dd, 1H, J 
= 6.0, 10.0 Hz, H-6’), 4.14-4.18 (m, 3H, H-3’, H-4’, H-5’), 4.46 (d, 1H, J = 3.8 Hz, H-
2’), 4.57 (d, 1H, J = 6.2 Hz, H-4), 5.84 (d, 1H, J = 3.8 Hz, H-1’), 6.20-6.27 (m, 2H, H-1, 
H-2), 7.27 (d, 1H, J = 5.5 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.48 (CH3), 26.47 (CH3), 26.741 (CH3), 27.03 (CH3), 
31.65 (C-3), 52.02 (OCH3), 66.74 (C-6’), 66.86 (C-4), 72.96 (C-5’), 79.83 (C-4’), 81.13 
(C-3’), 83.45 (C-2’), 105.37 (C-1’), 108.60 (Me2C), 111.92 (Me2C), 123.12 (C-1), 
125.75 (C-5), 133.07 (C-2), 136.50 (C-5a), 167.72 (C=O). 
 
LRMS (ESI+):  419.0 [M+Na]+. 
  
HRMS (ESI) calcd for C20H32O8N [M+NH4]+: 414.2122; Found: 414.2125. 
 
5-Endo-butoxy-3-oxo-2-oxa-bicyclo[2.2.2]oct-8-ene-4-carboxylic acid methyl ester 275 
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A solution of compound 226 (537 mg, 3.48 mmol) and butylvinyl ether (5 mL) was 
heated for 44 h at 60 oC in a sealed tube. The reaction mixture was cooled to room 
temperature and evaporated under reduced pressure.  The crude product was purified by 
flash chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N (92:6:12)), 
eluting with petroleum ether/EtOAc (5:1) to give the title compound 275 (680 mg, 77%) 
as a pale yellow oil. 
 
IR: (thin film) 2957, 2925, 2868, 1755, 1739, 1438, 1351, 1280, 1095, 975 cm-1.  
 
1H NMR (CDCl3, 600 MHz): δ 0.84 (t, 3H, J = 7.6 H-4’), 1.24 (sextet, 2H, J = 7.6 Hz, 
H-3’), 1.37-1.45 (m, 2H, H-2’), 1.65 (dt, 1H, J = 1.72, 13.8 Hz, H-6), 2.56 (ddd, 1H, J = 
3.8, 7.6, 13.8 Hz, H-6), 3.29-3.33 (m, H, H-1’), 3.42-3.46 (m, H, H-1’), 3.88 (s, 3H, 
OCH3), 4.33 (dt, 1H, J = 7.6, 1.2 Hz, H-5), 5.23 (ddd, 1H, J = 1.7, 3.6, 6.9 Hz, H-1), 
6.56 (dd, 1H, J = 5.2, 7.7 Hz, H-7), 6.76 (dd, 1H, J = 0.9, 7.7 Hz, H-8). 
 
13C NMR (CDCl3, 150.9 MHz): δ 13.76 (C-4’), 19.16 (C-3’), 31.62 (C-2’), 35.28 (C-6), 
52.94 (OCH3), 61.48 (C-4), 69.98 (C-1’), 72.79 (C-5), 74.30 (C-1), 129.75 (C-8), 
130.57 (C-7), 167.68 (C=O), 168.84 (C=O). 
 
LRMS (ESI+): 272.2 [M+NH4]+. 
 
HRMS (ESI) calcd for C13H22O5N [M+NH4]+: 272.1492; Found: 286.1490. 
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5-Endo-butoxy-3-oxo-2-oxa-bicyclo[2.2.2]oct-8-ene-7-carboxylic acid ethyl ester 277 
 
 
 
A solution of compound 227 (581 mg, 2.37 mmol) and butylvinyl ether (4 mL) was 
heated for 24 h at 100 oC in sealed tube.  The reaction mixture was cooled to room 
temperature and the solvent was removed under reduced pressure. The crude product 
was purified by flash chromatography on silica gel (pre-washed with petrol/EtOAc/Et3N 
(92:6:12)), eluting with petroleum ether/EtOAc (2:1) to give the title compound 277 
(486 mg, 76%) as a yellow oil. 
 
IR: (thin film) 2960, 1762, 1713, 1465, 1381, 1334, 1297, 1255, 1160, 1096, 1027, 910 
cm-1 
 
1H NMR (CDCl3): δ 0.87 (t, 3H, J = 7.4 H-4’), 1.26-1.32 (m, 5H, H-3’, OCH2CH3 ), 
1.47 (q, 2H, J = 6.9 Hz, H-2’), 1.58 (dt, 1H, J = 14.3, 1.6 Hz, H-6), 2.60 (ddd, 1H, J = 
3.8, 7.7, 14.3 Hz, H-6), 3.33-3.37 (m, H, H-1’), 3.43-3.46 (m, H, H-1’), 4.04-4.05 (m, 
1H, H-5), 4.09 (dd, 1H, J = 3.6, 6.2 Hz, H-5), 4.23-4.26 (m, 3H, OCH2CH3), 5.67 (ddd, 
1H, J = 1.9, 3.8, 7.4 Hz, H-1), 7.19 (d, 1H, J = 6.0 Hz, H-8). 
 
13C NMR (CDCl3): δ 13.76 (C-4’), 14.25 (OCH2CH3), 19.29 (C-3’), 31.65 (C-2’), 34.95 
(C-6), 47.64 (C-4), 61.37 (OCH2CH3), 69.33 (C-1’), 71.48 (C-5), 73.45 (C-1), 136.14 
(C-8), 138.07 (C-7), 162.23 (C=O), 170.83 (C=O). 
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LRMS (ESI+): 286.2 [M+NH4]+. 
 
HRMS (ESI) calcd for C14H24O5N [M+NH4]+: 286.1649; Found: 286.1656. 
 
Compounds 280a & 280b 
 
 
 
Compound 270a (400 mg, 1.01 mmol) was dissolved in DCM/H2O (3:1, 8 mL) and 
mCPBA (261 mg, 1.51 mmol) was added.  The reaction mixture was stirred at room 
temperature for 24 h.  The reaction was quenched with 1 M NaHSO4 (5 mL) and 
extracted with dichloromethane (3 x 25 mL).  The organic layer was washed with 
NaHCO3 (15 mL) and dried over MgSO4 and concentrated under reduced pressure.  The 
crude product was purified by flash chromatography on silica gel, eluting with 
petroleum ether/EtOAc (7:1, 5:1) to give compound 280b (99 mg, 24%) as a white 
crystalline solid and compound 280a (263 mg, 63%) as a white crystalline solid. 
 
(1R, 2S, 4R)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-7-oxa-
bicyclo[4.1.0]hept-5-ene-5-carboxylic acid methyl ester 280a  
 
mp: 95-97 oC. 
 
[α] 20D  = +5.6
 (c 0.125, CHCl3). 
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IR: (KBr) 2987, 2926, 2854, 1721, 1373, 1260, 1217, 1165, 1073, 849 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.32 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.44 (s, 3H, CH3), 
1.49 (s, 3H, CH3), 1.66 (dd, 1H, J = 5.0, 16.0 Hz, H-3), 2.84 (d, 1H, J = 16.0 Hz, H-3), 
3.43 (t, 1H, J = 4.1 Hz, H-1), 3.64 (m, 1H, H-2), 3.78 (s, 3H, OCH3), 3.90 (dd, 1H, J = 
6.9, 8.4 Hz, H-6’), 4.06 (m, 1H, H-4), 4.13 (m, 2H, H-3’, H-6’), 4.43 (m, 1H, H-5’), 
4.56 (m, 1H, H-4), 4.76 (d, 1H, J = 3.6 Hz, H-2’),  5.80 (d, 1H, J = 3.6 Hz, H-1’), 7.41 
(dd, 1H, J = 1.4, 4.3 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.39 (CH3), 26.27 (C-3), 26.47 (CH3), 26.95 (CH3), 
27.03 (CH3), 45.36 (C-1), 52.22 (OCH3), 55.70 (C-2), 67.74 (C-6’), 69.02 (C-4), 72.24 
(C-5’), 80.72 (C-4’), 81.16 (C-3’), 82.89 (C-2’), 105.54 (C-1’), 108.95 (Me2C), 111.80 
(Me2C), 132.29 (C-5), 140.25 (C-5a), 165.84 (C=O). 
 
LRMS (ESI+): 435.2 [M+Na+]. 
 
HRMS (ESI) calcd for C20H32O9N [M+NH4]+: 430.2072 ; Found: 430.2072. 
 
(1S, 2R, 4R)-4-(1’,2’:5’,6’-Di-O-isopropylidene-α-D-glucofuranose)-7-oxa-
bicyclo[4.1.0]hept-5-ene-5-carboxylic acid methyl ester  280b 
 
mp: 116-118 oC. 
 
[α] 20D  = -72.5
 (c 1.335, CHCl3).  
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IR: (KBr) 3076, 2989, 2937, 2889, 1696, 1574, 1418, 1304, 1261, 1075, 916 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.32 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.42 (s, 3H, CH3), 
1.49 (s, 3H, CH3), 2.21 (ddd, 1H, J = 4.0, 5.7, 15.5 Hz, H-3), 2.40 (ddd, 1H, J = 2.2, 6.2, 
15.5 Hz, H-3), 3.36 (t, 1H, J = 3.6 Hz, H-1), 3.51 (dt, 1H, J = 5.5, 2.2 Hz, H-2), 3.76 (s, 
3H, OCH3), 3.95 (dd, 1H, J = 5.5, 8.8 Hz, H-6’), 4.03 (d, 1H, J = 3.3 Hz, H-4’),  4.04-
4.07 (m, 2H, H-3’, H-6’), 4.22 (dt, 1H, J = 5.8, 8.4, H-5’), 4.29 (t, 1H, J = 6.0 Hz, H-4), 
4.78 (d, 1H, J = 3.6 Hz, H-2’),  5.81 (d, 1H, J = 3.6 Hz, H-1’), 7.00 (d, 1H, J = 3.6 H-
5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.75 (CH3), 26.59 (CH3), 27.22 (2 x CH3), 28.31 (C-
3), 46.33 (C-1), 50.31 (C-2), 52.37 (OCH3), 67.71 (C-4), 67.86 (C-6’), 72.57 (C-5’), 
81.26 (C-4’), 81.28 (C-3’), 82.60 (C-2’), 105.80 (C-1’), 109.30 (Me2C), 112.13 (Me2C), 
135.54 (C-5), 136.58 (C-5a), 166.11 (C=O). 
LRMS (ESI+): 435.1 [M+Na]+. 
 
HRMS (ESI) calcd for C20H32O9N [M+NH4]+: 430.2072 ; Found: 430.2071. 
 
4-(β-D-Glucose-1’,2’,3’,4’-tetraacetate)-cyclohexa-1,5-dienecarboxylic acid methyl 
ester 271a/b 
 
 
 
229 
 
A solution of compound 221 (1.07 g, 2.86 mmol, 2 eq.) and compound 226 (220 mg, 
1.43 mmol, 1 eq.) in DCM (1 mL) was heated for 3 days at 60 oC in a sealed tube.  The 
reaction mixture was cooled to room temperature and the solvent was removed under 
reduced pressure.  The crude product was purified by flash chromatography on silica gel 
(pre-washed with petrol/EtOAc/Et3N (92:6:12)), eluting with petroleum ether\EtOAc 
(5:1) to give a mixture of 5-endo-1/5-endo-2 250a & 250b (225 mg, 30%) as yellow oil 
and a mixture of compounds 271a/b (194 mg, 28%) as a yellow oil. 
 
Isomer  271a 
 
IR: (thin film) 2951, 2879, 1758, 1644, 1437, 1369, 1221, 1038, 914 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.97 (s, 3H, CH3), 1.98 (s, 3H, CH3), 1.99 (s, 3H, CH3), 
2.03(s, 3H, CH3), 2.36-2.42 (dt 1H, J = 14.1, 1.7 Hz, H-3), 2.77 (dd, 1H, J = 5.3, 14.6 
Hz, H-3), 3.53-3.57 (m, 1H, H-6’), 3.67 (dd, 1H, J = 3.1, 11.0 Hz, H-6’), 3.71 (dt, 1H, J 
= 3.4, H-5’), 3.77 (s, 3H, OCH3), 4.40 (dd, 1H, J = 6.9, 14.6 Hz, H-4), 5.04 (t, 1H J = 
9.5 Hz, H-2’), 5.13 (t, 1H, J = 9.5 Hz, H-4’), 5.18 (t, 1H, J = 9.6 Hz, H-3’),  5.66 (d, 1H, 
J = 8.3 Hz, H-1’), 6.14-6.18 (m, 1H, H-1), 6.21-6.24 (m, 1H, H-2), 7.20 (d, 1H, J = 5.5 
Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 20.66 (CH3), 20.70 (CH3), 20.78 (CH3), 20.95 (CH3), 
30.52 (C-6), 51.84 (OCH3), 61.50 (C-4), 66.67 (C-6’), 67.79 (C-4), 68.74 (C-4’), 70.44 
(C-2’), 73.17 (C-3’), 73.74 (C-5’), 91.84 (C-1’), 122.58 (C-1), 125.26 (C-5), 133.52 (C-
2), 136.05 (C-5a), 167.64 (C=O), 169.12 (C=O), 169.37 (C=O), 169.47 (C=O), 170.32 
(C=O). 
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Isomer  271b 
 
1H NMR (CDCl3, 600 MHz): δ 2.03 (s, 3H, CH3), 2.08 (s, 3H, CH3), 2.08 (s, 3H, CH3), 
2.11(s, 3H, CH3), 2.36-2.42 (m 1H, J = 1.7, 14.1 H-3), 2.77 (dd, 1H, J = 5.3, 14.6 Hz, 
H-3), 3.53-3.57 (m, 1H, H-6’), 3.67 (dd, 1H, J = 3.1, 11.0 Hz, H-6’), 3.79 (s, 3H, 
OCH3), 4.40 (dd, 1H, J = 6.9, 14.6 Hz, H-4), 5.07 (t, 1H J = 9.5 Hz, H-2’), 5.12 (t, 1H, J 
= 9.5 Hz, H-4’), 5.24 (t, 1H, J = 9.5 Hz, H-3’), 5.71 (d, 1H, J = 8.4 Hz, H-1’), 6.14-6.18 
(m, 1H, H-1), 6.21-6.24 (m, 1H, H-2), 7.24 (d, 1H, J = 5.7 Hz, H-5a).  
  
13C NMR (CDCl3, 150.9 MHz): δ 20.66 (CH3), 20.70 (CH3), 20.91 (CH3), 21.14 (CH3), 
30.61 (C-6), 51.91 (OCH3), 60.48 (C-4), 66.85 (C-6’), 68.06 (C-4), 68.62 (C-4’), 70.28 
(C-2’), 73.14 (C-3’), 74.37 (C-5’), 91.76 (C-1’), 122.58 (C-1), 125.11 (C-5), 133.50 (C-
2), 135.99 (C-5a), 167.57 (C=O), 169.04 (C=O), 169.40 (C=O), 170.18 (C=O), 170.69 
(C=O). 
 
LRMS (ESI+): 502.1 [M+NH4]+. 
 
HRMS (ESI) calcd for C22H32O12N [M+NH4]+: 502.1919; Found: 502.1917. 
 
(1S,2S,4R)-1-Azido-4-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-2-hydroxy-
cyclohex-5-enecarboxylic acid methyl ester 281 
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A solution of compound 280a (313 mg, 0.759 mmol) in DME/EtOH/H2O (2:1:1, 8 mL) 
was cooled to 0 oC. Sodium azide (294 mg, 4.52 mmol) was added followed by NH4Cl 
(240 mg, 4.49 mmol).  The reaction mixture was stirred at 0 oC for 1 h and then stirred 
at room temperature for 24 h.  The reaction mixture was concentrated under reduced 
pressure, diluted with water (15 mL) and extracted with EtOAc (4 x 50 mL).  The 
combined organic layers were washed with brine, dried over MgSO4 and concentrated 
under reduced pressure.  The crude product was purified by flash chromatography on 
silica gel, eluting with petroleum ether/EtOAc (4:1) to give the title compound 281 (293 
mg, 85%) as a yellow oil. 
 
[α] 20D  = -72.5
 (c 1.335, CHCl3). 
 
IR: (thin film) 3434, 2988, 2925, 2853, 2106, 1723, 1643, 1435, 1373, 1258, 1218, 1072 
cm-1. 
1H NMR (CDCl3, 600 MHz): δ 1.33 (s, 3H, CH3), 1.36 (s, 3H, CH3), 1.46 (s, 3H, CH3), 
1.51 (s, 3H, CH3), 1.85 (ddd, 1H, J = 2.5, 3.5, 15.5 Hz, H-3), 2.33 (ddd, 1H, J = 1.6, 3.4, 
15.5 Hz, H-3), 3.80 (s, 3H, OCH3), 3.90 (br s, 1H, H-3'), 4.02 (dd, 1H, J = 3.8, 8.9 Hz, 
H-6’), 4.08 (dd, 1H, J =1.2, 6.0 Hz, H-6’), 4.09-4.13 (m, 3H, H-1, H-2, H-4’), 4.17-4.20 
(m, 1H, H-5’), 4.48-4.49 (m, 1H, H-4), 5.07 (d, 1H, J = 3.8 Hz, H-2’), 5.82 (d, 1H, J = 
3.8 Hz, H-1’), 7.00 (d, 1H, J = 5.3 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 24.81 (CH3), 26.36 (CH3), 27.04 (CH3), 27.12 (CH3), 
27.75 (C-3), 52.27(OCH3), 58.74 (C-1), 66.17 (C-2), 66.49 (C-4), 67.90 (C-6’), 72.57 
(C-5’), 79.97 (C-4’), 81.18 (C-3’), 81.51 (C-2’), 105.89 (C-1’), 109.64 (Me2C), 111.95 
(Me2C), 132.52 (C-5), 135.18 (C-5a), 165.67 (C=O). 
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LRMS (ESI+): 478.3 [M+Na]+. 
 
HRMS (ESI) calcd for C20H33O9N4 [M+NH4]+: 473.2242; Found: 473.2244. 
 
(1R,2R,4R)-1-Azido-4-(1’,2’:5’,6’-di-O-isopropylidene-α-D-glucofuranose)-2-hydroxy-
cyclohex-5-enecarboxylic acid methyl ester 282 
 
 
 
A solution of compound 280b (59 mg, 0.143 mmol) in DME/EtOH/H2O (1:0.5:0.5, 2 
mL) was cooled to 0 oC. Sodium azide (56 mg, 0.861 mmol) was added followed by 
NH4Cl (45 mg, 0.841 mmol).  The reaction mixture was stirred at 0 oC for 1 h and then 
stirred at 45 oC for 16 h.  The reaction mixture was concentrated under reduced pressure, 
diluted with water (5 mL) and extracted with EtOAc (4 x 25 mL).  The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure.  The crude product was purified by flash chromatography on silica gel, 
eluting with petroleum ether/EtOAc (3:1, 2:1) to give the title compound 282 (58 mg, 
89 %) as colourless oil. 
 
[α] 20D  = +112.6
 (c 0.23, CHCl3). 
 
IR: (thin film) 3478, 2988, 2953, 2937, 2103, 1722, 1656, 1493, 1374, 1256, 1218, 1165, 
1074 cm-1. 
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1H NMR (CDCl3, 600 MHz): δ1H NMR (CDCl3, 600 MHz): δ 1.35 (s, 3H, CH3), 1.36 (s, 
3H, CH3), 1.44 (s, 3H, CH3), 1.50 (s, 3H, CH3), 1.57 (ddd, 1H, J = 1.7, 3.3, 13.8 H-3), 
2.33 (ddd, 1H, J = 2.4, 3.4, 13.8 Hz, H-3), 3.78 (s, 3H, OCH3), 3.94 (dd, 1H, J = 2.2, 8.8 
Hz, H-1), 3.97 (dd, 1H, J = 5.2, 8.8 Hz, H-6’), 4.04-4.05 (m, 2H, H-2, H-4’), 4.07 (d, 
1H, J = 3.1 Hz, H-3’), 4.10 (dd, 1H, J = 6.2, 8.8 Hz, H-6’), 4.22-4.25 (m, 1H, H-5’), 
4.48-4.49 (m, 1H, H-4), 4.93 (d, 1H, J = 3.6 Hz, H-2’), 5.81 (d, 1H, J = 3.6 Hz, H-1’), 
6.82 (d, 1H, J = 2.2 Hz, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ 25.48 (CH3), 26.44 (CH3), 27.03 (CH3), 27.04 (CH3), 
33.58 (C-3), 52.27 (OCH3), 64.69 (C-1), 67.55 (C-2) 67.94 (C-6’), 69.81(C-4), 72.42 
(C-5’), 80.89 (C-4’), 81.17 (C-3’), 82.13 (C-2’), 105.66 (C-1’), 109.25 (Me2C), 111.98 
(Me2C), 131.91 (C-5), 138.76 (C-5a), 165.29 (C=O). 
 
LRMS (ESI+): 477.9 [M+Na]+. 
  
HRMS (ESI) calcd for C20H29O9N3Na [M+Na]+: 478.1796; Found: 478.1801. 
 
(1S,2S,4R)-1-Azido-2-(tert-butyl-dimethyl-silanyloxy)-4-(1’,2’:5’,6’-di-O-
isopropylidene-α-D-glucofuranose)-cyclohex-5-enecarboxylic acid methyl ester 283 
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tert-Butyldimethylsilyl chloride (449 mg, 2.98 mmol) and imidazole (203 mg, 2.98 
mmol) were added to a solution of compound 281 (227 mg, 0.498 mmol, 1 eq.) in DCM 
(5 mL) and maintained at 0 oC for 30 min.  The reaction mixture was stirred at room 
temperature under a nitrogen atmosphere for 24 h.  The reaction mixture was cooled to 
0 oC, quenched with water (10 mL) and extracted with DCM (4 x 50 mL), dried over 
MgSO4 and concentrated under reduced pressure.  The crude product was purified by 
flash chromatography on silica gel, eluting with petroleum ether/EtOAc (6:1) to give the 
title compound 283 (223 mg, 79%) as a yellow oil. 
 
[α] 20D  = +1.5
 (c 0.71, CHCl3). 
 
IR: (thin film) 2988, 2955, 2934, 2888, 2859, 2104, 1726, 1438, 1373, 1254, 1074 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 0.11 [s, 3H, Si(CH3)2t-Bu], 0.15 [s, 3H, Si(CH3)2t-Bu], 
0.91 [s, 9H,C(CH3)3], 1.32 (s, 3H, CH3), 1.33 (s, 3H, CH3), 1.40 (s, 3H, CH3), 1.50 (s, 
3H, CH3), 1.72 (dt, 1H, J = 12.7, 9.2 Hz, H-3), 2.51 (ddd, 1H, J = 3. 8, 6.5, 12.7 Hz, H-
3), 3.59 (ddd, 1H, J = 3.8, 8.3, 16.2 Hz, H-2), 3.75 (s, 3H, OCH3), 3.95 (dd, 1H, J = 5.0, 
8.6 Hz, H-6’), 4.03-4.06 (m, 3H, H-1, H-4’, H-6’), 4.08 (d, 1H, J = 2.9 Hz, H-3’), 4.19-
4.23 (m, 1H, H-5’), 4.49 (dddd, 1H, J = 1.4, 3.0, 6.5, 10.5 Hz, H-4), 4.81 (d, 1H, J = 3.6 
Hz, H-2’), 5.79 (d, 1H, J = 3.6 Hz, H-1’), 6.50-6.51 (m, 1H, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ -4.88 & -4.58 [Si(CH3)2], 17.96 (CMe3), 25.46 (CH3), 
25.72 [3 x SiC(CH3)3], 26.36 (CH3), 26.98 (CH3), 27.01 (CH3), 37.19, (C-3), 52.07 
(OCH3), 65.24 (C-1), 67.52 (C-6’), 71.70 (C-2), 72.34 (C-4), 72.44 (C-5’), 80.97 (C-4’), 
81.18 (C-3’), 82.38 (C-2’), 105.51 (C-1’), 109.02 (Me2C), 111.87 (Me2C), 134.18 (C-5), 
137.23 (C-5a), 165.86 (C=O). 
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LRMS (ESI+):  592.2 [M+Na]+. 
 
HRMS (ESI) calcd for C26H47O9N7Si [M+NH4]+: 587.3107; Found: 587.3115. 
 
(1S,2S,4R)-1-Amino-2-(tert-butyl-dimethyl-silanyloxy)-4-(1’,2’:5’,6’-di-O-
isopropylidene-α-D-glucofuranose)-cyclohex-5-enecarboxylic acid methyl ester 284 
 
 
 
PPh3 (171 mg, 0.654 mmol, 1.9 eq.) was added to a solution of compound 283 (196 mg, 
0.344 mmol) in THF (10 mL) and water (0.1 mL).  The reaction mixture was heated 
under reflux for 3 h, cooled to room temperature and the solvent was removed under 
reduced pressure. The crude product was purified by flash chromatography on silica gel, 
eluting with petroleum ether/EtOAc (4:1) to give the title compound 284 (168 mg, 90%) 
as a pale yellow oil. 
 
[α] 20D  = -61.4
 (c 1.17, CHCl3). 
 
IR: (thin film) 2986, 2955, 2934, 2888, 2858, 1722, 1438, 1372, 1217, 1166, 1073 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1H NMR (CDCl3, 600 MHz): δ 0.11 [s, 3H, Si(CH3)2], 
0.114 [s, 3H, Si(CH3)2], 0.91 [s, 9H, SiC(CH3)3], 1.32 (s, 3H, CH3), 1.33 (s, 3H, CH3), 
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1.40 (s, 3H, CH3), 1.50 (s, 3H, CH3), 1.69 (dt, 1H, J = 9.1, 12.9 Hz, H-3), 2.49 (ddd, 1H, 
J = 3.6, 6.7, 12.9 Hz, H-3), 3.59 (ddd, 1H, J = 3.6, 8.3, 12.0 Hz, H-2), 3.50-3.51 (m, 1H, 
H-1), 3.74 (s, 3H, OCH3), 3.95 (dd, 1H, J = 5.2, 8.6 Hz, H-6’), 4.03-4.08 (m, 3H, H-3’, 
H-4’, H-6’), 4.21-4.24 (m, 1H, H-5’), 4.52-4.56 (m, 1H, H-4), 4.83 (d, 1H, J = 3.6 Hz, 
H-2’), 5.80 (d, 1H, J = 3.6 Hz, H-1’), 6.66 (br s, 1H, H-5a). 
 
13C NMR (CDCl3, 150.9 MHz): δ -4.43 & -4.05 [Si(CH3)2], 18.1 [C(CH3)3], 25.53 
(CH3), 25.87 [3 x C(CH3)3], 26.46 (CH3), 27.04 ( CH3), 27.07 (CH3), 37.8 (C-3), 51.92 
(OCH3), 55.88 (C-1), 67.51 (C-6’), 72.48 (C-5’), 73.03 (C-4), 74.51 (C-2), 80.94 (C-4’), 
81.07 (C-3’), 82.40 (C-2’), 105.62 (C-1’), 109.01 (Me2C), 111.89 (Me2C), 132.13 (C-5), 
142.89 (C-5a), 166.56 (C=O). 
 
LRMS (ESI+): 544.2 (MH+).  
 
HRMS (ESI) calcd for C26H46O9NSi [M+NH4]+: 544.2936; Found: 544.2945. 
 
[(1S,2S,4R)-1-Azido-2-(tert-butyl-dimethyl-silanyloxy)-4-(1’,2’:5’,6’-di-O-
isopropylidene-α-D-glucofuranose)-cyclohex-5-enyl]-methanol 290 
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iBu2Al-H (3.5 mL, of a 1 M solution in toluene, 3.5 mmol, 13 eq.) was added dropwise 
to a solution of compound 283 (155 mg, 0.272 mmol) in dry toluene (2 mL) maintained 
at -78 oC under a dry nitrogen atmosphere. The reaction was monitored by TLC.  After 
5 hours the reaction mixture was quenched at -78 oC by addition of a 1 M solution of 
potassium sodium tartarate (5 mL) and then EtOAc (15 mL).  The reaction mixture was 
warmed to room temperature and stirred for 30 mins.  The organic layer was separated 
and the aqueous phase was extracted with EtOAc (4 x 50 mL).  The combined organic 
extracts were dried over MgSO4 and concentrated under reduced pressure.  The crude 
product was purified by flash chromatography on silica gel, eluting with petroleum 
ether/EtOAc (5:1) to give the title compound 290 (121 mg, 82 %) as a pale yellow oil. 
 
 [α] 20D  = 9.1
 (c 2.59, CHCl3). 
 
IR: (thin film): 3473, 2986, 2955, 2933, 2887, 2859, 2102, 1463, 1373, 1256, 1217, 
1163, 1075, 1020, 941, 840 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 0.12 [s, 3H, Si(CH3)2], and 0.15 [s, 3H, Si(CH3)2], 0.91 
[s, 9H, SiC(CH3)3], 1.32 (s, 6H, 2 x CH3), 1.40 (s, 3H, CH3), 1.50 (s, 3H, CH3), 1.71 (dt, 
1H, J = 12.7, 10.1 Hz, H-3), 1.95 (br s, 1H, OH), 2.51 (ddd, 1H, J = 3.6, 5.5, 12.7 Hz, 
H-3), 3.62 (ddd, 1H, J = 3.6, 8.3, 12.5 Hz, H-2), 3.92-3.94 (m, 1H, H-1), 3.96 (dd, 1H, J 
= 5.2, 8.6 Hz, H-6’), 4.02 (d, 1H, J = 2.9 Hz, H-3’), 4.04-4.10 (m, 4H, H-4’, H-6’, 
CH2OH), 4.23 (dt, 1H, J = 8.1, 5.5 Hz, H-5’), 4.27-4.29 (m, 1H, H-4), 4.63 (d, 1H, J = 
3.6 Hz, H-2’), 5.57 (m, 1H, H-5a), 5.88 (d, 1H, J = 3.6 Hz, H-1’). 
 
13C NMR (CDCl3, 150.9 MHz): δ -4.76 & -4.50 [Si(CH3)2], 18.06 (CMe3), 25.44 (CH3), 
25.82 [3 x C(CH3)3], 26.37 (CH3), 26.94 (CH3), 27.01 (CH3), 37.53, (C-3) ,63.75 
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(CH2OH), 65.93 (C-1), 67.52 (C-6’), 71.71 (C-2), 72.30 (C-4), 74.44 (C-5’), 80.41 (C-
4’), 80.92 (C-3’), 82.75 (C-2’), 105.45 (C-1’), 109.16 (Me2C), 112.22 (Me2C), 124.99 
(C-5a), 141.00 (C-5). 
 
LRMS (ESI+): 564.2 (MNa+). 
 
HRMS (ESI) calcd for C25H47O8N4Si [M+NH4]+: 559.3158; Found: 559.3164. 
 
[(1S,2S,4R)-1-Amino-2-(tert-butyl-dimethyl-silanyloxy)-4-(1’,2’:5’,6’-di-O-
isopropylidene-α-D-glucofuranose)-cyclohexyl]-methanol 291 
 
 
 
Pd/C (10% weight) (97 mg) was added to a stirred solution of compound 290 (323 mg, 
mmol) in EtOAc (10 mL).  The reaction mixture was stirred for 21 hours under a 
hydrogen atmosphere. The solution was filtered through celiteTM and the solvent was 
removed under reduced pressure to give the title compound 291 (quantitative yield) as a 
pale yellow oil.  
 
[α] 20D  = 5.8
 (c 1.86, CHCl3). 
 
IR: (thin film) 3361, 3294, 2988, 2945, 2934, 2893, 2859, 1460, 1373, 1255, 1216, 1165, 
1076, 1022, 961, 838 cm-1. 
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1H NMR (CDCl3, 600 MHz): δ 0.085 & 0.092 [s, 3H, Si(CH3)2], 0.88 [s, 9H, 
SiC(CH3)3], 1.29 (s, 3H, CH3), 1.30 (s, 3H, CH3), 1.29-1.30 (m, 1H, H-5a) 1.40 (s, 3H, 
CH3), 1.48 (s, 3H, CH3), 1.55 (q, 1H, J = 12.2 Hz, H-3), 1.94-1.96 (d, 1H, J = 13.4, H-
5a), 2.13 (dt, 1H, J = 14.3, 4.3 Hz, H-3), 2.25-2.29 (m, 1H, H-5), 2.69 (t, 1H, J = 10.5 
Hz, H-1), 3.22 (ddd, 1H, J = 4.3, 9.3, 15.1 Hz, H-2), 3.53 (dd, 1H, J = 6.0, 11.2 Hz, H-
6), 3.73 (dt, 1H, J = 4.8, 11.9 Hz, H-4), 3.93-3.94 (m, 2H, H-3’, H-6’), 3.96 (dd, 1H, J = 
3. 8, 11.2 Hz, H-6), 4.00 (dd, 1H, J = 2.9, 8.6 Hz, H-4’), 4.06 (dd, 1H, J = 6.0, 8.6 Hz, 
H-6’), 4.17 (dt, 1H, J = 8.8, 5.3 Hz, H-5’), 4.89 (d, 1H, J = 3.6 Hz, H-2’), 5.85 (d, 1H, J 
= 3.6 Hz, H-1’). 
 
13C NMR (CDCl3, 150.9 MHz): δ -4.46 & -3.91 [Si(CH3)2], 18.07 (CMe3), 25.43 (CH3), 
25.91 [3 x C(CH3)3], 26.30 (CH3), 26.86 (CH3), 27.01 (CH3), 31.18 (C-5a), 34.94 (C-3), 
40.84 (C-5), 52.10 (C-1), 61.71 (C-6), 67.67 (C-6’), 72.33 (C-5’), 75.15 (C-2), 78.45 
(C-4), 81.02 (C-4’), 81.17 (C-3’), 83.37 (C-2’), 105.38 (C-1’), 109.19 (Me2C), 112.11 
(Me2C). 
 
LRMS (ESI+): 546.1 (MH+). 
 
HRMS (ESI) calcd for C25H48O8NSi [M+H]+: 518.3144; Found: 518.3135. 
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(1S,2S,4R)-1-Azido-2-(tert-butyl-dimethyl-silanyloxy)-4-(1’,2’-di-O-isopropylidene-α-D-
glucofuranose-)5-hydroxymethyl-cyclohex-5-ene 292 
 
 
 
Compound 283 (97 mg, 0.179 mmol) was dissolved in AcOH/H2O/TFA (9:1:0.5) 10.5 
mL) and stirred at room temperature for 4 h and then concentrated under reduced 
pressure.  The crude product was purified by flash chromatography eluting with 
petroleum ether/EtOAc (3:1) to give the title compound 292 (82 mg, 92%) as a pale 
yellow oil. 
[α] 20D  = -25.5
 (c 0.38, CHCl3). 
 
IR: (thin film) 3430, 2953, 2931, 2890, 2858, 2102, 1463, 1376, 1256, 1217, 1163, 1075, 
1016, 960 cm-1. 
 
1H NMR (MeOD, 600 MHz): δ -0.14 & -0.15 [s, 3H, Si(CH3)2], 0.91 [s, 9H, SiC(CH3)3], 
1.28 (s, 3H, CH3), 1.43 (s, 3H, CH3), 1.70 (dt, 1H, J = 9.8, 12.4 Hz, H-3), 2.51 (ddd, 1H, 
J = 3.6, 5.7, 12.4 Hz, H-3), 3.52 (dd, 1H, J = 5.7, 11.7 Hz, H-6’), 3.68 (ddd, 1H, J = 3.6, 
8.3, 15.6 Hz, H-2), 3.69 (dd, 1H, J = 2.9, 11.5 Hz, H-6’), 3.75-3.78 (m, 1H, H-5’), 3.91-
3.93 (m, 1H, H-1), 3.97 (d, 1H, J = 13.4 Hz, H-6), 4.04-4.06 (m, 2H, H-3’, H-4’), 4.06-
4.09 (m, 1H, H-6), 4.34-4.36 (m, 1H, H-4), 4.72 (d, 1H, J = 3.8 Hz, H-2’), 5.55-5.56 (m, 
1H, H-5a), 5.82 (d, 1H, J = 3.8 Hz, H-1’). 
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13C NMR (MeOD, 150.9 MHz): δ -6.13 & -5.71 [Si(CH3)2], 17.53 (CMe3), 25.44 (CH3), 
25.82 [3 x C(CH3)3], 25.14 (CH3), 25.72 (CH3), 36.96, (C-3), 61.20 (C-6), 64.11 (C-6’), 
66.18 (C-1), 68.35 (C-5’), 71.73 (C-2), 71.83 (C-4), 79.28 (C-4’), 79.54 (C-3’), 81.81 
(C-2’), 105.31 (C-1’), 111.55 (Me2C), 122.44 (C-5a), 142.11 (C-5). 
 
LRMS (ESI+): 524.2 [M+Na]+. 
 
HRMS (ESI) calcd for C22H43O9N4Si [M+NH4]+: 519.2845; Found: 519.2847. 
 
(1S,2S,4R)-1-Amino-2-(tert-butyl-dimethyl-silanyloxy)-4-(1,2,:5,6-di-O-isopropylidene-
α-D-glucofuranose)-cyclohexanecarboxylic acid methyl ester 294 
 
 
 
Pd/C (10% weight) (26 mg) was added to a stirred solution of compound 283 (178 mg, 
0.312 mmol) in EtOAc (10 mL).  The reaction mixture was stirred for 16 hours under a 
hydrogen atmosphere. The solution was filtered through celite and the solvent was 
removed under reduced pressure to give the title compound 294 (quantitative yield) as a 
pale yellow oil.  
 
[α] 20D  = +28.5
 (c 4.83, CHCl3). 
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IR: (thin film) 2986, 2953, 2935, 2889, 2858, 1735, 1458, 1373, 1256, 1216, 1076, 1021, 
941, 838 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 0.078 & 0.083 [s, 3H, Si(CH3)2], 0.89 [s, 9H, 
SiC(CH3)3], 1.30-1.31 (m, 4H, H-3, CH3), 1.33 (s, 3H, CH3), 1.40 (s, 3H, CH3), 1.48 (s, 
3H, CH3), 1.99 (m, 3H, H-3, H-3, H-5a), 3.05-3.07 (m, 1H, H-5), 3.08-3.12 (m, 1H, H-
1), 3.17 (ddd, 1H, J = 4.8, 8.9, 13.8 Hz, H-2), 3.68 (s, 3H, OCH3), 3.67-3.69 (m, 1H, H-
5’), 3.93 (dd, 1H, J = 5.8, 8.6 Hz, H-6’), 4.0 (d, 1H, J = 2.9 Hz, H-3’), 4.06-4.09 (m, 2H, 
H-4’, H-6’), 4.18-4.22 (m, 1H, H-4), 4.46 (d, 1H, J = 3.6 Hz, H-2’), 5.83 (d, 1H, J = 3.6 
Hz, H-1’). 
13C NMR (CDCl3, 150.9 MHz): δ 150.9 MHz): δ -4.46 & -3.87 [Si(CH3)2], 18.12 
(CMe3), 25.50 (CH3), 25.92 [3 x C(CH3)3], 26.36 (CH3), 26.88 (CH3), 26.99 (CH3), 
31.53 (C-5a), 35.62 (C-3), 43.48 (C-5), 51.66 (C-1), 51.77 (OCH3), 67.56 (C-6’), 72.69 
(C-5’), 75.60 (C-2), 76.85(C-4), 81.19 (C-4’), 81.50 (C-3’), 83.82 (C-2’), 105.83 (C-1’), 
109.10 (Me2C), 111.95 (Me2C), 172.91 (C=O). 
 
LRMS (ESI+): 546.1 [M+H]+. 
 
HRMS (ESI) calcd for C26H48O9NSi [M+H]+: 546.3093; Found: 546.3085. 
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(1S,2S,4R)-2-(Tert-butyl-dimethyl-silanyloxy)-4-(1’,2’,:5’,6’-di-O-isopropylidene-α-D-
glucofuranose)-1-(4-phenyl-[1,2,3]triazol-1-yl)-cyclohex-5-enecarboxylic acid methyl 
ester 296 
 
 
 
Compound 283 (68 mg, 0.119 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (4 mL), phenyl acetylene (36.5 mg, 0.357 mmol) was added followed by 
sodium ascorbate (0.036 mmol, 36 µL of a freshly prepared 1M solution in water) and 
copper(II) sulphate pentahydrate (0.018 mmol, 7.1 mg in 100 µL of water).  The 
reaction mixture was heated at 85 oC for 30 hours.  The solvent was removed under 
reduced pressure and the crude product was purified by flash chromatography on silica 
gel, eluting with petroleum ether/EtOAc (3:1) to give the title compound 296 (79 mg, 
99 %) as a pale yellow oil. 
 
[α] 20D  = -5.0
 (c 2.6, CHCl3). 
 
IR: (thin film) 2988, 2956, 2932, 2893, 2858, 1725, 1657, 1611, 1460, 1437, 1373, 1334, 
1257, 1163, 1124, 1074, 957, 840 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ -0.40 & -0.15 [2 x s,  2 x 3H, Si(CH3)2], 0.77 [s, 9H, 
SiC(CH3)3], 1.35 (s, 3H, CH3), 1.36 (s, 3H, CH3), 1.42 (s, 3H, CH3), 1.52 (s, 3H, CH3), 
1.91 (dt, 1H, J = 16.3, 9.5 Hz, H-3), 2.68 (ddd, 1H, J = 2.8, 6.4, 13.1 Hz, H-3), 3.77 (s, 
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3H, OCH3), 4.00 (dd, 1H, J = 5.0, 8.8 Hz, H-6’), 4.05-4.13 (m, 3H, H-2, H-4’, H-6’), 
4.17 (d, 1H, J = 2.8 Hz, H-3’), 4.25-4.29 (m, 1H, H-5’), 4.72-4.74 (m, 1H, H-4), 4.89 (d, 
1H, J = 3.4 Hz, H-2’), 5.05-5.07 (m, 1H, H-1), 5.84 (d, 1H, J = 3.4 Hz, H-1’), 6.82-6.83 
(m, 1H, H-5a), 7.33-7.36 (m, 1H, Ar-H), 7.42-7.45 (m, 2H, Ar-H), 7.79 (s, 1H, triazole-
H), 7.80-7.82 (m, 2H, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): δ -5.59 & -4.88 [Si(CH3)2], 17.84 [CMe3], 25.60 [3 x 
C(CH3)3 and CH3], 26.44 (CH3), 27.06 (CH3), 27.11 (CH3), 37.69, (C-3), 52.26 (OCH3), 
64.98 (C-1), 67.68 (C-6’), 71.60 (C-2), 72.46 (C-4), 72.52 (C-5’), 81.04 (C-4’), 81.44 
(C-3’), 82.46 (C-2’), 105.61 (C-1’), 109.15 (Me2C), 112.03 (Me2C), 121.26 & 147.55 
(triazole), 125.88 (2 x Ar-CH), 128.40 (Ar-CH), 129.03 (2 x Ar-CH), 130.48 (Ar-C), 
134.82 (C-5), 135.52 (C-5a), 165.72 (C=O). 
LRMS (ESI+): 672.2 [M+H]+. 
 
HRMS (ESI) calcd for C34H50O9N3Si [M+NH4]+: 672.3311; Found: 672.3321. 
Methyl 6-O-tert-butyldimethylsilyl-α-D-mannopyraoside 335 
 
 
 
tert-butylchlorodimethylsilane (8.53 g, 56.65 mmol) and catalytic amount of DMAP 
were added to a stirred solution of α-D-methylmannopyronnoside (10.1 g, 52.04 mmol) 
in pyridine (20 mL) at 0 oC.  The reaction mixture was stirred at room temperature and 
the progress of the reaction was monitored by TLC [MeOH/CHCl3 (9:1)].  After 
completion (approx. 4 hours), the reaction mixture was diluted with EtOAc (100 mL) 
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and washed with 3 % sulphuric acid (3 x 50 mL), saturated aq. NaHCO3 (3 x 50 mL) 
and saturated brine (3 x 50 mL).  The organic layer was dried over MgSO4 and 
concentrated under reduced pressure.  The crude product was purified by flash 
chromatography, eluting with ether to give the title compound 335 (8.00 g, 52 %) as a 
white solid.  
 
mp. 102.2-103.6 oC. 
 
IR: (Thin film) 3512, 2934, 2857, 2249, 1463, 1405, 1389, 1361, 1334, 1253, 1197, 
1112 cm-1. 
 
1H NMR (CDCl3, 360 MHz) δ 0.1 [s, 6H, Si(CH3)2], 0.2 [s, 9H, SiC(CH3)3], 3.36 (s, 3H, 
OCH3), 3.54-3.59 (m, 1H, H-5), 3.73 (t, 1H, J = 9.0 Hz, H-4), 3.79-3.80 (m, 2H, H-3 
and H-6), 3.85-3.88 (m, 2H, H-2, H-6), 4.69 (d, 1H, J = 1.1 Hz, H-1). 
 
13C NMR (CDCl3, 90.6 MHz) δ: -4.76 & -4.45 [Si(CH3)2], 18.54 [CMe3], 26.00 
[C(CH3)3], 54.92 (OCH3), 65.13 (C-6), 67.1 (C-4), 70.46 (C-2), 71.70 (C-5), 73.32 (C-
3), 100.43 (C-1). 
 
Anal. Calcd. For C13H28O6Si: C, 50.62, H, 9.15. Found: C, 51.85, H, 8.60. 
 
LRMS (ESI+): 331.2 [M+Na]+. 
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Methyl 2,3,4-tri-O-benzyl-6-O-tert-butyldimethyl-silyl-α-D-mannopyranoside 337 
 
 
 
Sodium hydride (4.43 g, 38.4 mmol) was added portion wise to a solution of compound 
335 (7.88 g, 25.6 mmol) in DMF (50 mL) at 0 oC.  The reaction mixture was stirred at 
room temperature for 1 h.  BnBr (10.93 mL, 30.6 mmol) was added to the mixture at 0 
oC.  The reaction mixture was stirred at room temperature for 4 hours.  The mixture was 
diluted with EtOAc (100 mL) and washed with water (3 x 50 mL) and saturated aq. 
sodium chloride (3 x 50 mL).  The organic layer was dried over MgSO4 and 
concentrated under reduced pressure.  The crude product was purified by flash 
chromatography, eluting with petroleum ether/EtOAc 20:1 to give the title compound 
337 (7.34 g, 50 %) as a colourless oil. 
 
[α] 20D  = +19.2
 (c 0.515, CHCl3). 
 
IR: (thin film): 4057, 3063, 3030, 2927, 2855, 2336, 1948, 1869, 1807, 1605, 1586, 
1496, 1454, 1361, 1325, 1251, 1207, 1107, 1061 cm-1.  
 
1H NMR (CDCl3, 360 MHz):  δ 0.01 [m, 6H, Si(CH3)2], 0.83 [s, 9H, SiC(CH3)3], 3.29 (s, 
3H, OCH3), 3.50-3.52 (m, 1H, H-5), 3.70 (s, 1H, H-2), 3.76-3.79 (m, 2H, H-3 and H-6), 
3.82-3.87 (m, 2H, H-6 and H-4),), 4.54-4.59 (m, 3H, ArCH2), 4.62 (s, 1H, H-1) 4.66 (s, 
2H, ArCH2),  4.86 (d, 1H, J = 11.0 Hz, ArCH2), 7.19-7.30 (m, 15H, Ar-H). 
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13C NMR (CDCl3, 90.6 MHz): δ -4.86 & -4.70 [Si(CH3)2], 18.73 [CMe3], 26.35 
[C(CH3)3], 54.87 (OCH3), 63.23 (C-6), 72.54, 72.93, 75.37 (3 x s, 3 x ArCH2), 73.53 
(C-3), 75.32 (C-4), 80.67 (C-5), 99.08 (C-1), 127.91-128.75 (Ar-CH), 138.92 (Ar-C), 
139.06 (Ar-C), 139.19 (Ar-C). 
 
LRMS (ESI+): 601.3 [M+Na]+. 
 
Methyl 2,3,4-tri-O-benzyl-α-D-mannopyranoside 338 
 
 
 
1M sulphuric acid (1 mL) was added to a stirred solution of compound 337 (7.18 g, 12.7 
mmol) in methanol (25 mL) at 0 oC.  The reaction mixture was stirred at room 
temperature for 4 hours.  The reaction mixture was diluted with EtOAc (100 mL) and 
washed with saturated aq. NaHCO3 (3 x 50 mL), water (3 x 50 mL) and saturated aq. 
sodium chloride or formula (3 x 50 mL).  The organic layer was dried over MgSO4 and 
concentrated under reduced pressure.  The crude product was purified by flash 
chromatography, eluting with petroleum ether/EtOAc 2:1 to give the title compound 
338 (5.40 g, 92%) as a colourless oil.  
 
[α] 20D = +32.3
 (c 5.75, CHCl3). 
 
IR: (Thin film) 3478, 3063, 3030, 2927, 2246, 1952, 1878, 1810, 1725, 1604, 1496, 
1452, 1363, 1322, 1280, 1208 cm-1. 
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1H NMR (CDCl3, 360 MHz) δ: 2.52 (OH), 3.35 (s, 3H, OCH3), 3.39-3.71 (m, 1H, H-5), 
3.84 (dd, 1H, J = 4.0, 7.0 Hz, H-6), 3.90 (d, 1H, J = 3.0 Hz, H-2), 3.94 (dd, 1H, J = 3.0, 
7.0 Hz, H-6), 3.98 (d, 1H, J = 3.0 Hz, H-3), 4.05 (t, 1H, J = 9.5 Hz, H-4), 4.7 (s, 2H, 
ArCH2), 4.71, (s, 1H, H-1), 4.74-4.86 (m, 3H, ArCH2), 5.01 (d, 3H, J = 11.0 Hz, 
ArCH2), 7.37-7.47 (m, 15H, Ar-H). 
 
13C NMR (CDCl3, 90.6 MHz): δ 55.34 (OCH3), 62.76 (C-6), 72.54 (C-5), 72.65, 73.40, 
75.65 (3 x s, 3 x ArCH2), 75.11 (C-2), 75.27 (C-4), 80.63 (C-3), 99.74 (C-1), 128.04-
129.11 (Ar-CH), 138.67 (Ar-C), 138.88 (Ar-C), 138.92 (Ar-C). 
 
LRMS (ESI+): 487.3 [M+Na]+. 
 
Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-amino-α-D-mannopyranoside 339 
 
 
Pd/C (10% weight) (744 mg) was added to a stirred solution of compound 342 (1.35 g, 
2.76 mmol) in methanol (10 mL).  Hydrogen gas was bubbled for 1 hour.  The reaction 
mixture was stirred for a further 12 hours under a hydrogen atmosphere. The solution 
was filtered through celite to give 339 (997 mg, 79%) as a yellow syrup. 
 
IR: (Thin film) 4057, 5650, 3386, 3087, 2916, 2334, 2102, 1951, 1877, 1810, 1723, 
1669, 1605, 1586, 1494, 1453, 1364, 1320, 1286 cm-1,  
 
1H NMR (CDCl3, 360 MHz): δ 1.16 (br, 2H, NH2), 2.73 (dd, 1H, J = 6.2 Hz, H-6), 2.93 
(dd, 1H, 1H, J = 2.5, 11.0 Hz, H-6), 3.18 (s, 3H, OCH3), 3.70 (m, 1H, H-5), 3.65-3.70 
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(m, 2H, H-2 and H-4), 3.79 (dd, 1H, J = 3.0, 6.0 Hz, H-3), 4.53 (s, 2H, ArCH2), 4.7 (s, 
1H, H-1), 4.61 (m, 3H, ArCH2), 4.83 (d, 1H, J = 11.0 Hz, ArCH2), 7.14-7.27 (m, 15H, 
Ar-H). 
 
13C NMR (CDCl3, 90.6 MHz): δ 43.72 (C-6), 55.10 (OCH3), 75.51, 73.30, 72.54 
(ArCH2), 73.68 (C-5), 75.09 (C-2), 76.29 (C-4), 80.88 (C-3), 99.54 (C-1), 127.75-
128.66 (Ar-CH).138.97 (Ar-C), 138.91 (Ar-C), 138.78 (Ar-C).  
 
LRMS (ESI+): 464.42 [M+H+]. 
 
Methyl 2,3,4-tri-O-benzyl-6-O-toluenesufonyl-α-D-mannopyranoside 341 
 
 
 
TsCl (2.9 g, 15.2 mmol) was added portion wise to a solution of compound 338 (2.02 g, 
4.35 mmol) in pyridine (20 mL) at 0 oC.  The reaction mixture was stirred at room 
temperature for 12 hours, the solvent was removed under reduced pressure and residue 
was purified by flash chromatography, eluting with petroleum ether/EtOAc 4:1 to give 
the title compound 341 (2.36g, 88 %) as white crystals.    
 
mp: 108.0-110.7 oC 
 
IR: (KBr) 3029, 2920, 2853, 2353, 1593, 1496, 1454, 1363, 1190, 1177, 1097, 1068 cm-
1. 
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1H NMR (CDCl3, 360 MHz) δ: 2.43 (s, 3H, CH3), 3.27 (s, 3H, OCH3), 3.76 (t, 1H, J = 
2.4 Hz, H-2), 3.81 (d, 1H, J = 9.0 Hz, H-3 ), 3.87 (dd, 1H, J = 5.0, H-5), 4.23 (dd, 1H, J 
= 2.4, 12.4 H-6), 4.30 (dd, 1H, J = 2.0, 12.4 Hz, H-6 ), 4.49 (d, 1H, J = 11.0 Hz, ArCH2), 
4.60 (s, 2H, ArCH2), 4.68 (s, 1H, H-1), 4.70-4.75 (m, 2H, ArCH2), 4.91 (d, 1H, J = 11.0 
Hz, ArCH2), 7.2 (m, 2H, Ar-H), 7.27-7.34 (m, 15H, Ar-H), 7.80 (d, 2H, J = 8.0 Hz, Ar-
H). 
  
13C NMR (CDCl3, 90.6 MHz) δ: 22.05 (Ar-Me), 55.30 (OCH3), 69.65 (C-6), 70.32 (C-
5), 74.45 (C-4), 74.66 (C-2), 75.41, 73.06, 72.43, (3s, 3 x ArCH2), 80.46 (C-3), 99.24 
(C-1), 128.30-128.80(Ar-CH), 130.15 (Ar-C), 133.41(Ar-C), 138.45-138.63, (Ar-CH), 
145.0 (Ar-C). 
 
Anal. Calcd. For C35H38O8S: C, 70.11, H, 6.54. Found: C, 70.04, H, 6.39 
 
LRMS (ESI+): 641.3 [M+H]+. 
 
Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-azido-α-D-mannopyranoside 342 
 
 
 
Sodium azide (1.24 g, 19.1 mmol) was added to a stirred solution of compound 341 
(2.36 g, 3.81 mmol) in DMF (10 mL).  The reaction mixture was stirred at 90 oC for 4 
hours.  The reaction mixture was diluted with EtOAc (150 mL) and washed with water 
(4 x 50 mL), dried over Na2SO4, filtered and evaporated under reduced pressure to give 
the title compound 342 (1.80 g, 97%) as a colourless syrup.  
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[α] 20D = 42.1
 (c 10.8, CHCl3). 
 
IR: (Thin film) 4058, 3649, 3327, 3063, 3030, 3004, 2915, 2334, 2098, 1952, 1877, 
1810, 1726, 1605, 1586, 1496, 1453, 1363, 1285, 1208, 1062 cm-1. 
 
1H NMR (CDCl3, 360 MHz) δ: 3.48  (s, 3H, OCH3), 3.57 (dd, 1H, J = 6.5, 12.7 Hz, H-
6), 3.61 (dd, 1H, J = 2.4, 12.7 Hz, H-6), 3.90-3.93 (m, 1H, H-5), 3.96 (s, 1H, H-4), 4.05 
(m, 2H, H-2, and H-3), 4.72 (s, 1H, H-1), 4. 73 (s, 2H, ArCH2), 4.84-4.93 (m, 3H, 
ArCH2), 5.12 (d, J = 11.0 Hz, ArCH2), 7.33-7.56 (m, 15H, Ar-H). 
 
13C NMR (CDCl3, 90.6 MHz): δ 51.96 (C-6), 55.38 (OCH3), 75.65, 73.21, 72.47 
(PhCH2), 71.98 (C-5), 74.83 (C-4), 75.90 (C-2), 80.43 (C-3), 99.45 (C-1), 128.89-
128.07 (Ar-CH), 138.76 (Ar-C), 138.67 (Ar-C), 138.64 (Ar-C). 
 
LRMS (ESI+): 512.2 [M+Na]+. 
 
Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-cyclohexylamine-α-D-mannopyranoside 343 
 
 
 
Cyclohexanone (111 mg, 1.13 mmol) was added to a stirred solution of compound 339 
(348 mg, 0.37 mmol) in DCM (15 mL) containing molecular sieves.  The reaction 
mixture was refluxed for 4 hours, filtered and the solvent was removed under reduced 
pressure.  The residue was dissolved in methanol (20 mL); stirred and excess sodium 
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borohyride was added in portions over 3 hours.  The solution was filtered and the 
solvent was removed under reduced pressure.  Th crude product was purified by flash 
chromatography, eluting with petroleum ether/EtOAc (10:1) to give the title compound 
343 (231 mg, 56%) as a yellow syrup.  
 
[α] 20D = +40.8
 (c 1.16, CHCl3). 
 
IR: (thin film) 3064, 3030, 2926, 2853, 1495, 1454, 1363, 1124, 1062, 969 cm-1. 
 
1H NMR (CDCl3, 360 MHz):  δ 0.79 (m, 1H), 1.00 (t, 2H, J = 12.0 Hz, Haxial), 1.1 (m, 
2H, Haxial), 1.52 (d, 1H, J = 5.0 Hz, Heq), 1.63 (d, 2H, J = 12.0 Hz, Heq), 1.75 (t, 2H, J = 
13.0 Hz, Heq), 2.33 (m, 1H, CNH), 2.68 (dd, 1H, J = 4.0, 12.4 Hz, H-6), 2.96 (dd, 1H, J  
= 2.0, 12.4 Hz, H-6), 3.23 (s, 3H, OCH3), 3.65 (m, 1H, H-5),  3.71 (m, 1H, H-2), 3.75 (d, 
J = 9.0 Hz, H-4), 3.80 (dd, 1H, J = 3.0, 6.0 Hz, H-3), 4.50 (s, 2H, ArCH2), 4.57 (s, 1H, 
H-1), 4.60 (m, 3H, ArCH2), 4.86 (d, 1H, J = 11.0 Hz, ArCH2), 7.19-7.30 (m, 15H, Ar-
H). 
 
13C NMR (CDCl3, 125.8 MHz): δ 25.45 and 26.60 (C-3’), 33.68 and 33.91 (C-2’), 48.40 
(C-6), 55.27 (OCH3), 56.94 (CHN), 71.27 (C-5), 72.64 (ArCH2), 73.22 (ArCH2), 75.47 
(ArCH2), 75.06 (C-2), 77.44 (C-4), 80.73 (C-3), 99.53 (C-1), 127.93-128.76 (Ar-CH), 
138.74 (Ar-C), 138.98 (Ar-C), 139.06 (Ar-C). 
 
LRMS (ESI+):  546.3 [M+H]+. 
 
HRMS (ESI) calcd for C34H44O5N [M+H]+: 546.3214; Found: 546.3201. 
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Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-Benzy-α-D-mannopyranoside 344 
 
 
 
Benzaldehyde (114 mg, 1.07 mmol) was added to a stirred solution of compound 339 
(332 mg, 0.72 mmol) in DCM (15 mL) containing molecular sieves.  The reaction 
mixture was refluxed for 4 hours, filtered and the solvent was removed under reduced 
pressure.  The residue was dissolved in methanol (20 mL); stirred and excess sodium 
borohydride was added in portions over 3 hours.  The solution was filtered and the 
solvent was removed under reduced pressure.  The crude product was purified by flash 
chromatography, eluting with petroleum ether/EtOAc (10:1) to give the title compound 
344 (352 mg, 89%) as a yellow syrup.  
[α] 20D = +16.3
 (c 4.67, CHCl3). 
 
IR: (thin film) 3063, 3031, 2917, 1612, 1454, 1364, 1111, 1065, 968 cm-1. 
 
1H NMR (CDCl3, 500 MHz): δ 2.71 (dd, 1H, J' = 7.6, 12.4 Hz, H-6'), 2.91 (dd, 1H, J' = 
2.4, 12.4 Hz H-6), 3.30 (s, 3H, OCH3), 3.59 (m, 1H, H-4), 3.61 (s, 1H, ArCH2N), 3.70 (t, 
1H, J = 2.0 Hz, H-2), 3.72 (d, 1H, J = 14.0 Hz, ArCH2N), 3.80 (dd, 1H,  J = 3.0, 6.0 Hz, 
H-5), 3.84 (m, 1H, H-3), 4.29 (d, 1H, J = 11.0 Hz, ArCH2), 4.50 (s, 2H, ArCH2), 4.60 (s, 
1H, H-1), 4.63 (m, 3H, ArCH2), 4.70 (d, 1H, J = 11.0 Hz, ArCH2), 6.88 (m, 2H, Ar-H), 
7.12-7.30 (m, 18H, Ar-H). 
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13C NMR (CDCl3, 125.8 MHz): δ 54.89 (C-6), 55.48 (OCH3), 59.25 (ArCH2N), 72.51, 
73.11, 75.18 (ArCH2), 72.71 (C-5), 75.00 (C-2), 76.91 (C-4), 80.72 (C-3), 99.41 (C-1), 
127.09-129.19 (Ar-CH), 138.77 (Ar-C), 138.82 (Ar-C), 138.94 (Ar-C), 140.32 (Ar-C). 
 
LRMS (ESI+):  554.2 [M+H]+. 
 
HRMS (ESI) calcd for C35H40O5N1 [M+H]+: 554.2901; Found: 554.2907. 
 
Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-(4-dimethoxybenzylamine)-α-D-mannopyranoside 
345 
 
 
Anisaldehyde (163 mg, 1.20 mmol) was added to a stirred solution of compound 339 
(371 mg, 0.8 mmol) in DCM (20 mL) containing molecular sieves.  The reaction 
mixture was refluxed for 4 hours then filtered. The solvent was removed under reduced 
pressure.  The residue was dissolved in methanol (20 mL); stirred and excess sodium 
borohydride was added in portions over 3 hours.  The solution was filtered and solvent 
was removed under reduced pressure.  The crude product was purified by flash 
chromatography, eluting with petroleum ether/EtOAc (5:1) to give the title compound 
345 (388 mg, 83%) as a yellow syrup.  
 
[α] 20D = +35.1
 (c 1.45, CHCl3). 
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IR: (thin film) 3030, 2924, 2830, 1609, 1512, 1454, 1251, 1115, 1065, 968 cm-1 
 
1H NMR (CDCl3, 600 MHz): δ 2.80 (dd, 1H, J = 7.9, 12.0 Hz, H-6), 3.05 (dd, 1H, J = 
2.4, 12.0 Hz, H-6),  3.37 (s, 3H, OCH3), 3.76 (3H, OCH3), 3.76 (s, 1H, ArCHN), 3.80 
(m, 1H, ArCHN), 3.82 (d, 1H, J = 6.6 Hz, H-4), 3.87 (d, 1H, J = 2.9 Hz, H-5), 3.88 (m, 
1H, H-2), 3.93 (d, 1H, J = 18.2 Hz, H-3,), 4.52 (d, 1H, J = 1.1 Hz, ArCH2), 4.59 (s, 2H, 
ArCH2), 4.69 (m, 2H, H-1, ArCH2), 4.73 (d, 1H, J = 12.4 Hz, ArCH2), 4.88 (d, 1H, J = 
11.0 Hz, ArCH2), 6.83 (d, 1H, J = 8.6 Hz, Ar-H),  7.17 (d, 1H, J = 6.8 Hz, Ar-H), 7.25-
7.37 (m, 2H, Ar-H), 7.25-740 (m, 15H, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): δ 48.5 (C-6), 52.08 (ArCH2N), 55.34, 55.44, (2 x 
OCH3), 72.23, 73.07, 75.03 (ArCH2), 69.3 (C-5), 74.58 (C-2), 76.45 (C-4), 80.16 (C-3), 
99.24 (C-1), 127.70-128.75 (Ar-CH, Ar-C), 130.62 (Ar-CH), 138.25 (Ar-C), 138.34 
(Ar-C), 138.44 (Ar-C) 
 
LRMS (ESI+): 584.3 [M+H]+. 
 
HRMS (ESI) calcd for C36H42O6N1 [M+H]+: 584.3007; Found: 584.3008. 
 
Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-(3,4-dimethoxybenzylamine)-α-D-
mannopyranoside 346 
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3,4-dimethoxybenzaldehyde (154 mg, 0.93 mmol) was added to a stirred solution of 
compound 339 (287 mg, 0.62 mmol) in DCM (20 mL) containing molecular sieves.  
The reaction mixture was refluxed for 4 hours, filtered and the solvent was removed 
under reduced pressure.  The residue was dissolved in methanol (20 mL); stirred and 
excess sodium borohydride was added in portions over 3 hours.  The solution was 
filtered and solvent was removed under reduced pressure.  The crude product was 
purified by flash chromatography, eluting with petroleum ether/EtOAc (3:1) to give the 
title compound 346 (233 mg, 61%) as a yellow syrup.  
 
[α] 20D = +33.8 (c 4.14, CHCl3).
 
 
IR: (thin film) 3030, 3003, 2908, 2834, 1592, 1515, 1454, 1265, 1237, 1132, 1064, 1028, 
968 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 2.85 (dd, 1H, J = 7.2, 12.4 Hz, H-6), 3.01 (dd, 1H, J = 
2.8, 12.4 Hz, H-6),  3.32 (s, 3H, OMe), 3.73 (d, 1H, J = 13.1 Hz, H-4), 3.78 (m, 1H, H-
5), 3.80 (m, 2H, H-2, ArCHN), 3.85 (s, 3H, OCH3), 3.86 (3H, OCH3), 3.88 (m, 2H, H-3, 
ArCHN), 4.57 (d, 1H, J = 1.1 Hz, ArCH2), 4.62 (d, 2H, J = 1.0 Hz, ArCH2), 4.69 (d, 1H, 
J = 1.4 Hz, H-1), 4.72 (d, 1H, J = 12.4 Hz, ArCH2), 4.78 (d, 1H, J = 12.3 Hz,  ArCH2), 
4.91 (d, 1H, J = 11.0 Hz, ArCH2), 6.79 (d, 1H, J = 7.9 Hz, Ar-H),  6.85 (dd, 1H, J = 2.0, 
16.1 Hz, Ar-H), 6.91 (d, 1H, J = 2.1 Hz, Ar-H), 7.2-7.21 (m, 2H, Ar-H), 7.25-740 (m, 
14H, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): δ 50.16 (C-6), 53.67 (ArCH2N), 54.91, 55.88, 55.91 (3 
x OCH3), 72.31, 72.95, 74.90 (ArCH2), 71.01 (C-5), 74.72 (C-2), 76.82 (C-4), 80.38 (C-
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3), 100.0 (C-1), 127.69-128.47 (Ar-CH), 133.03 (Ar-C), 138.40 (Ar-C), 138.60 (Ar-C), 
138.63 (Ar-C), 140.05 (Ar-C), 149.00 (Ar-C). 
 
LRMS (ESI+): 614.4 [M+H]+. 
 
HRMS (ESI) calcd for C37H44O7N1 [M+H]+: 614.3112; Found: 614.3106. 
 
6-cyclohexylamine-6-deoxy-methyl-α-D-mannopyranoside 351 
 
 
 
Pd/C (10% weight) (20 mg) was added to a stirred solution of compound 343 (155 mg, 
0.13 mmol) in methanol (10 mL).  The reaction mixture was stirred for 4 days under a 
hydrogen atmosphere.  The solution was filtered through celite and washed with EtOAc.  
The solvent was removed under reduced pressure to give the title compound 351 (62 mg, 
79%) as a colourless oil. 
 
IR: (thin film) 3393, 2939, 2858, 1580, 1451, 1413, 1133, 1061, 966 cm-1 
 
1H NMR (MeOD, 600 MHz): δ 1.18-1.26 (m, 1H, cy), 1.34-1.43 (m, 5H, cy), 1.70 (d, 
1H, J = 12.2 Hz, cy), 1.86-1.90 (m, 2H, cy), 2.10-2.17 (m, 1H, cy), 3.06-3.09 (m, 1H, 
cy), 3.18 (dd, 1H, J = 8.4, 12.5 Hz, H-6), 3.29 (s, 3H, OCH3), 3.38 (dd, 1H, J = 2.9, 12.5 
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Hz, H-6), 3.50 (t, 1H, J = 9.6 Hz, H-4), 3.65 (dd, 1H, J = 3.4, 18.7 Hz, H-3), 3.73 (m, 
1H, H-5), 3.80 (dd, 1H, J = 1.8, 6.7 Hz, H-2), 4.67 (d, 1H, J = 1.8 Hz, H-1). 
 
13C NMR (MeOD, 150.9 MHz): δ 24.26 and 24.32 (C-3’), 24.79 (C-4’), 28.64 and 
29.11 (C-2’), 57.69 (C-1’), 45.69 (OCH3), 68.51 (C-4), 68.54 (C-2), 70.51 (C-3), 70.56 
(C-5), 101.81 (C-1). 
 
LRMS (ESI+): 276.1 [M+H]+, 298.1 [M+Na]+. 
 
HRMS (ESI) calcd for C13H26O5N1 (MNH4+): 276.1805; Found: 276.1806. 
 
6-O-Toluenesulfonyl-6-deoxy-methyl-α-D-mannopyranoside 352 
 
 
 
Methyl mannopyranoside (10.1 g, 52.01 mmol) was dissolved in pyridine (100 mL) and 
cooled to 0 oC, TsCl (14.49 g, 76.0 mmol) was added in portions .  The reaction mixture 
was stirred at 0 oC for 8 hours.  The solvent was removed under reduced pressure and 
the residue was purified by flash chromatography, eluting with DCM/MeOH (25:1) to 
give the title compound 352 (13.1 g, 72 %) as a colourless syrup.. 
 
[α] 20D = -101.3
 (c 6.98, CHCl3). 
 
IR: (thin film) 3440, 2932, 2918, 1599, 1445, 1358, 1176, 1096, 1063, 980 cm-1 
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1H NMR (CDCl3, 600 MHz): δ 2.43 (s, 3H, CH3), 3.29 (s, 3H, OCH3), 3.67-3.75 (m, 3H, 
H-2, H-3, H-5), 3.89 (s, 1, H-4), 4.27 ( d, 1H, J = 10.6 Hz, H-6), 4.32 (dd, 1H, J = 5.0, 
10.6 Hz, H-6), 4.64 (s, 1H, H-1),  7.31 (d, 2H, J = 8.2 Hz, Ar-H), 7.78 (d, 2H, J = 8.2 
Hz, Ar-H). 
 
13C NMR (CDCl3, 150.9 MHz): δ 21.74 (Me), 55.13 (OCH3) 69.68 (C-6), 67.09 (C-4), 
70.10 (C-2), 70.57 (C-3), 71.10 (C-5), 101.03 (C-1), 128.11 (Ar-CH), 129.98 (Ar-CH), 
132.69 (Ar-C), 145.08 (Ar-C). 
 
LRMS (ESI+): 349.4 [M+H]+, 371.4 [M+Na]+ 
 
6-Azido-6-deoxy-methyl-α-D-mannopyranoside 353 
 
 
 
Sodium azide (6.15 g, 94.6 mmol) was added portionwise to a stirred solution of 
compound 352 (11.72 g, 33.7 mmol) in DMF (100 mL). The reaction mixture was 
stirred at 90 oC for 5 hours.  The solution was filtered to remove white solid and the 
filtrate was evaporated under reduced pressure.  The residue was purified by flash 
chromatography eluting with DCM/MeOH (10:1) to give the title compound 353 (7.1 g, 
96 %) as a colourless syrup. 
 
[α] 20D = +71.1
 (c 9.87, CHCl3). 
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IR (Thin film):  3399, 3011, 2934, 2838, 2102, 1655, 1445, 1282, 1096, 965 cm-1      
  
1H NMR (MeOD, 600 MHz): δ 3.38 (s, 3H, OCH3), 3.4 (dd, 1H, J = 6.0, 8.4 Hz, H-6), 
3.46 (dd, 1H, J = 2.4, 13.0 Hz, H-6), 3.54 (t, 1H, J = 9.5 Hz, H-4), 3.58-3.62 (m, 2H, H-
3 and H-5), 3.78 (dd, 1H, J = 3.3, 7.0 Hz, H-2), 4.62 (d, 1H, J = 1.7 Hz, H-1). 
13C NMR (MeOD, 150.9 MHz): δ 51.56 (C-6), 54.02 (OCH3), 68.11 (C-4), 70.61 (C-2), 
71.02 (C-3), 72.34 (C-5), 101.48 (C-1). 
 
LRMS (ESI+): 242.2 [M+Na]+. 
 
6-Amino-6-deoxy-methyl-α-D-mannopyranoside 354 
 
 
 
Pd/C (10% weight) (3.1 g) was added to a stirred solution of compound 353 (10.1 g, 
46.1 mmol) in methanol (100 mL).  The reaction mixture was stirred for 20 hours under 
a hydrogen atmosphere. The solution was filtered through celite and the solvent was 
removed under reduced pressure.  The crude product was purified by flash 
chromatography, eluting with DCM/MeOH (2:1) to give the title compound 354 (6.4 g, 
72 %) as a colourless syrup.                                                                                 
 
[α] 20D = +69.7
 (c 1.71, MeOH). 
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IR: (thin film) 3362, 2997, 2923, 2839, 2507, 1568, 1451, 1384, 1199, 1134, 1061, 972 
cm-1 
 
1H NMR (MeOD, 600 MHz): δ 2.79 (dd, 1H, J  = 7.0, 13.4 Hz, H-6'), 2.97 (dd, 1H, J = 
2.7, 13.3 Hz, H-6), 3.35 (s, 3H, OCH3), 3.40-3.43 (m, 1H, H-5), 3.50 (t, 1H, J = 9.6 Hz, 
H-4), 3.63 (dd, 1H, J = 3.4, 9.5 Hz, H-3), 3.77 (dd, 1H, J = 1.8, 3.3 Hz, H-2), 4.62 (d, 
1H, J = 1.4 Hz, H-1),  
 
13C NMR (MeOD, 150.9 MHz): δ 42.24 (C-6), 54.01 (OCH3), 68.50 (C-4), 70.85 (C-2), 
71.14 (C-3), 72.74 (C-5), 101.50 (C-1). 
 
LRMS (ESI+): 194.2 [M+H]+, 216.2 [M+Na]+. 
 
6-Benzyl-6-deoxy-methyl-α-D-mannopyranoside 356 
 
 
 
Benzaldehyde (260 mg, 14.8 mmol) was added to a stirred solution of compound 354 
(316 mg, 1.64 mmol), MeOH (20 mL) containing molecular sieves.  The reaction 
mixture was refluxed for 24 hours, filtered and the solvent removed under reduced 
pressure.  The residue was dissolved in methanol (20 mL); stirred and excess sodium 
borohydride was added in portions over 4 hours.  The solution was treated with 2M 
NaOH (20 mL), filtered and the solvent removed under reduced pressure.  The residue 
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was purified by flash chromatography, eluting with DCM/MeOH (10:1) to give the title 
compound 356 (295 mg, 63%) as a colourless syrup.  
 
[α] 20D = +45
 (c 3.02, MeOH). 
 
IR: (thin film) 3321, 2928, 2835, 1597, 1551, 1452, 1385, 1133, 1063, 978 cm-1. 
 
1H NMR (D2O, 600 MHz): δ 2.77 (dd, 1H, J = 9.7, 12.5 Hz, H-6), 3.00 (d, 1H, J = 12.5 
Hz, H-6), 3.14 (s, 3H, OCH3), 3.34 (t, J = 9.7 Hz, H-4), 3.53-3.56 (m, 2H, H-3, H-5), 
3.71 (s, 1H, H-2), 3.77 (s, 2H, ArCH2), 4.51 (s, 1H, H-1), 7.18-7.23 (m, 4H, Ar-H), 7.66 
(d, 1H, J = 7.4 Hz, Ar-H). 
 
13C NMR (D2O, 150.9 MHz): δ 48.34 (C-6), 51.87 (CH2Ar), 55.04 (OCH3), 68.59 (C-4), 
69.11 (C-2), 69.80 (C-3), 70.21 (C-5), 100.91 (C-1), 127.45 (Ar-CH), 128.4 (Ar-CH), 
128.57 (Ar-CH), 129.07 (Ar-CH), 130.17 (Ar-C). 
 
LRMS (ESI+):  284.2 [M+H]+. 
 
HRMS (ESI) calcd for C14H22O5N [M+H]+: 284.1492; Found: 284.1489. 
 
6-(4-Dimethoxybenzylamine)-6-deoxy-methyl-α-D-mannopyranoside 357 
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Anisaldehyde (293 mg, 2.16 mmol) was added to a stirred solution of compound 354 
(278 mg, 1.44 mmol) in MeOH (20 mL) containing molecular sieves.  The reaction 
mixture was refluxed for 24 hours, filtered and the solvent removed under reduced 
pressure.  The residue was dissolved in methanol (20 mL); stirred and excess sodium 
borohydride was added in portions over 4 hours.  The solution was treated with 2M 
NaOH (20 mL), filtered and the solvent removed under reduced pressure.  The residue 
was purified by flash chromatography, eluting with DCM/MeOH (5:1) to give the title 
compound 357 (274 mg, 59 %) as a colourless syrup.  
 
[α] 20D = +30
 (c 0.30, MeOH). 
 
IR: (thin film) 3345, 3004, 2924, 2850, 1677, 1612, 1514, 1455, 1250, 1061, 972 cm-1 
 
1H NMR (MeOD, 600 MHz): δ 2.83 (dd, 1H, J = 8.2, 12.7 Hz, H-6), 3.06 (dd, 1H, J = 
2.8, 12.7 Hz, H-6), 3.36 (s, 3H, OCH3), 3.46 (t, 1H, J = 9.6 Hz, H-4), 3.61-3.65 (m, 2H, 
H-3, H-5), 3.76 (s, 3H, OCH3), 3.78 (s, 2H, ArCH2), 3.83 (d, 1H, J = 3.8 Hz, H-2), 4.61 
(s, 1H, H-1), 6.90 (t, 2H, J = 8.2 Hz, Ar-H), 7.29 (t, 2H, J = 8.2 Hz, Ar-H). 
 
13C NMR (DMSO, 150.9 MHz): δ 48.44 (C-6), 51.26 (CH2Ar), 53.51 (OCH3), 53.59 
(OMe), 68.47 (C-4), 69.11 (C-2), 69.79 (C-3), 70.07 (C-5), 100.77 (C-1), 127.58 (Ar-C), 
129.32 (Ar-CH), 158.85 (Ar-CH), 158.91 (Ar-C). 
 
LRMS (ESI+): 314.1 [M+H]+. 
 
HRMS (ESI) calcd for C15H24O6N [M+H]+: 314.1598; Found: 314.1591. 
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6-(3,4-Dimethoxybenzylamine)-6-dexoxy-methyl-α-D-mannopyranoside 358 
 
 
 
3,4-Dimethoxybenzylaldehyde (377 mg, 2.27 mmol) was added to a stirred solution of 
compound 354 (292 mg, 1.51 mmol) in MeOH (20 mL) containing molecular sieves.  
The reaction mixture was refluxed for 24 hours, filtered and the solvent removed under 
reduced pressure.  The residue was dissolved in methanol (20 mL); stirred and excess 
sodium borohydride was added in portions over 4 hours.  The solution was treated with 
2M NaOH (20 mL), filtered and the solvent removed under reduced pressure.  The 
residue was purified by flash chromatography, eluting with DCM/MeOH (5:1) to give 
the title compound 358 (274 mg, 53%) as a white solid.  
 
[α] 20D = +45.8
 (c 0.665, MeOH). 
 
IR: (thin film) 3436, 2959, 2927, 2859, 1463, 1272, 1123, 1072, 957 cm-1 
 
1H NMR (D2O, 600 MHz): δ 2.59 (dd, 1H, J = 9.1, 12.4 Hz, H-6), 2.82 (dd, 1H, J = 1.9, 
12.4 Hz, H-6), 3.23 (s, 3H, OCH3), 3.35 (t, J = 9.6 Hz, H-4), 3.51 (m, 1H, H-5), 3.57 (d, 
J = 3.4 Hz, H-3), 3.59-3.60 (m, 2H, ArCH2), 3.69 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 
3.76 (s,1H, H-2), 4.57 (s, 1H, H-1), 6.81 (d, 1H, J = 8.2 Hz, Ar-H), 6.86-6.89 (m, 2H, 
Ar-H). 
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13C NMR (D2O, 150.9 MHz): δ 48.80 (C-6), 52.20 (CH2Ar), 54.80 (OCH3), 55.66 
(OCH3), 55.75 (OCH3), 68.89 (C-4), 69.88 (C-2), 70.38 (C-3), 70.66 (C-5), 100.86 (C-
1), 111.83 (Ar-CH), 112.29 (Ar-CH) 121.43 (Ar-CH), 132.11 (Ar-C), 147.32 (Ar-C), 
148.06 (Ar-C). 
 
LRMS (ESI+): 344.2 [M+H]+, 366.0 [M+Na]+. 
 
HRMS (ESI) calcd for C16H26O7N [M+H]+: 344.1704; Found: 344.1701. 
 
6-(2-Methoxycyclohexyl)-6-deoxy-methyl-α-D-mannopyranoside 359 
 
 
 
2-Methoxycyclohexanone (280mg, 2.18 mmol) was added to a stirred solution of 
compound 354 (281 mg, 1.45 mmol) in MeOH (20 mL) containing molecular sieves.  
The reaction mixture was refluxed for 24 hours, filtered and the solvent removed under 
reduced pressure.  The residue was dissolved in methanol (20 mL); stirred and excess 
sodium borohydride was added in portions over 4 hours.  The solution was treated with 
2M NaOH (20 mL), filtered and the solvent removed under reduced pressure.  The 
residue was purified by flash chromatography, eluting with DCM/MeOH (10:1) to give 
the title compound 359 (274 mg, 49 %) as a white solid.  
  
[α] 20D = +20.3
 (c 0.29, CHCl3). 
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IR: (KBr) 3468, 2957, 2917, 2850, 1576, 1464, 1261, 1096, 871 cm-1. 
 
1H NMR (CDCl3, 600 MHz): δ 1.08 (m, 2H, Cy), 1.21 (m, 2H, Cy), 1.69 (m, 1H, Cy), 
1.76 (m, 1H, Cy), 2.08 (d, 1H, J = 1.3 Hz, Cy), 2.16 (m, 1H, Cy), 2.38 (dt, 1H, J = 10.3, 
4.0 Hz, Cy), 2.92 (m, 2H,), 2.94 (dd, 1H, J = 4.1, 11.5 Hz, H-6), 305 (dd, 1H, J = 4.0, 
11.5  Hz, H-6), 3.34 (s, 3H, OCH3), 3.35 (s, 3H, OCH3), 3.55 (m, 1H, H-4), 3.78 (m, 2H, 
H-3, H-5), 3.91 (s, 1H, H-2), 4.69 (s, 1H, H-1). 
 
13C NMR (CDCl3, 150.9 MHz): δ 24.21 (cy), 24.26 (cy), 29.12 (cy), 29.96 (cy), 61.80 
(cy), 77.32 (cy), 49.51 (C-6), 55.15 (OCH3), 56.20 (OCH3), 68.65 (C-4), 70.17 (C-2), 
71.65 (C-3), 72.32 (C-5), 100.96 (C-1). 
 
LRMS (ESI+): 306.1 [M+H]+. 
 
HRMS (ESI) calcd for C14H28O6N [M+H]+: 306.1911; Found: 306.1909. 
 
6-O-Toluenesulfonyl-methyl-α-D-glucopyranoside 395 
 
 
 
Compound 394 (12.1 g, 62.4 mmol) was dissolved in pyridine (100 mL) and cooled to 0 
oC followed by portionwise addition of TsCl (18.0 g, 94.4 mmol.  The reaction mixture 
was stirred at 0 oC for 8 hours.  The solvent was removed under reduced pressure and 
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residue was purified by flash chromatography, eluting with DCM/MeOH (25:1) to give 
the  title compound 395 (14.9 g, 69 %) as a colourless syrup. 
  
[α] 20D = +82.5
 (c 6.66, MeOH). 
 
IR: (thin film) 3393, 3026, 2930, 1598, 1450, 1360, 1176, 1147, 1097, 1057, 972 cm-1. 
 
1H NMR (CDCl3, 600 MHz): 1.25 (s, 3H, CH3), 2.16 (s, 3H, OCH3), 2.24-2.31 (m, 2H, 
H-2, H-3), 2.52-2.56 (m, 2H, H-5, H-6), 2.71 (s, 1H, H-6), 3.06-3.15 (m, 1H, H-4), 3.49 
(d, 1H, J = 3.8 Hz, H-1), 6.16 (d, 2H, J = 8.1 Hz, Ar H), 6.62 (d, 2H, J = 8.3 Hz, Ar H). 
 
13C NMR (CDCl3, 150.9 MHz): δ 21.74 (CH3), 55.47 (OCH3) 69.48 (C-6), 69.29 (C-4), 
69.64 (C-2), 71.86 (C-3), 74.20 (C-5), 99.43 (C-1), 128.09 (Ar-CH), 129.96 (Ar-CH), 
132.81 (Ar-C), 145.05 (Ar-C). 
 
LRMS (ESI+): 371.2 [M+Na]+. 
 
6-Azido-6-dexoxy-methyl-α-D-glucopyranoside 396 
 
 
 
Sodium azide (8.6 g, 94.6 mmol) was added portionwise to a stirred solution of 
compound 395 (13.1 g, 33.7 mmol) in DMF (100 mL).  The reaction mixture was 
stirred at 90 oC for 5 hours.  The solution was filtered to remove white solid.  The 
268 
 
solvent was removed under reduced pressure.  The crude product was purified by flash 
chromatography, eluting with DCM/MeOH (15:1) to give the title compound 396 (6.53 
g, 79%) as a colourless syrup. 
 
[α] 20D = +121.3
 (c 13.3, CHCl3). 
 
IR: (thin film) 3376, 2928, 2103, 1443, 1353, 1285, 1192, 1147, 1102, 1049, 898 cm-1. 
 
1H NMR (MeOD, 600 MHz): δ 3.23 (t, 1H, J = 9.6 Hz, H-4), 3.32 (s, 3H, OCH3), 3.37 
(dd, 1H, J = 3.4, 16.5 Hz, H-6), 3.39 (dd, 1H, J = 4.9, 13.2 Hz, H-6), 3.47 (dd, 1H, J = 
2.2, 13.2 Hz, H-2), 3.65 (dt, 1H, J = 9.6, 1.9 Hz, H-5), 4.67 (d, 1H, J = 9.2 Hz, H-1). 
 
13C NMR (MeOD, 150.9 MHz): δ 51.40 (C-6), 54.43 (OCH3), 71.22 (C-4), 71.31 (C-2), 
72.08 (C-3), 73.53 (C-5), 99.96 (C-1). 
 
LRMS (ESI+):  242.1 [M+Na]+. 
 
4-Carbomethoxy-1-(methyl-α-D-mannopyranoside)-1H-[1,2,3]triazole 398 
 
 
 
Compound 353 (237 mg, 1.08 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), methyl propiolate (91 mg, 1.08 mmol) was added followed by 
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sodium ascorbate (0.108 mmol, 108 µL of a freshly prepared 1M solution in water) and 
copper(II) sulphate pentahydrate (0.0108 mmol, 2.70 mg in 100 µL of water).  The 
reaction mixture was heated at 80 oC for 15 hours.  The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, eluting with 
DCM/MeOH (25:1) to give the title compound 398 (229 mg, 70%) as a yellow oil. 
 
[α] 20D = +63.3
 (c 2.19, MeOH). 
IR: (thin film) 3406, 3008, 2932, 2839, 1730, 1543, 1375, 1231, 1059, 972 cm-1 
 
1H NMR (MeOD, 600 MHz): δ 3.05 (s, 3H, OCH3), 3.50 (t, 1H, J = 9.6 Hz, H-3), 3.64 
(dd, 1H, J = 3.4, 18.7 Hz, H-4), 3.76 (dd, 1H, J = 1.7, 6.7 Hz, H-2), 3.80 (dt, 1H, J = 
18.4, 2.4, Hz, H-5), 3.89 (s, 3H, CO2Me), 4.57 (s, 1H, H-1), 4.59 (dd, 1H, J = 8.59, 14.3 
Hz, H-6), 4.89 (dd, 1H, J = 2.4, 14.3 Hz, H-6), 8.54 (s, 1H, triazol-H). 
 
13C NMR (MeOD, 150.9 MHz): δ 51.2 (C-6), 51.4 (OCH3), 53.8 (OMe), 68.2 (C-4), 
70.4 (C-2), 70.9 (C-3), 71.1 (C-5), 101.5 (C-1), 129.7, 161.1 (triazole), 138.8 (CO2Me). 
 
LRMS (ESI+): 304.2 [M+H]+, 326.2 [M+Na]+. 
 
HRMS (ESI) calcd for C11H21O7N4: 321.1405; Found: 321.1404. 
 
4-Hydroxylmethyl-1-(methyl-α-D-mannopyranoside)-1H-[1,2,3]triazole 401 
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Compound 353 (322 mg, 1.47 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), propargyl alcohol (83 mg, 1.47 mmol) was added, followed by 
sodium ascorbate (0.147mmol, 147 µL of a freshly prepared 1M solution in water) and 
copper(II) sulphate pentahydrate (0.0147 mmol, 3.7 mg in 100 µL of water).  The 
reaction mixture was stirred at room temperature for 40 hours.  The solvent was 
removed under reduced pressure and the crude product was purified by flash 
chromatography, eluting with DCM/MeOH (20:1) to give the title compound 401 (222 
mg, 58%) as an off-white solid. 
 
mp: 176-177 oC. 
 
[α] 20D = +7.3
 (c 8.3, MeOH). 
 
IR: (KBr) 3288, 2957, 2938, 2866, 2836, 1415, 1227, 1137, 1076, 967 cm-1 
 
1H NMR (MeOD, 600 MHz): δ 3.061 (s, 3H, OCH3) 3.49 (t, 1H, J = 9.7 Hz, H-4), 3.64 
(dd, 1H, J = 3.4, 18.8 Hz, H-3), 3.75 (dd, 1H, J = 1.7, 6.3 Hz, H-2), 3.78 (dd, 1H, J = 
2.2, 18.4 Hz, H-5), 4.49 (dd, 1H, J = 8.8, 14.1 Hz, H-6), 4.56 (d, 1H, J = 1.3 Hz, H-1), 
4.64 (s, 2H, CH2OH ), 4.83 (dd, 1H, J = 2.2, 14.1 H-6), 7.94 (s, 1H, triazole-H). 
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13C NMR (MeOD, 150.9 MHz): δ 51.21 (C-6), 53.85 (OCH3), 55.13 (CH2OH), 68.33 
(C-4), 70.54 (C-2), 71.03 (C-3), 71.48 (C-5), 101.48 (C-1), 124.23, 147.60 (triazole) 
 
LRMS (ESI+): 276.0 [M+H]+, 298.1 [M+Na]+. 
 
HRMS (ESI) calcd for C10H18O6N3 [M+H]+ : 276.1190; Found: 276.1192. 
 
4-Phenyl1-(methyl-α-D-mannopyranoside)-1H-[1,2,3]triazole 402 
 
 
 
Compound 353 (263 mg, 1.2 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), phenyl acetylene (123 mg, 1.2 mmol) was added followed by 
sodium ascorbate (0.12 mmol, 120 µL of a freshly prepared 1M solution in water) and 
copper(II) sulphate pentahydrate (0.012 mmol, 3.0 mg in 100 µL of water).  The 
reaction mixture was heated at 80 oC for 15 hours.  The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, eluting with 
DCM/MeOH (40:1) to give the title compound 402 (120 mg, 45%) as a colourless oil. 
 
[α] 20D = +19.6
 (c 0.26, MeOH). 
 
IR: (thin film) 3366, 2930, 2837, 1464, 1444, 1229, 1199, 1132, 1057, 960 cm-1 
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1H NMR (MeOD, 600 MHz): δ 3.05 (s, 3H, OCH3), 3.57 (t, 1H, J = 3.3 Hz, H-4), 3.68 
(dd, 1H, J = 3.3, 18.7 Hz, H-3), 3.78 (dd, 1H, J = 1.7, 6.7 Hz, H-2), 3.84 (m, 1H, H-5), 
4.56 (dd, 1H, J = 8.76, 14.3 Hz, H-6), 4.60 (d, 1H, J = 1.2, H-1), 4.89 (dd, 1H, J = 2.2, 
14.3 Hz, H-6), 7.31 (t, 1H, J = 1.2 Hz, Ar-H), 7.39 (t, 2H, J = 7.9 Hz, Ar-H), 7.78 ( d, 
2H, J = 7.2 Hz, Ar-H), 8.34 (s, 1H, triazole-H). 
 
13C NMR (MeOD, 150.9 MHz): δ 51.4 (C-6), 53.8 (OCH3), 68.4 (C-4), 70.6 (C-2), 71.1 
(C-3), 71.5 (C-5), 101.5 (C-1), 122.4, 147.3 (triazole), 122.4 (Ar-CH), 128.0 (Ar-CH), 
130.40 (Ar-C), 147.28 (Ar-C). 
 
LRMS (ESI+): 322.2 [M+H]+, 344.3 [M+Na]+. 
 
HRMS (ESI) calcd for C15H20O5N3: 322.1397; Found: 322.1403. 
 
4-Butyl-1-(methyl-α-D-mannopyranoside)-1H-[1,2,3]triazole 403 
 
 
 
Compound 353 (207 mg, 0.95 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), 1-hexyne (78 mg, 0.95 mmol) was added followed by sodium 
ascorbate (0.095 mmol, 95 µL of a freshly prepared 1M solution in water) and copper(II) 
sulphate pentahydrate (0.01 mmol, 2.40 mg in 100 µL of water).  The reaction mixture 
was heated at 80 oC for 15 hours.  The solvent was removed under reduced pressure and 
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the residue was purified by flash chromatography, eluting with DCM/MeOH (20:1) to 
give the title compound 403 (230 mg, 76%) as white crystals 
 
mp: 138-139 oC. 
 
[α] 20D = +71.9
 (c 2.05, MeOH). 
 
IR: (KBr) 3367, 3166, 2868, 1553, 1446, 1366, 1311, 1196, 1088 cm-1. 
 
1H NMR (MeOD, 600 MHz): δ 0.921 (t, 3H, J = 6.7 Hz, -CH3), 1.33 (sextet, 2H, J = 7.4 
Hz, -CH2-), 1.61 (m, 2H, -CH2-), 2.67 (t, 2H, J = 7.6 Hz, -CH2-), 3.03 (s, 3H, OCH3), 
3.49 (t, 1H, J = 9.6 Hz, H-4), 3.63 (dd, 1H, J = 3.4, 18.7 Hz, H-3), 3.73 (dd, 1H, J = 2.2, 
18.5 Hz, H-5), 3.75 (dd, 1H, J = 1.5, 6.7 Hz, H-2), 4.43 (dd, 1H, J = 8.76, 14.1 Hz, H-6), 
4.55 ( d, 1H, J = 1.5 Hz, H-1), 4.80 (dd, 1H, J = 2.2, 14.1 Hz, H-6), 7.76 (s, 1H, 
triazole-H). 
 
13C NMR (MeOD, 150.9 MHz): δ 12.8 (C-4’), 21.8 (C-3’), 24.6 (C-2’), 31.5 (C-1’), 
51.16 (C-6), 53.68 (OCH3), 68.4 (C-4), 70.5 (C-2), 71.1 (C-3), 71.6 (C-5), 101.5 (C-1), 
123.2, 147.6 (triazole). 
 
LRMS (ESI+): 302.1 [M+H]+, 324.2 [M+Na]+. 
 
HRMS (ESI) calcd for C13H24O5N3: 302.1710; Found: 302.1705. 
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4-Cyclohexyl-1-(methyl-α-D-mannopyranoside)-1H-[1,2,3]triazole 404 
 
 
 
 
Compound 353 (228 mg, 1.04 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), cyclohexyl acetylene (113 mg, 1.04 mmol) was added, followed 
by sodium ascorbate (0.104 mmol, 104 µL of a freshly prepared 1M solution in water) 
and copper(II) sulphate pentahydrate (0.0104 mmol, 2.60 mg in 100 µL of water).  The 
reaction mixture was heated at 80 oC for 15 hours.  The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography eluting with 
DCM/MeOH (20:1) to give the title compound 404 (192 mg, 56%) as white crystals.  
 
mp: 119-121 oC. 
 
[α] 20D = +33.2
 (c 0.545, MeOH). 
 
IR: (KBr) 3393, 2928, 2852, 1450, 1381, 1246, 1131, 1059, 969 cm-1 
 
1H NMR (MeOD, 600 MHz): δ 1.27 (m 1H, cy), 1.40 (q, 4H, cy), 1.71 (d, 1H, J = 12.8 
Hz, cy), 1.78 (m, 2H, cy), 1.96 (m, 2H, cy), 2.70 (m, 1H, cy), 3.02 (s, 3H, OCH3), 3.51 
(t, 1H, J = 9.4 Hz, H-4), 3.64 (dd, 1H, J = 3.3, 18.6 Hz, H-3), 3.73 (dt, 1H, J = 11.4, 9.5 
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Hz, H-5), 3.76 (dd, 1H, J = 1.7, 6.5 Hz, H-2), 4.43 (dd, 1H, J = 8.9, 14.1 Hz, H-6), 4.56 
(d, 1H, 1.2 Hz, H-1), 4.82 (dd, 1H, J = 2.06, 14.1 Hz, H-6), 7.75 (s, 1H, triazol-H). 
13C NMR (MeOD, 150.9 MHz): δ 25.78 (C-4’), 25.91 (C-3’), 32.87 (C-2’), 35.14 (C-1’), 
51.21 (C-6), 53.74 (OCH3), 68.42 (C-4), 70.54 (C-2), 71.10 (C-3), 71.66 (C-5), 101.44 
(C-1), 121.93, 152.98 (triazole). 
 
LRMS (ESI+): 328.3 [M+H]+, 350.3 [M+Na]+. 
 
HRMS (ESI) calcd for C15H26O5N3: 328.1867; Found: 328.1866. 
 
4-Carbomethoxy-1-(methyl-α-D-glucopyranoside)-1H-[1,2,3]triazole 405 
 
 
 
Compound 396 (239 mg, 1.09 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), methyl propiolate (92 mg, 1.09 mmol) was added, followed by 
sodium ascorbate (0.109 mmol, 109 µL of a freshly prepared 1M solution in water) and 
copper(II) sulphate pentahydrate (0.011 mmol, 2.72 mg in 100 µL of water).  The 
reaction mixture was heated at 80 oC for 15 hours.  The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, eluting with 
DCM/MeOH (20:1) to give the title compound 405 (229 mg, 69%) as a white solid 
mp: 155-157 oC. 
 
[α] 20D = +100.6
 (c 0.79, MeOH). 
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Vmax (KBr): 3433, 3121, 3003, 2935, 2901, 1725, 1438, 1350, 1236, 1144, 1072 cm-1. 
 
1H NMR (MeOD, 600 MHz): δ 3.11 (s, 3H, OCH3), 3.29 (quintet, 1H, J = 1.6 Hz, H-4), 
3.33 (dd, 1H, J = 3.8, 17.2 Hz, H-2), 3.59 (t, 1H, J = 9.3 Hz, H-3),  (dt, 1H, J =  7.2, 9.2 
Hz, H-5), 3.89 (s, 3H, OMe), 4.59 (dd, 1H, J = 8.08, 14.1 Hz, H-6), 4.61 (d, 1H, J = 3.8 
Hz, H-1), 4.85 (d, 1H, J = 2.58 Hz, H-6), 8.51 (s, 1H, triazole-H). 
 
13C NMR (MeOD, 150.9 MHz): δ 51.24 (C-6), 51.37 (OCH3), 54.21 (OMe), 70.08 (C-
4), 71.62 (C-2), 71.69 (C-3), 73.53 (C-5), 99.99 (C-1), 129.74, 161.09 (triazole), 138.93 
(C=O). 
 
LRMS (ESI+): 304.1 [M+H]+, 326.2 [M+Na]+. 
 
HRMS (ESI) calcd for C11H21O7N4: 321.1405; Found: 321.1405. 
 
4-Hydroxymethyl-1-(methyl-α-D-glucopyranoside)-1H-[1,2,3]triazole 406 
 
 
 
Compound 396 (271 mg, 1.24 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), propargyl alcohol (63 mg, 1.24 mmol) was added followed by 
sodium ascorbate (0.124 mmol, 139 µL of a freshly prepared 1M solution in water) and 
copper(II) sulphate pentahydrate (0.0124 mmol, 3.1 mg in 100 µL of water).  The 
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reaction mixture was heated at 80 oC for 15 hours.  The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, eluting with 
DCM/MeOH (40:1) to give the title compound 406 (242 mg, 85%) as an off-white solid. 
 
mp: 220-223 oC. 
 
[α] 20D = +22.4
 (c 1.65, MeOH). 
 
IR(KBr): 3371, 3296, 2915, 2839, 1363, 1229, 1196, 1151, 1092 cm-1. 
 
1H NMR (D2O, 600 MHz): δ 2.97 (s, 3H, OCH3), 3.07 (t, 1H, J = 9.1 Hz, H-4), 3.36 (dd, 
1H, J = 3.7, 19.6 Hz, H-2), 3.50 (t, 1H, J = 9.6 Hz, H-3),  (dt, 1H, J = 12.0, 10.1 Hz, H-
5), 4.48 (dd, 1H, J = 8.1, 14.8 Hz, H-6), 4.56 (s, 2H, CH2OH) 4.57 (d, 1H, J = 3.8 Hz, 
H-1), 4.69 (m, 1H, H-6), 7.88 (s, 1H, triazole-H). 
 
13C NMR (D2O, 150.9 MHz): δ 50.85 (C-6), 54.55 (OCH3), 54.78 (CH2OH), 69.9 (C-4), 
70.83 (C-2), 71.06(C-3), 73.02 (C-5), 99.15 (C-1), 125.14, 146.82 (triazole). 
 
LRMS (ESI+): 276.1 [M+H]+, 298.0 [M+Na]+. 
 
HRMS (ESI) calcd for C10H18O6N3 [M+H]+ : 276.1190; Found: 276.1191. 
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4-Phenyl1-(methyl-α-D-glucopyranoside)-1H-[1,2,3]triazole 407 
 
 
 
Compound 396 (305 mg, 1.39 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), phenyl acetylene (142 mg, 1.39 mmol) was added, followed by 
sodium ascorbate (0.139 mmol, 139 µL of a freshly prepared 1M solution in water) and 
copper(II) sulphate pentahydrate (0.014 mmol, 3.5 mg in 100 µL of water).  The 
reaction mixture was heated at 80 oC for 15 hours.  The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, eluting with 
DCM/MeOH (40:1) to give the title compound 407 (151 mg, 34%) as a white solid. 
 
mp: 206-207 oC. 
 
[α] 20D = +90.2
 (c 1.48, CHCl3). 
 
IR (KBr): 3397, 3336, 2924, 2891, 2840, 1608, 1466, 1375, 1223, 1155, 1047 cm-1. 
 
1H NMR (MeOD, 600 MHz): δ 3.13 (s, 3H, OCH3), 3.15 (m, 1H, H-4), 3.36 (dd, 1H, J 
= 3.8, 19.5 Hz, H-2), 3.61 (t, 1H, J = 9.3 Hz, H-3), 3.89 (dt, 1H, J = 10.2, 8.3 Hz, H-5), 
4.55 (dd, 1H, J = 8.1, 14.3 Hz, H-6), 4.64 (d, 1H, J = 3.6 Hz, H-1), 4.84 (d, 1H, J = 2.4 
Hz, H-6), 7.32 (t, 1H, J = 7.5 Hz, Ar H), 7.41 (t, 2H, J = 7.7 Hz, Ar H), 7.79 ( d, 2H, J = 
7.8 Hz, Ar H), 8.32 (s, 1H, triazole H). 
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13C NMR (MeOD, 150.9 MHz): δ 51.20 (C-6), 54.18 (OCH3), 70.41 (C-4), 71.55 (C-2), 
71.68 (C-3), 73.63 (C-5), 99.95 (C-1), 122.29, 147.30 (triazole), 122.29 (Ar-CH), 
125.29 (Ar-CH), 128.0 (Ar-CH), 128.66 (Ar-CH), 130.36 (Ar-C),  
 
LRMS (ESI+): 344.0 [M+Na]+. 
 
HRMS (ESI) calcd for C15H20O5N3: 322.1397; Found: 322.1396. 
 
4-Cyclohexyl-1-(methyl-α-D-glucopyranoside)-1H-[1,2,3]triazole 408 
 
 
 
Compound 396 (307 mg, 1.40 mmol) was dissolved in a 1:1 mixture of water and tert-
butyl alcohol (12 mL), cyclohexyl acetylene (152 mg, 1.40 mmol) was added followed 
by sodium ascorbate (0.140 mmol, 140 µL of a freshly prepared 1M solution in water) 
and copper(II) sulphate pentahydrate (0.0140 mmol, 3.5 mg in 100 µL of water).  The 
reaction mixture was heated at 80 oC for 15 hours.  The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography, eluting with 
DCM/MeOH (30:1) to give the title compound 408 (305 mg, 67%) as a white solid. 
 
mp: 157-159 oC. 
 
IR: (KBr) 3362, 2925, 2852, 1548, 1450, 1364, 1195, 1151, 1049 cm-1. 
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1H NMR (MeOD, 600 MHz): δ 1.27 (m, 1H, cy), 1.42 (m, 4H, cy), 1.72 (m, 1H, cy), 
1.79 (m, 2H, cy), 1.98 (m, 2H, cy), 2.70 (m, 1H, CHN), 3.09 (s, 3H, OCH3), 3.12 (m, 
1H, H-4), 3.35 (dd, 1H, J = 3.7, 19.3 Hz, H-2), 3.59 (t, 1H, J = 3.8 Hz, H-3), 3.79 (dt, 
1H, J = 10.3, 8.4 Hz, H-5), 4.43 (dd, 1H, J = 8.4, 15.1 Hz, H-6), 4.60 (d, 1H, J = 3.8 Hz, 
H-1), (dd, 1H, J = 2.3, 15.1 Hz, H-6), 7.72 (s, 1H, triazole-H). 
 
13C NMR (MeOD, 150.9 MHz): δ 25.63 (C-4’), 25.76 (C-3’), 32.73 (C-2’), 35.0 (C-1’), 
50.94 (C-6), 53.99 (OCH3), 70.43 (C-4), 71.54 (C-2), 71.89 (C-3), 73.49(C-5), 99.72 
(C-1), 121.75, 152.89 (triazole). 
 
LRMS (ESI+): 328.1 [M+H]+. 
 
HRMS (ESI) calcd for C15H26O5N3: 328.1867; Found: 328.1864. 
 
Biological Assay 
 
Determination of the Inhibition of Jack bean α-mannosidase:162
Materials: 
  
The NaOAc Buffer (pH = 4.5, containing 2 mM ZnCl2) was prepared by combining 
150 mL of a 0.2 M solution of AcOH (made by dissolving 5.72 mL in 500 mL water), 
100 mL of a 0.2 M solution of NaOAc (made by dissolving 8.20 g in 500 mL water) 
and ZnCl2 (273 mg) and making up the resulting solution to 1000 mL with water. The 
pH was adjusted to 4.5, if necessary, by adding either NaOAc or AcOH solution. 
The borate buffer (pH = 9.0) was prepared by mixing 100 mL of a 0.02 M solution of 
boric acid (made by dissolving 1.24 g of H3BO4 in 100 mL of H2O) with 400 mL of a 
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0.005 M solution of sodium tetraborate decahydrate (made by dissolving 9.53g  in 500 
mL of H2O). 
The enzyme stock solution ([E] = 95 mU/mL) was prepared by diluting 5 μL of Jack 
bean α-mannosidase (Sigma M-7257, 95 U/mL, supplied as a suspension in 3.0 M 
(NH4)2SO4 and 0.1 mM Zn(OAc)2), with 4995 μL NaOAc-buffer (pH = 4.5, containing 
2 mM Zn Cl2). 
The substrate stock solution ([S] = 20.0 mM) was prepared by dissolving p-
nitrophenyl-α-D-mannopyranoside (18.4 mg, 61 mmol) in 3050 μL of NaOAc buffer 
(pH = 4.5, containing 2 mM ZnCl2). 
Procedure: 
The inhibition tests were performed by incubating 50 μL of enzyme solution and 20 μL 
of inhibitor solution or H2O for 30 min at 25 oC.  The reaction was started by addition of 
30 μL of substrate solution.  The velocity of the substrate hydrolysis was determined by 
quenching the reaction after 5 min by adding 100 μL of borate buffer and measuring the 
absorption at 405 nm. 
Calculations: 
KM (1.5 mM) was determined by performing the above experiment with six different 
substrate concentrations (with enzyme and H2O) and plotting the inverse substrate 
concentration vs. inverse rate of hydrolysis (Lineweaver Burk plot).  The IC50 values 
were determined by performing the above experiment with six different inhibitor 
concentrations at a substrate concentration corresponding to KM.  Determination of the 
inhibition constants (Ki) was performed at different concentrations of the inhibitor 
(usually six) bracketing the Ki or IC50 value at six different substrate concentrations 
bracketing the KM.  IC50 values were calculated by plotting the inhibitor concentration 
vs. the rate of hydrolysis. Ki and α values were determined from the replot of the slopes 
and the replot of the 1/v axis intercepts of Lineweaver Burk plots  
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 MTT Assay 
Cell lines: 
Colorectal HCT116 p53+/+ (both p53 alleles intact) and HCT116 p53-/-  (both p53 alleles 
disrupted) were used. (Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., 
Brown J. P., Sedivy J. M., Kinzler K. W., Vogelstein B. Science, 1998, 282, 1497–
1501). 
Preparation of test compounds: 
Test compound was dissolved in DMSO to make up a 400 mM solution. From this 
stock solution appropriate aliquots were used to make up a 100µM solution of the test 
compounds in RPMI 1640 medium (final DMSO content was ≤ 0.1%). Similarly, 
appropriate aliquots were used this from this 100 µM solution to make up a further 9 
solutions of the test compounds in RPMI 1640 medium. The solutions were stored at -
20 oC until required.   
Procedure: 
Cells were plated in 96-well plates with 200 μL of cell suspension (0.5 x 104 cell/mL) 
per well.  Cells were left to adhere overnight at 37 oC in humidified incubator with 5% 
CO2. The cells were then treated with a range of concentrations of the test compound for 
60 minutes. Each plate also contained a blank group (no test compound). Plates were 
then incubate for further 96 h (in 5% CO2 and 95% air humidified incubator at 37 oC) 
before 20 μL of MTT solution (5 mg/mL) were added to each well. The plate was then 
incubated in the dark at 37 oC for 4 h.  The supernatant was removed and formazan 
crystals were dissolved by addition of DMSO (150 μL).  The absorbance was read 
immediately at 540 nm and % cell survival calculated as follows: 
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This assay was performed in triplicate.  The mean IC50 (the concentration of drug that is 
required for 50% growth inhibition) ± SD was determined. 
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